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The Ryanodine Receptor type 2 (RyR2) the major calcium-release channel in the 
heart, where it is fundamental for excitation-contraction coupling, the process transducing 
electrical signals into mechanical contraction. The role of RyR2 dysfunction as a trigger 
of cardiac arrhythmia due to inherited mutations is firmly established, but the fundamental 
mechanisms of RyR2 regulation in normal cardiac physiology, and dysregulation in other 
forms of inherited and acquired heart disease remain partially understood. In this 
dissertation, we took advantage of three novel genetically-engineered animal models with 
mutations in RyR2 to better understand of the role of this ion channel in the healthy and 
diseased heart. 
First, we derived a congenic mouse line with ablation of the S2808 phosphorylation 
to revisit the hypothesis that this site is critical for RyR2 regulation, and sort out one of 
the differences between two mouse models generated by different laboratories that have 
fueled a long-standing controversy: the genetic background. Consistent with previous 
studies performed in Sv129/C57Bl6 mice, our data demonstrate that S2808A mice in the 
C57Bl/6 background behave like WT when subjected to acute and chronic stress. These 
data support the idea that S2808 phosphorylation is unlikely fundamental for RyR2 
regulation during the normal adrenergic response or heart failure progression. 
Furthermore, they suggest that the genetic background may not be the cause for the 




Second, we used a novel RyR2 knock-out rabbit model to elucidate the effects of 
decreased RyR2 expression on cardiac function and the possible underlying 
compensatory mechanisms. We show that homozygous knock-out of RyR2 is lethal, while 
heterozygous knock-out decreases RyR2 expression by 60% without producing an 
abnormal phenotype. Our data indicate that RyR2 deficiency is likely compensated by 
upregulation of channel function by decreasing the phosphorylation of S2031. Hence, 
RyR2 function is likely backed by a protein reserve, and channel deficiency is readily 
compensated. Nonetheless, during acute adrenergic stimulation the contraction velocity 
and calcium release are slower in cardiomyocytes from mutant animals, suggesting that 
a 40% RyR2 level may be insufficient to maintain calcium release flux during acute stress. 
These results give additional significance to phosphorylation of S2031, a site often 
ignored in the regulatory scheme of RyR2.  
Third, we performed a multi-level characterization of the novel mutation P1124L, 
identified in a patient with hypertrophic cardiomyopathy. Since this is one of a handful of 
RyR2 mutations associated with structural remodeling of the heart, its study may uncover 
novel pathogenic mechanisms of RyR2 dysregulation. We show that P1124L induces 
conformational changes in the SPRY2 domain of RyR2, affecting the sensitivity of the 
channel to cytosolic and luminal calcium. In a mouse model, P1124L produces cardiac 
hypertrophy and increases the susceptibility to arrhythmia. While we have yet to fully 
elucidate the underlying pathogenic mechanisms, these studies suggest that specific 
RyR2 mutations may cause cardiac hypertrophy while at the same inducing arrhythmias 




These three stories share a common aim: to obtain a better understanding of RyR2 
regulation in cardiac pathophysiology. From the regulatory role of phosphorylation to the 
clinical relevance of mutations in the RYR2 gene and the underlying pathogenic 
mechanisms, each model addressed in this dissertation provides novel insights into the 
role of RyR2 as an essential player in excitation-contraction coupling, and the possible 





CHAPTER 1  
Background and Significance 
 
1.1. Introduction 
Calcium (Ca2+) is the most ubiquitous and versatile signaling molecule in living 
organisms. In the heart, Ca2+ plays a remarkable dual role, serving as both signaling 
molecule for gene transcription and triggering signal for contraction. Hence, the cardiac 
regulation of intracellular [Ca2+] ([Ca2+]i) is a particularly complex process that follows an 
exquisitely orchestrated sequence of events, ultimately allowing cardiac myocytes to 
differentiate the global, rapid and cyclic [Ca2+]i oscillations required for contraction — 
excitation-contraction (e-c) coupling — from the localized, subcellular and typically long-
term changes in [Ca2+]i that regulate gene transcription. Indeed, there is a ~20,000-fold 
transmembrane [Ca2+] gradient that is essential for endowing Ca2+ with such versatility. 
During the last two decades, hundreds of mutations in Ca2+ handling proteins have 
been linked to inherited cardiac disorders, offering genetic evidence that dysregulation of 
Ca2+ homeostasis has profound pathological relevance. The inherited phenotype most 
associated with cardiac Ca2+ dysregulation is an electrical disturbance (arrhythmia); 
catecholaminergic polymorphic ventricular tachycardia (CPVT) is the quintessential 
manifestatio of arrhythmogenic Ca2+ disorders of the heart. Nevertheless, as genetic 




evidence suggests that cardiac Ca2+ dysregulation accounts for more than arrhythmia 
and may lead to structural cardiomyopathy and more complex phenotypes as well.  
The cardiac Ryanodine Receptor (RyR2), the subject of this dissertation, is one of 
the most relevant Ca2+ handling proteins because it conducts most of the Ca2+ required 
for heart contraction. Numerous studies have associated RyR2 dysfunction with heart 
failure progression, arrhythmia and, more recently, with structural remodeling of the 
cardiac muscle. This chapter reviews the relevant literature in the field and provides a 
framework for the latter chapters, which address specific questions about RyR2 regulation 
and function in health and disease. 
1.2. Overview of Calcium Homeostasis in the Heart 
While studying the effect of inorganic salts on several tissues in the late 19th 
century, physiologist Sidney Ringer realized that Ca2+ is an essential ion for cardiac 
contraction. Working with isolated heart preparations, he noticed that removing Ca2+ from 
his buffers stopped hearts from beating, while adding it back restored and maintained 
their contractility.1 At the time, Ringer almost certainly was unaware that extracellular Ca2+ 
only accounts for a small fraction of the Ca2+ needed for the heart to contract. Every action 
potential (AP) in a cardiac myocyte is accompanied by a transient elevation of the free 
[Ca2+]i from approximately 100 nM during diastole to nearly 1 μM during systole in order 
to activate the myofilaments and produce contraction.2 This series of events, through 
which membrane depolarization is converted to mechanical contraction, is termed 
excitation-contraction (e-c) coupling (Figure 1.1). In adult cardiomyocytes, the amount of 
extracellular Ca2+ entering the cell during an action potential is insufficient to elicit a full 




humans and 90% in mice) flows out of the sarcoplasmic reticulum (SR),3 an intracellular 
Ca2+ store, through the amplifying mechanism of Ca2+-induced Ca2+ release (CICR).4  
The e-c coupling in cardiac muscle mechanism begins during the AP, when a 
relatively small inward Ca2+ current (ICaL) from L-type Ca2+ channels (LTCCs) activates 
RyR2 channels, which in turn release more Ca2+ from the SR. Hence, RyR2 acts as both 
an intracellular Ca2+ sensor and a Ca2+ channel, amplifying a small Ca2+ signal and 
potentially turning CICR into a self-sustaining, regenerative process. However, CICR 
reliably stops in intact, healthy cardiomyocytes, and relaxation ensues once Ca2+ is 
removed from the cytosol. Several mechanisms have been proposed to terminate CICR: 
stochastic attrition, which implies that all LTCC and RyR2 channels within a specific 
region shut down simultaneously;2 RyR2 adaptation, which suggests that channels are 
unable to reopen until they recover due to a decrease in their responsiveness to sustained 
increases of [Ca2+];5-7 and local depletion of the SR, in which release termination occurs 
when the regions of the SR store reach a critical minimum threshold that closes local 
RyR2s.8 None of these mechanisms have been demonstrated to work independently; 
therefore, it is reasonable to assume that, under normal circumstances, a combination of 
the three are likely to work in concert to terminate CICR.9  
Following release termination, two main molecular players contribute to cytosolic 
Ca2+ removal: the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2a) refills the SR, 
while the Na+/Ca2+ exchanger (NCX) extrudes Ca2+ from the cell. To maintain Ca2+ 
equilibrium during repetitive contractions, Ca2+ that enters the cell through LTCC must be 
extruded by the NCX, while the Ca2+ released by RyR2 must return to the SR. A smaller 




mechanisms such as the sarcolemmal Ca2+ ATPase (PMCA) and the mitochondrial Ca2+ 
uniporter.3 NCX is an electrogenic transporter, which transports three Na+ ions in one 
direction while carrying a single Ca2+ ion in the opposite direction; hence, the extrusion of 
Ca2+ via NCX creates an inward depolarizing current that becomes more evident in the 
late phases of the AP.  
CICR takes place at specialized regions of the cell where the external membrane 
is near the SR, mostly within the T-tubule (TT) network of the myocyte. In these tightly 
spaced microdomains, clusters of ~20 LTCCs provide the activating Ca2+ signal for ~100 
RyR2s, forming a Ca2+ release unit (CRU).3 Any Ca2+ release event originating from a 
single CRU is referred to as a Ca2+ spark, while the global cytosolic Ca2+ transient results 
from the temporal and spatial summation of Ca2+ sparks coordinated during e-c coupling 
by the AP and ICaL.10 Isolated Ca2+ sparks during diastole are normal and most likely 
originate from activation of a single CRU through stochastic openings of RyR2 channel 
or LTCC.11 However, diastolic propagation of Ca2+ sparks through the cell as Ca2+ waves 
and synchronization of spontaneous sparks into diastolic Ca2+ transients are often 
observed in pathologic conditions. 
1.3. Adrenergic Regulation of Calcium Homeostasis 
The sympathetic branch of the autonomous nervous system increases the 
dynamic output of the heart in response to increased metabolic demand of the organism. 
Indeed, this system provides an essential component of the cardiac fight-or-flight 
response through activation of β1-adrenergic receptors (β1-AR) by catecholamines: for 
example, heart rate increases due to direct effect on the sinus node (positive chronotropic 




ventricular myocytes (positive inotropic and lusitropic effect, respectively), among others. 
Although the role of Ca2+ signaling in sinus node automaticity is still emerging,12 its 
importance for modulating inotropy (cardiac muscle contractility) and lusitropy (rate of 
cardiac muscle relaxation) has long been established.2 Canonical β1-AR signaling in the 
heart involves activation of adenylyl cyclase (AC), which converts adenosine triphosphate 
(ATP) into cyclic adenosine monophosphate (cAMP). cAMP stimulates protein kinase A 
(PKA) activation, which in turn phosphorylates at least three key players of e-c coupling: 
LTCC, enhancing peak ICaL and promoting increased SR Ca2+ content; phospholamban 
(PLB) at S16, relieving its partial inhibition on SERCA2a and thus accelerating SR 
refilling; and cardiac troponin I (cTnI), decreasing the Ca2+ affinity of the myofilaments 
and accelerating cross-bridge detachment. These effects result in larger and faster Ca2+ 
transients, hence increasing contractile force and allowing faster relaxation. PKA also 
phosphorylates RyR2 in at least two sites (S2031 and S2808, human nomenclature), but 
the physiological role of these modifications is still unclear.13,14  
Non-canonical β1-AR signaling, on the other hand, requires the exchange protein 
directly activated by cAMP 2 (Epac2) to activate the Ca2+/calmodulin-dependent kinase II 
(CaMKII) through an unknown mechanism.15,16 CaMKII, which is also independently 
activated during adrenergic stimulation by the increased Ca2+ cycling, phosphorylates 
many of the same protein targets of PKA, including LTCC, PLB (at T17) and RyR2 (at 
S2808 and S2814); yet, chronic activation of CaMKII is considered more deleterious.17 A 
key difference is that CaMKII increases SR Ca2+ leak — as observed in heart failure — 
perhaps by phosphorylating RyR2-S2814, while the role of PKA in SR Ca2+ leak is a 




regardless of the specific controversies, it is sufficiently clear that adrenergic signaling in 
the heart boosts Ca2+ cycling by directly affecting e-c coupling machinery at all levels: 
sarcolemma, SR, and myofilaments. 
1.4. Ryanodine Receptor Structure and Function 
The Ca2+-release channel/Ryanodine Receptor (RyR) is the largest ion channel 
known in nature. It derives its name from the alkaloid ryanodine, found in the plant Ryania 
speciosa,21 a high-affinity ligand that binds to the open state of the channel and locks it 
in a sub-conductance state.22 Ryanodine was fundamental for the initial purification and 
characterization of the channel, hence the name.23,24 Four identical subunits, each 
containing nearly 5000 amino acids and a combined molecular mass >2 million Da, form 
a functional channel (Figure 1.2). There are three mammalian isoforms , each encoded 
by a different gene contained in a different chromosome, that share ~65% sequence 
identity: RyR1 is predominantly expressed in skeletal muscle, RyR2 is the cardiac 
isoform, and RyR3, the least known of the three isoforms, is expressed in several tissues 
including the brain.25 RyRs are expressed in several other tissues, including vascular 
smooth muscle and regions of the brain; however, the best-studied function of RyR is in 
e-c coupling in skeletal (RyR1) and cardiac (RyR2) muscle. It should be noted that RyR2 
is commonly referred to as the “cardiac isoform,” which is true (it is the only isoform 
expressed in the heart) but misleading, since RyR2 is also the major isoform expressed 
in the brain.26 The 35% sequence difference between RyR1 and RyR2 accounts for 
dramatic differences in e-c coupling mechanism,25 sensitivity to Ca2+,27 and regulation by 




RyR2 is well-conserved among species. The human RyR2 (hRyR2), for example, 
shares 97% sequence identity with the mouse RyR2 (mRyR2; the primary model 
organism used in the field), 99% with the rabbit RyR2 (rRyR2; a larger mammalian model 
commonly used in heart failure studies), and >99% with the porcine RyR2 (pRyR2; the 
species used for the most recent structural studies described below). In this introductory 
chapter and in the concluding remarks in CHAPTER 5 hRyR2 nomenclature will be used 
unless specifically stated otherwise. In the chapters discussing experimental models, the 
nomenclature of the species under study will be used: mRyR in CHAPTER 2 and 
CHAPTER 4; rRyR2 in CHAPTER 3. Please note that in the following sections “RyR” will 
be used as a collective reference to the three isoforms whenever such generalization is 
necessary. 
1.4.1. Structural Hierarchy 
Elucidating the molecular architecture of RyR has been difficult, in part because 
its colossal size makes the channel nearly impossible to crystallize. The most informative 
approach for studying the molecular structure of the channel is cryo-electron microscopy 
(cryo-EM), which initially yielded maps of RyR1 with overall resolution of up to 9.6 Å.29 
Later, discrete domains were crystallized, solved at resolutions below 2 Å,30-32 and 
docked into previous cryo-EM maps, providing a general idea of protein architecture, as 
well as domain arrangement and interaction. The size hurdle was partially overcome 
using a combination of enhanced computer power, clever purification steps and improved 
detector, when three laboratories published the highest-resolution cryo-EM structures of 
RyR1 available to date at a maximum average resolution of 3.8 Å.33-35 More recently, 




respectively.36 des Georges et al. went even further, obtaining ~4 Å maps of RyR1 in 
various states, including structures with Ca2+, ATP, caffeine, and ryanodine bound to the 
channel.37  
Remarkably, both RyR1 and RyR2 share a similar structural hierarchy (Figure 1.2), 
which includes: 1) a central tower forming the core of the protein and including, from top 
to bottom, N-terminal domain (NTD), and central (CD) and pore-forming (PFD) domains 
on the C-terminus end; 2) a corona, which tops the central tower and is formed by two 
helical domains (HD1 and HD2) and the handle domain; and 3) a peripheral region, 
composed of five smaller domains (SPRY1-3, P1-2). Even with these high-resolution 
maps, docking known crystal structures of individual domains in cryo-EM structures 
remains problematic, particularly in the periphery of the channel where the resolution of 
the cryo-EM maps is poor. However, the central tower has the highest level of detail. 
Opening of the channel involves an intricate reorganization of specific motifs within the 
central tower, in which the NTD and CD act as scaffolds that integrate and transmit signals 
to the PFD. The PFD is made by 6 transmembrane segments per subunit, and the S6 
helix forms the Ca2+-conducting pore. Furthermore, the C-terminal end of the protein, 
located after the cytosolic extension S6, docks in a pocket of the CD, forming an 
“activation module” where Ca2+, ATP, and caffeine bind to RyR.37. Finally, each subunit 
has an S1-S2 luminal loop33,34,37 that might serve as an interaction site for other SR 
proteins such as triadin, junctin, and calsequestrin. 
1.4.2. Macromolecular Complex Formation 
The bulk of RyR2 is localized in the cytoplasm, and spans most of the gap between 




variety of proteins that serve as accessory regulators of the channel. Many of these 
proteins bind to RyR2 permanently, while others do so in a Ca2+-dependent manner.38 
Hence, some authors have called RyR2 channels “allosteric giants”,39 not only because 
of their colossal size, but because of their role as scaffolds of a macromolecular complex. 
Some components of this complex include calmodulin (CaM), two FK506-binding proteins 
(FKBP12 and FKBP12.6) and the soluble resistance-related Ca2+ binding protein (sorcin). 
These three RyR2 partners are briefly discussed below, butRyR2 also binds to PKA, 
protein phosphatases 1 (PP1) and 2A (PP2A), phosphodiesterase 4D3 and CaMKII.40 
Certainly, this suggests that regulation of RyR2 by phosphorylation is important, but this 
claim requires further examination. 
CaM is a 149-amino acid, 16.7 kDa Ca2+-binding protein ubiquitously expressed 
from three different genes (CALM1, CALM2 and CALM3) encoding for the same protein 
product, is the best-known partner of RyR2. The importance of CaM in regulating 
numerous cellular functions is highlighted by this apparent genetic redundancy. Each 
terminus of the protein forms a globular domain that contains two Ca2+-binding sites, and 
these regions are joined by a flexible linker that allows conformational changes upon 
binding of Ca2+.41 CaM, in its Ca2+-bound or Ca2+-free forms, directly interacts with RyR2. 
At high [Ca2+] Ca2+-CaM decreases the open probability of RyR2.42 Interestingly, mice 
expressing RyR2 channels unable to bind CaM develop severe cardiac hypertrophy and 
die perinatally.43 
FKBP12 and FKBP12.6 are two immunophilins named after their molecular weight 
that bind to RyR with high affinity. The recent cryo-EM studies took advantage of this 




maintained throughout the purification steps and both appear in the cryo-EM 
micrographs.33 RyR2, on the other hand, dissociates from FKBP12 during the purification 
(Figure 1.2).36 In the heart, the expression of FKBP12 is higher than that of FKBP12.6, 
but the latter has much higher affinity for RyR2.44 Hence, RyR2 channels bind both 
isoforms, but Guo et al. determined that only 10–20% of RyR2 channels contain 
FKBP12.6, while all FKBP12.6 is bound to RyR2. FKBP12.6 is thought to stabilize the 
closed state of RyR2, thus some refer to it as Ca2+-channel-stabilizing protein 2 (calstabin 
2). Nevertheless, the physiological role of this interaction is widely disputed. 
Finally, sorcin is a 21.6 kDa Ca2+-binding protein expressed in several tissues. In 
the heart, sorcin is thought to modulate Ca2+ by directly interacting with several e-c 
coupling targets,45,46 including RyR2,47 SERCA2a,48 and NCX.49,50 The specific role of 
sorcin in regulating cardiac function and in the development of heart disease is currently 
under investigation in our laboratory. 
1.4.3. Regulation by Phosphorylation 
hRyR2 contains 353 serine and 222 threonine residues, many of which are 
susceptible to phosphorylation based on computational analysis of consensus 
sequences.51 Experimentally, however, only three phosphorylation sites have been 
identified (S2031, S2808, and S2814), which are phosphorylated by two kinases (PKA 
and CaMKII). 
S2808 was the first site to come under scrutiny after Witcher et al.52 identified it as 
a CaMKII-dependent phosphorylation site in 1991. More than 10 years later, the Marks 
laboratory published a series of elegant studies in which S2808 was relabeled as a PKA-




and critically involved in heart failure (HF) progression.53,54 This site has a high level of 
basal phosphorylation20,57 and is phosphorylated in vitro by both CaMKII and PKA (Figure 
1.3, Table 1.1). According to Marks’ hypothesis, S2808 phosphorylation increases further 
in ischemic HF, causing the channel to be unstable or “leaky”. However, several studies 
from many laboratories have challenged these conclusions (reviewed in refs. 14,19,58). 
This phospho-site will be discussed in more detail in CHAPTER 2. 
S2814 was identified by Wehrens et al. in 2004 as a CaMKII-dependent 
phosphorylation site.59 Respress et al.60 later implicated this site in the pathogenesis of 
non-ischemic HF where the phosphorylation level is significantly increased. Thus, genetic 
ablation of this site by substituting serine with the non-phosphorylatable residue alanine 
(S2814A) resulted in relative protection against the deleterious effects of transverse aortic 
constriction — but not myocardial infarction — in mice. In this context, phosphorylation of 
S2814 by CaMKII results in hyperactive or “leaky” RyR2 channels. Like S2808, this site 
is highly phosphorylated in the absence of adrenergic stimulation.57,58 However, S2814 is 
only phosphorylated in vitro by CaMKII (Figure 1.3, Table 1.1). 
Finally, in 2005 Xiao et al. introduced S2031 as an exclusive PKA site,61 despite 
being part of a CaMKII consensus sequence.51 Remarkably, it can be phosphorylated in 
vitro by activation of endogenous CaMKII (Figure 1.3); however, this is not the case in 
HEK293 cells transfected with RyR2 and CaMKII.61 S2031 has not been studied to the 
same extent as the previous two phosphorylation sites. Unlike S2814, basal 
phosphorylation of S2031 is low but detectable.57 It also is readily phosphorylated by PKA 
in vitro57,61,62 and ex vivo.13 Mice with genetic ablation of the S2031 site (S2030A, as per 




that, despite the low basal phosphorylation, S2031 has an important regulatory role at 
least in rodents. This site will be discussed in more detail in CHAPTER 3. 
Despite the solid experimental evidence suggesting that RyR2 is phosphorylated 
downstream of β1-AR activation,13 it is unclear whether RyR2 phosphorylation is required 
for the adrenergic response.58 So far, the description of the three known phosphorylation 
sites suggests that phosphorylation of RyR2 results in increased channel activity. By 
removing SR load and ICaL regulation by β1-AR activation, Ginsburg and Bers63 elegantly 
demonstrated that RyR2 phosphorylation may be involved in speeding up Ca2+ release, 
while SR load and ICaL mediate the actual increase in the amount Ca2+ release. 
Furthermore, Valdivia et al. showed that single channels phosphorylated by PKA respond 
with higher open probabilities (PO) upon rapid exposure to increased [Ca2+].7 However, 
they rapidly undergo adaptation and stabilize at a lower PO than non-phosphorylated 
channels.64 Remarkably, three expected functional outcomes of phosphorylation have 
been reported for channel activity: increase,52,54 decrease,65,66 and no effect.67 Many of 
these studies have looked at the overall phosphorylation state of the channel rather than 
focusing on a single phosphorylation site. From the size of the channel, and the multitude 
of phosphorylation sites, it is apparent that interpretation of these data is difficult, as 
phosphorylation sites may work in concert rather than independently to modulate RyR2 
function. 
Using 32P incorporation assays, Takasago et al.68 showed that RyR2 can be 
phosphorylated in vitro by CaMKII, PKA, and protein kinases C and G (PKC and PKG, 
respectively). Furthermore, CaMKII-dependent incorporation of 32P was ~4 times greater 




each PKA site. These data indicate that at least 6 more CaMKII sites remain to be 
discovered. Finally, it is important to mention that other post-translational modifications of 
RyR2 have been reported to influence channel function, even synergistically with 
phosphorylation.55 
1.5. Ryanodine Receptor Dysfunction in Heart Disease 
Congenital mutations and acquired post-translational modifications of several Ca2+ 
handling proteins may lead to cardiac arrhythmia and heart failure. Here our discussion 
will be focused on catecholaminergic polymorphic ventricular tachycardia, heart failure, 
and inherited structural cardiomyopathies 
1.5.1. Catecholaminergic Polymorphic Ventricular Tachycardia 
CPVT is a severe inherited syndrome characterized by ventricular 
tachyarrhythmias triggered by physical or emotional stress in the absence of structural 
disease or changes in the resting electrocardiogram.69-71 Patients often develop 
bidirectional tachycardia, potentially leading to ventricular fibrillation and sudden cardiac 
death; however, idiopathic ventricular fibrillation has also been observed.72 Mutations in 
four genes are currently implicated in the pathogenesis of CPVT, resulting in four CPVT 
types: ryanodine receptor 2 (RYR2, CPVT1),73 calsequestrin 2 (CASQ2, CPVT2),74 triadin 
(TRDN, CPVT3),75,76 and calmodulin (CALM, CPVT4).77  
CPVT is a disorder that may be entirely attributed to altered intracellular Ca2+ 
cycling. The most accepted mechanism for the onset of arrhythmia involves spontaneous 
release of Ca2+ from the SR during diastole in myocytes harboring RyR2 channels 
destabilized by mutations in the channel protein itself or in the ancillary proteins of 




from the cell, and is also an electrogenic transporter. Thus, if the spontaneous Ca2+ 
release is synchronized and of sufficient critical mass, the resulting inward NCX current 
can drive the membrane potential to threshold and trigger an extemporaneous action 
potential known as a delayed after depolarization (DAD; Figure 1.4 B,D). Further 
repetition of this cycle and spontaneous synchronization of DADs occurring in a large 
group of myocytes may lead to ventricular arrhythmias,11 which become polymorphic as 
sites of ectopic electrical activity appear in different regions of the heart.78 Recent 
evidence suggests that arrhythmogenic focal activity may be more prominent in Purkinje 
cells where the subcellular structure, limited inter-cellular connections, and low 
electrotonicity favor the generation and propagation of DADs.79,80 
More than 200 different mutations in RYR2 have been identified in patients with 
CPVT1 (this number is steadily increasing); however, only a handful have been fully 
characterized. Historically, three regions of RyR2 are considered canonical clusters of 
CPVT1 mutations. These regions — CPVT-I (residues 77–466), CPVT-II (residues 2246–
2534), and CPVT-III (residues 3778–4967) — are arbitrarily defined based on mutation 
frequency, location of putative regulatory regions, and overlap with mutation sites in RyR1 
associated with skeletal muscle diseases;81 furthermore, CPVT1 clusters are often 
depicted in a linear representation of an RyR2 subunit (see figure 2 in ref. 81), 
oversimplifying the complex three-dimensional structure of the protein. With the recent 
high resolution cryo-EM maps, it is possible to limit these sections to four specific 
structural domains (Figure 1.5 C); of the mutation sites, 17% are localized in the NTD 
(residues 1–642, CPVT-I), ~21% occur within HD1 (residues 2110–2678, CPVT-II), and 




~25%), corresponding to CPVT-III and CPVT-IV, respectively. Intriguingly, only ~7% of 
the mutations fall in the peripheral domains (residues 643–2109 and 2679–3611), located 
outside the canonical CPVT regions, while the clear majority falls within the central tower 
of the channel (Figure 1.5 B). If genetic mutations are equally likely to arise anywhere in 
RYR2, those occurring in the peripheral domains are either more deleterious (or perhaps 
lethal) or they are innocuous compared to those within the canonical sites, and thus do 
not appear in the clinical spectrum. However, over 1000 variants scattered all over RYR2 
(background genetic testing noise) are present in whole-exome sequencing studies 
(WES) of the general population,82,83 and some disease-causing mutations may appear 
in these studies with low frequency. 
The specific molecular mechanism(s) by which RyR2 mutations produce 
arrhythmia is still unclear. To date, three specific hypotheses have been proposed to 
explain arrhythmogenesis due to RyR2 mutations that cause CPVT: defective inter-
domain interaction,84 enhanced dissociation of FKBP12.6,85,86 increased sensitivity to 
activation by luminal69 and cytosolic Ca2+,87 or a combination thereof. The molecular 
heterogeneity associated with RyR2 mutations has become more evident in studies of 
novel mutations; two examples in the literature provide solid experimental evidence. 
V2475F produces at least three molecular defects that contribute to pathogenicity: 
increased sensitivity to cytosolic Ca2+, increased sensitivity to luminal Ca2+, and altered 
PKA phosphorylation.87 The relative contribution of each molecular defect to 
arrhythmogenesis was not assessed independently. A4860G is, perhaps, a more evident 
example of mechanistic heterogeneity because it is not activated by neither luminal88 nor 




cytosolic activation of A4860G channels promotes SR overload. Eventually, SR overload, 
ICaL, and other sympathetically-induced activating factors converge to produce a burst of 
Ca2+ that prolongs the AP due to enhanced activation of NCX (Figure 1.4 C,E). The latter 
may lead to reactivation of other depolarizing currents, EADs, focal ectopic activity, and 
ultimately ventricular fibrillation. 
As more RyR2 mutations undergo molecular scrutiny, the variety of arrhythmia 
mechanisms will undoubtedly increase. Due to the staggering number of possible 
functional alterations, it remains to be seen whether it will be possible to predict the 
dominant molecular defects leading to arrhythmia based upon the location of the mutation 
in the overall structure of RyR2. This remains challenging, but doing so would enable 
therapies to be tailored for CPVT1 according to the RyR2 domain affected. Confounding 
this goal is the fact that the overall clinical phenotype of CPVT1 is shared by most RyR2 
mutations, regardless of the underlying molecular phenotype. 
1.5.2. Heart Failure 
HF is the advanced and typically progressive manifestation of other underlying 
conditions that deteriorate cardiac function, such as myocardial infarction or 
cardiomyopathy, making the heart unable to meet the metabolic demands of the 
organism.90 As such, the clinical definition and diagnosis of HF are complex, and the 
structural, functional, and electrophysiological remodeling occurring in failing hearts is 
intricate and likely dependent on the underlying etiology. Hence, not all studies agree on 
whether specific changes in protein expression or function are relevant for HF.91,92 
Nevertheless, Ca2+ mishandling is a common finding in failing hearts, and involves 




prolonged action potentials, decreased SR Ca2+ content and decreased Ca2+ release.95 
Furthermore, the contribution of NCX to cytosolic Ca2+ removal is increased compared to 
that of non-failing cardiac myocytes,95 while the activity and expression of SERCA2a are 
decreased.96 Hence, the higher NCX and lower SERCA2a synergize to decrease the SR 
content, lower Ca2+ release and, ultimately, produce contractile dysfunction and weak 
failing hearts. 
Patients with HF are also more susceptible to develop cardiac arrhythmia. Pogwizd 
et al. showed, using a rabbit model of non-ischemic HF, that arrhythmogenesis is 
enhanced by increased activity of NCX, reduced IK1 — the current determining the resting 
membrane potential — and residual responsiveness to β-AR stimulation.97 Also, failing 
myocytes show increased SR Ca2+ leak mediated by RyR2, as shown by Shannon et al.98 
Therefore, the cellular mechanisms for cardiac arrhythmias in HF are similar to those of 
CPVT: β1-AR activation promotes increased SR Ca2+ content — as in normal conditions 
— which leads to enhanced spontaneous Ca2+ release (SCR) during diastole in failing 
hearts due to “leaky” RyR2 channels. When this extemporaneous Ca2+ is extruded by 
NCX, the cell membrane depolarizes possibly triggering DADs. Moreover, since IK1 is 
lower, any given amount of Ca2+ extruded by NCX will have a larger depolarizing effect 
on the membrane potential than in healthy hearts. 
One area of controversy in the field of HF is regarding the role of RyR2 on the 
pathophysiology of the syndrome. Several studies have noticed variability in the 
expression and function of RyR2 in human and animal HF.3,92,99,100 Zhang et al., for 
example, did not detect a change in RyR2 expression in mice four weeks after myocardial 




the same approach (Figure 2.5).102 Hence, the study of the effect of RyR2 expression on 
cardiac function has generated sparse interest in the field. But regardless of protein 
expression level, the most contentious issue is the phosphorylation of the channel. In a 
seminal study, Marx et al. showed that in human failing hearts, PKA-mediated 
“hyperphosphorylation” of RyR2 is increased, prompting the dissociation of FKBP12.6 
from the macromolecular complex.54 In single channels, phosphorylation of RyR2 by PKA 
produced sub-conductance states — partial conductance because of incomplete closing 
of the channel — that make the channels “leaky”54 and might account for the increased 
escape of Ca2+ from the SR as measured by Shannon et al.98 Later, the same laboratory 
showed that this is mediated exclusively by PKA phosphorylation of S2808.53 Thus, 
S2808A mice were partially protected against HF in a model of ischemic HF — i.e. after 
myocardial infarction. As discussed in previous sections, this is controversial for many 
reasons including the already high basal phosphorylation level of S2808. The lack of 
confirmatory studies from independent investigators of key aspects of this hypothesis is, 
perhaps, the strongest argument against it.19,51,103 However, the low abundance of 
FKBP12.6 — only enough to occupy a small fraction of the total RyR2 content of a 
myocyte — and the RyR2-FKBP12.6 binding affinity and kinetics19,104 are also important 
aspects to consider.  
The more recent study suggesting that S2814 phosphorylation by CaMKII is the 
underlying cause of SR Ca2+ leak in HF seems to hold better against scrutiny.60 With the 
exception of FKBP12.6 dissociation from RyR2 and the appearance of sub-conductance 
states, the general idea is the same as described above: RyR2 gets “hyper-




become “leaky.” The caveat is that in the authors’ scheme, S2814 is only relevant in non-
ischemic HF, while S2808 is relevant only in ischemic HF. This idea, however, is difficult 
to reconcile with both phosphorylation sites located within the same domain of RyR2. 
Nonetheless, the experimental evidence in support of the pathogenic role of S2814 
phosphorylation in HF and other forms of heart disease continues to grow. Ultimately, the 
existence of Ca2+ mishandling in HF is well-documented, and elucidating the role of RyR2 
will require further investigation. 
1.5.3. Inherited Structural Cardiomyopathy 
Structural cardiomyopathies are a complex and heterogeneous group of heart 
diseases that involve mechanical dysfunction of the heart, often from genetic etiology, 
and display ventricular hypertrophy or dilation.105,106 Among them, hypertrophic 
cardiomyopathy (HCM) is the most common congenital cardiac disease, affecting one in 
every 500 individuals.107,108 HCM is considered to be a sarcomeric disease because the 
vast majority of patients with a positive genetic diagnosis carry a mutation in the genes 
encoding myosin-binding protein C (MYBPC3), β-myosin heavy chain (MYH7), or another 
component of the myofilaments.109 Nonetheless, approximately half of the patients 
undergoing genetic testing are negative for mutations in the HCM panel, which screens 
~15 associated genes.109 These are considered idiopathic cases; however, mutations in 
several other genes have been recently identified in HCM patients, including those 
encoding Ca2+ handling proteins such as PLB, CASQ2, junctophilin 2, sorcin, and 
RyR2.110 It is noteworthy that at least two of these proteins are also involved in CPVT. 
The first direct evidence suggesting that RyR2 mutations can lead to structural 




characterized a mouse model expressing a mutant RyR2 with impaired regulation by CaM 
(RyR2-W3587A/L3591D/F3603A, ADA).43,111,112 Interestingly, mice homozygous for the 
mutation developed severe hypertrophy and died within two weeks of birth, a 
phenomenon likely associated with increased Erk1/2-p90RSK-GSK-3β rather than CaM-
CaN-NFAT and CaM-CaMKII-HDAC signaling.111 The observation that a mutation in 
RyR2 is sufficient to induce severe hypertrophy, albeit not being a clinically relevant 
mutation, suggested that RyR2 could cause cardiomyopathy in humans. To date, three 
types of cardiomyopathy have been associated with RyR2 mutations in the clinical setting, 
all with low confidence levels: HCM (T1107M),113 left ventricular non-compaction (LVNC, 
in-frame deletion of exon 3)114-116 and arrhythmogenic right ventricular cardiomyopathy 
(ARVC, several mutations).117,118 
In an effort to determine the pathogenic mechanisms associated with these 
mutations, Tang et al.119 measured the activation and termination threshold for 
spontaneous Ca2+ release (SCR) in a heterologous system with RyR2 expression. All 
CPVT, LVNC, and ARVC mutations studied increased both activation and termination 
thresholds for SCR. Importantly, A1107M, the mouse analog of T1107M, behaved 
differently from all the other mutations, showing normal activation but decreased 
termination threshold, and was thus classified as a loss-of-function. Lau and Van 
Petegem30 mapped A1107 to SPRY2, a small but structurally complex domain. SPRY2 
is one of the peripheral domains of RyR2 not considered a hotspot for CPVT mutations 
(Figure 1.5, discussed above); however, it might be relevant for inter-subunit interactions 
because it spans the gap between the handle domain and HD2 of two adjacent 




1107 can easily accommodate an alanine or a threonine, while the bulkier side chain of 
methionine produces a shift in the amino acid backbone, affecting interactions with 
neighboring amino acids.30 Remarkably, T1107M has also been identified in patients with 
CPVT.81 Altogether, these data strengthen the overall pathogenic role of T1107M, but 
weakens its role in structural cardiomyopathy. 
The in-frame deletion of exon 3, associated with LVNC, showed similar SCR 
properties to other CPVT and ARVC mutations studied by Tang et al.119 Nevertheless, 
the same group created a mouse with a comparable genetic deletion to characterize the 
in vivo phenotype.120 The homozygous mutation was embryonic lethal, but heterozygous 
mice survived with no evident changes in cardiac structure and normal susceptibility to 
stress-induced arrhythmia. Remarkably, these mice had decreased cardiac expression 
of RyR2, similar to a previously characterized RyR2 heterozygous knock-out mice.121 
Because there are no reports quantifying RyR2 expression in patients harboring an RYR2 
allele with exon 3 deletion, it is difficult to assess whether the clinical phenotype is 
associated with decreased RyR2 expression or with the presence of the mutant protein 
product. Nevertheless, exon 3 deletion also appears in cohorts of CPVT patients.81 
Finally, ARVC is an autosomal dominant congenital cardiomyopathy characterized 
by progressive fibro-fatty replacement of the myocardium that can lead to ventricular 
arrhythmias and heart failure. ARVC is more often caused by mutations in genes 
encoding components of the cardiac desmosome, including plakophilin-2 (PKP2), 
plakoglobin (JUP), and others; however, as many as 40–50% of patients do not harbor 
mutations in the five main desmosomal ARVC genes.122 Rampazzo et al.123 first mapped 




q43. Tiso et al.117 later identified RYR2 as the gene harboring the disease-causing 
mutation. Interestingly, the clinical presentation of ARVC2 in these patients resembled 
CPVT in that arrhythmias could be elicited by exercise, had high penetrance, and affected 
males and females equally117 — characteristics that are not typical of ARVC. Although a 
clear association between RyR2 mutations and ARVC remains unproven, a recent study 
that analyzed 64 “typical” ARVC patients without desmosomal mutations found 6 rare 
missense RYR2 variants yielding 9% incidence among probands (6/64) — clearly higher 
than the control population.124 Thus, although the causal association between RyR2 
variants and ARVC was not direct, the study reopened the possibility that RyR2 mutations 
may lead to structural alterations characteristic of ARVC. Alternatively, it is possible that 
specific RyR2 variants may aggravate the phenotype associated resulting from mutations 
in other proteins present in these patients.125 
Important steps have been taken to establish a definitive link between RyR2 
mutations and structural cardiomyopathy; yet, all efforts are overshadowed by reports 
associating specific variants with both arrhythmogenic disorders and structural 
cardiomyopathy.81,118 Thus, the mechanism(s) by which a given mutation in RYR2 
triggers pathological remodeling instead of a purely arrhythmogenic syndrome (CPVT) 
remains unknown. However, it is evident that RyR2 mutation can produce a wide 
spectrum of cardiac alterations — yet the underlying mechanisms that determine the 
phenotype will remain unknown until novel mutations identified only in patients with 
structural cardiomyopathy are fully characterized. The most straightforward link between 
Ca2+ dysregulation and structural cardiomyopathy involves activation of the CaM-CaN-




and have been shown to be relevant to hypertrophy and heart failure.126 Nevertheless, 
the lack of a connection between these pathways and the hypertrophic phenotype of the 
ADA mouse discussed above foreshadows a more complex mechanism. 
1.6. Scope of this Dissertation 
Ca2+ signaling is pivotal for the control of contractility, action potentials, gene 
transcription, mitochondrial activity, and several other important functions of cardiac cells. 
As the regulatory valve of SR Ca2+ release in the heart, RyR2 has an undeniable role in 
each of these processes. Today, the role of RyR2 dysregulation as a trigger of cardiac 
arrhythmias has been firmly established. CPVT, caused by mutations in RyR2 and/or its 
accessory proteins, is the most salient example of intracellular Ca2+ signaling gone awry 
and causes lethal ventricular arrhythmias. HF, on the other hand, offers a provocative 
example of how similar arrhythmogenic mechanisms are also associated with acquired, 
rather than inherited, Ca2+ mishandling and RyR2 dysfunction. As our understanding of 
the intimate and bidirectional connection between RyR2 dysfunction and membrane 
potential increases, this frontier is extending ever more firmly beyond CPVT and into the 
territories of atrial fibrillation, long QT syndrome, and other arrhythmogenic syndromes 
that will require ample discussion in the future. Although Ca2+-dependent arrhythmias are 
known to exacerbate the malignancy of structural diseases such as HCM and heart 
failure, no study has yet established a direct causal relationship between RyR2 
dysregulation and pathological structural remodeling. The idea that they directly cause 
such diseases remains tantalizing at best. Moreover, no animal model generated to date 





This project was initially intended to study the mechanisms by which RyR2 
mutations, specifically the novel HCM-associated mutation P1124L, might produce 
structural cardiomyopathy rather than CPVT. Along the way, the scope of the project was 
expanded to include two aspects of RyR2 regulation that contribute not only to 
pathogenesis, but to normal cardiac function: phosphorylation and expression. While 
seemingly independent, these three subprojects respond to the same general aim: to 
obtain better understanding about RyR2 regulation in the healthy and diseased heart. Our 
overall working hypothesis is that RyR2 expression and phosphorylation are fundamental 
to control cardiac function, and may be involved in dysregulation of Ca2+ handling in heart 
disease. Each of the subprojects discussed in the following chapters takes advantage of 
an animal model harboring specific RyR2 mutations used to test this hypothesis: 
CHAPTER 2 discusses a series of experiments developed using a mouse derived 
from the S2808A model published by our laboratory in 2007.13 This project was designed 
to sort out one of the fundamental differences between two mouse models generated by 
different laboratories that have fueled a long-standing controversy regarding the role of 
S2808 phosphorylation on RyR2 regulation. The aim of these experiments was to test the 
hypothesis that the genetic background of S2808A mice contributes to impairing their 
cardiac adrenergic response and abating their progression to heart failure after 
myocardial infarction. This chapter uses mRyR2 nomenclature (Table 1.1). 
CHAPTER 3 discusses the characterization of a novel RyR2 knock-out rabbit 
model, which we used as a tool to test the hypothesis that decreased RyR2 expression 
is sufficient to cause cardiac dysfunction in rabbits as compared to the relative lack of 




of RyR2 is embryonic-lethal, but heterozygotes show haploinsufficiency. Decreased 
RyR2 expression is commonly observed in failing hearts92 and in patients with HCM.99,100 
We also discussed earlier that decreased expression of RyR2 was reported in mice with 
deletion of exon 3 associated with LNVC and CPVT. Hence, this rabbit model allowed us 
to understand the contribution of RyR2 expression to the pathology of heart disease in a 
mammalian model closer to the human. This chapter uses rRyR2 nomenclature (Table 
1.1). 
CHAPTER 4 discusses the molecular, cellular and whole-animal characterization 
of P1124L, an RyR2 mutation identified by Michael Ackerman’s laboratory in a patient 
with HCM. This mutation is a good candidate to elucidate the mechanisms of RyR2 
dysfunction that might lead to structural cardiomyopathy because it has only been 
associated with human HCM. We determined that this mutation induces cardiac 
hypertrophy and arrhythmia in mice. In this chapter, we use mRyR2 nomenclature, unless 
otherwise stated. 
Finally, CHAPTER 5 integrates the key findings described in the previous chapters 
into the larger scheme of RyR2 regulation. While this dissertation does not put an end to 
specific controversies or affirms beyond doubt the role of RyR2 in generating structural 
cardiomyopathy, it certainly improves our understanding of RyR2 regulation in the context 
of cardiac function and leads to important advances in the field of cardiac e-c coupling. 
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Figure 1.1. Cardiac Excitation-Contraction Coupling. 
Schematic representation of excitation-contraction coupling in a ventricular myocyte. Panel A represents 
the cell under basal conditions and panel B under adrenergic stimulation. Each panel is to be interpreted 
independently, but the plasma-membrane Ca2+ ATPase (PMCA), Na+/K+ ATPase (NaK), and mitochondrion 
shown at the bottom are common both panels.  
A. Cardiac excitation-contraction coupling in basal conditions. Ca2+ current through L-type Ca2+ channels 
(LTCC) activates ryanodine receptors 2 (RyR2), which in turn release Ca2+ from the sarcoplasmic reticulum 
(SR) leading to contraction of the myofilaments. Ca2+ is then extruded from the cell through the Na+/Ca2+ 
exchanger (NCX) and resequestered into the SR by the carco/endoplasic reticulum Ca2+ ATPase (SERCA). 
Other players such as PMCA and mitochondria also participate in Ca2+ extrusion from the cytosol to a lesser 
extent. B. Stimulation of β1-adrenergic receptors (β1-AR) by catecholamines (NE/E) promotes activation 
adenylyl cyclase (AC), which converts ATP into cAMP. The latter activates PKA, which phosphorylates (P) 
several protein targets including LTCC, RyR2, phospholamban (PLB), and troponin I. This leads to 
increased Ca2+ cycling and positive inotropy and lusitropy. Non-canonical β1-AR signaling that leads to 







Figure 1.2. Ryanodine Receptor Structure and Domain Assignment. 
The atomic coordinates and domains of the porcine RyR2 as reported by Peng et al.36 (PDB ID 5GO9) were 
used to identify equivalent domains in the human RyR2. Domains are color-coded in all panels. A. Single 
RyR2 channel observed from the dyadic cleft. Black lines delimit the four subunits. B. Side view of an RyR2 
channel showing two opposite subunits. The central tower of the channel, composed, from top to bottom, 
by the N-terminal domain (NTD), the central domain (CD), and pore-forming domain (PFD), is highlighted. 
C. Schematic of a single RyR2 subunit drawn to scale. Black boxes indicate inter-domain regions. Panels 
A-B were prepared using PyMOL Molecular Graphics software. Arrowheads indicate the approximate 
location of the three known phosphorylation sites. 
 
 
Figure 1.3. In vitro Phosphorylation of RyR2 by PKA and CaMKII. 
RyR2 from mouse heart homogenates was back-phosphorylated in vitro with the addition of either the 
catalytic subunit of PKA and ATP (A), or the addition of CaM, Ca2+, and ATP to activate the endogenous 
CaMKII (B). Control reactions were performed in the absence of PKA (A) and CaM (B). Phosphorylation 
levels were assessed using phospho-specific antibodies. Western blots were performed as described in 





Figure 1.4. Cellular Mechanisms of CPVT.  
A. Cardiac excitation-contraction coupling and action potential wave-form in a normal myocyte. B. 
Spontaneous Ca2+ release in myocytes harboring gain-of-function RyR2 mutations and stimulated with 
catecholamines. Extemporaneous Ca2+ release during diastole due to increased cytosolic and/or luminal 
sensitivity to Ca2+can produce delayed after-depolarization (DAD) and lead to trigger activity. C. RyR2 
channels harboring a loss-of-function mutation do not respond to luminal or cytosolic Ca2+. When the SR 
reaches a critical Ca2+ load during an AP, both wild type and hypoactive channels produce a burst of Ca2+ 
that prolongs the AP by activating the NCX, leading to an early after-depolarization (EAD). D-E. 
Representative action potential (top panel) and Ca2+ transient (middle and lower panels) traces recorded in 
cardiac myocytes from heterozygous RyR2-R4496C (RC+/-, gain-of-function) and RyR2-A4860G (AG+/-, 
loss-of-function) mice stimulated at 1Hz in the presence of 300 nM isoproterenol. In panel D, notice the 
several Ca2+ waves unable to trigger full APs in the D. Arrows indicate triggered stimuli. Asterisks indicate 
DADs and arrowheads indicate AP prolongation and EADs. (For D-E, data kindly provided by Xi Chen and 







Figure 1.5. RyR2 Mutations Associated with CPVT.  
The four domains containing most of the CPVT mutations are color-coded in all panels: N-terminal domain 
(NTD), orange; helical domain 1 (HD1), green; central domain (CD), blue; and pore-forming domain (PFD), 
magenta. All other domains are colored gray. A. Single RyR2 channel observed from the dyadic cleft. Black 
lines delimit the four subunits. B. Side view of an RyR2 channel showing two opposite subunits. The side 
chain of ~200 residues susceptible to CPVT mutations are identified with spheres and colored according to 
the domain. C. Top. Schematic of a single RyR2 subunit the drawn to scale with superimposed lines 
representing the location of 200 residues susceptible to CPVT mutations. The current delimitation of the 
three CPVT mutation clusters, as defined by Medeiros et al.,81 is indicated with dashed lines. Solid lines 
indicate a proposed delimitation based on specific domains (mutation data compiled from the Human Gene 
Mutation Database127 and from the literature). Bottom. Location of 1422 RyR2 residues with reported 
missense variants, drawn at the same scale as top panel. Arrows indicate the position of 29 variants that 





Table 1.1. Characterized Phosphorylation Sites in RyR2. 
Current nomenclature, basal phosphorylation, kinase, and initial reference of the three known 
phosphorylation sites of RyR2. Reference sequences of RyR2 are: human Q92736, rabbit P30957, mouse 
E9A401 (Uniprot128). 
Site Basal  
Phosphorylation** Kinase Reference Human Rabbit Mouse 
S2031 S2031 S2030 ?–Low PKA Xiao et al.61 
S2808 S2809 S2807* ~50% PKA, CaMKII Witcher et al.52 
S2814 S2815 S2813* ~50% CaMKII Wehrens et al.59 
* These sites are referred to in the literature as S2808 and S2814, respectively. Residue numbers 
changed in February 2015 after the removal of A2266 from the reference sequence. To maintain 
coherence with the literature, these sites will continue to be referred to as S2808 and S2814 throughout 
the text. 




CHAPTER 2  
Ablation of RyR2-S2808 Phosphorylation Does Not Alter the Adrenergic 
Response or the Progression to Heart Failure in Mice 
 
2.1. Introduction 
Heart failure (HF) is a complex, multi-factorial syndrome characterized by 
incapacity of the heart to meet metabolic demands; HF is clinically manifested by 
dyspnea, fatigue, limited exercise capacity and fluid retention.90 Although the underlying 
mechanisms of HF are varied and complex, dysregulation of intracellular calcium (Ca2+) 
handling is a defining feature that is thought to be involved in the most prominent 
pathophysiological observations: structural remodeling of the heart, impaired cardiac 
contractility, and increased propensity to arrhythmia.95,97,129  
Cardiac contraction requires Ca2+ cycling for excitation-contraction (e-c) coupling, 
the process transducing electrical signals into mechanical force. A normal contraction 
occurs when ryanodine receptors (RyR2) release Ca2+ from the sarcoplasmic reticulum 
(SR) upon activation by a small inward Ca2+ current (ICaL) mediated by L-type Ca2+ 
channels. Relaxation then ensues from the removal of Ca2+ from the cytosol by the SR 
Ca pump (SERCA2a) and the Na+/Ca2+ exchanger (NCX). In HF, the abundance, 
phosphorylation levels, and activity of several e-c coupling proteins and their regulatory 
partners are altered.92,130 In 2000, Marks et al communicated that in HF, RyR2 is 




regulatory protein FKBP12.6 and renders the channel hyperactive by inducing long-
lasting sub-conductance states.54 In subsequent papers, the group provided compelling 
evidence that S2808 is the only PKA phosphorylation site in RyR254 and that ablation of 
this site in mice (S2808A) blunts the normal cardiac adrenergic response55 and improves 
the outcome of ischemic HF.53 Thus, Marks et al. assigned the Ca2+ mishandling 
characteristic of HF to S2808 hyperphosphorylation and subsequent dissociation of 
FKBP12.6. However, many laboratories have failed to reproduce key elements of this 
hypothesis.19,58 Our laboratory independently generated a S2808A mouse model and 
observed a normal progression to HF following transverse aortic constriction.13 Later, 
Houser’s group, using the same mice, reported normal adrenergic response131 and 
unaltered progression to HF following myocardial infarction (MI).101  
Although the discrepancies between these two mouse models are striking, the 
underlying causes have not been explored yet. One of the most patent differences 
between both S2808A models is the genetic background: the studies by the Marks 
laboratory were conducted using mice on the C57Bl/6 background, while the Valdivia and 
Houser laboratories used a mixed Sv129/C57Bl6 background.13,53 This variable is 
relevant, since important phenotypic differences have emerged from identical genetic 
alterations in various mouse strains. Background genes from the parental strains may 
interact with the mutated gene in a manner that could severely compromise the 
interpretation of phenotype. In this study, we explored the effect of the genetic 
background as the source of these divergent results. We backcrossed the Valdivia lab’s 
mouse model into a congenic C57Bl/6 strain and followed an experimental approach 




C57Bl/6 genetic background (1) have a normal response to adrenergic stimulation at the 
whole animal and cellular levels, and (2) show identical progression towards HF 
compared to wild type controls up to four weeks after MI. Therefore, it is unlikely that the 
genetic background of the mice is the source of the diametrically opposite results obtained 
by the Marks and Valdivia/Houser groups. These data support the notion that 
phosphorylation of S2808 is unlikely to be essential for the cardiac adrenergic response 
and is perhaps irrelevant in HF progression. 
2.2. Results 
2.2.1. Direct Sequencing of Ryr2 
For this work, we derived a congenic mouse line in the C57Bl/6 genetic 
background from the S2808A mice generated in our laboratory (Figure 2.1) and first 
described by Benkusky et al.13 This model has been thoroughly characterized by our 
laboratory13 and several collaborators.101,131-133 All these reports have used Western blots 
to confirm the absence of S2808 phosphorylation in homozygous mice. However, 
changes in neighboring amino acids that alter the antibody epitope can produce a 
confounding result. Therefore, we sequenced the genomic region containing the 
underlying mutation to validate the model from a genetic perspective. 
This mouse was created using homologous recombination with a targeting vector 
containing exons 54-56 and a floxed neomycin (NEO) resistance cassette within an 
intronic region. We amplified and sequenced the region of exon 56 containing the codon 
of interest together with a fragment of the downstream intron. Three mutations were 
identified in exon 56 of S2808A mice (Figure 2.2): two of them were silent mutations in 




from encoding a serine to an alanine substitution. Thus, we confirmed that the genetic 
mutation is at the expected location within Ryr2 and that the surrounding exon encodes 
for the same amino acid sequence as the WT gene. The intron downstream of exon 56 
contains a short deletion within a non-complexity region (dominated by C and A) and an 
insertion from the targeting vector containing the remaining loxP site from the Cre-
mediated deletion of the NEO resistance cassette. 
2.2.2. Analysis of Cardiac Function and Structure After Myocardial Infarction 
We utilized a similar approach to that used by Wehrens et al.53 and Zhang et al.101 
to assess cardiac function after MI in S2808A mice. Animals were followed using 
echocardiography up to 4 weeks after the induction of myocardial infarction by ligation of 
the left anterior descending (LAD) coronary artery (Figure 2.1 C). During this period, 
survival was not statistically different (p = 0.298) between WT and S2808A mice (9 out of 
12 and 10 out of 11, respectively; Figure 2.1 D). Figure 2.3 and Table 2.1 summarize the 
echocardiographic parameters measured in WT and S2808A mice before, and one and 
four weeks after MI. Consistent with previous reports,13,101,131 we did not observe 
structural or functional differences between WT and S2808A mice at basal level. 
Following MI, both groups showed equivalent deteriorating cardiac function that involved 
a significant decrease in ejection fraction (Figure 2.3 A) and fractional shortening (Figure 
2.3 B), and an increase in LV diameter (Figure 2.3 C). The interventricular septum wall 
thickness (Figure 2.3 D) and stroke volume (Figure 2.3 E) remained unchanged in both 
groups. Once established, all deteriorating parameters remained unchanged up until 4 
weeks post-MI, with no significant difference between WT and S2808A. This indicates 




statistically higher in S2808A mice 4 weeks post-MI (WT 485±22 vs. S2808A 582±19 
bpm, p = 0.009; Figure 2.3 F). Interestingly, heart rate in S2808A mice appeared to be 
part of a continuum of processes that was uncovered by MI, because it tended to be 
higher at baseline (WT 476±21 vs. S2808A 539±13 bpm, p = 0.175) and reached 
statistical significance 1 week post-MI (WT 484±21 vs. S2808A 563±15 bpm, p = 0.047). 
Finally, cardiac output was not statistically different between WT and S2808A mice 4 
weeks post-MI (WT 18.2±1.9 vs. S2808A 23.0±2.1 mL/min, p = 0.337), likely reflecting 
variability in stroke volume (Figure 2.3 E).  
The structural observations described above were accompanied by a significant 
and comparable increase of heart weight for both groups (Figure 2.4 A). Also, both WT 
and S2808A mice had a similar, non-significant tendency toward increased lung weight 
after MI (Figure 2.4 B). Finally, liver weight was not significantly different at any time point 
(Figure 2.4 C). The overarching conclusion from this work is that preventing S2808 
phosphorylation does not impact the most salient cardiac parameters under basal 
conditions, nor does it affect their deterioration towards heart failure after MI. 
2.2.3. Expression and Phosphorylation of E-C Coupling Proteins 
The e-c coupling apparatus relies on a well-organized network of proteins that 
becomes disrupted during HF. Thus, we measured the abundance and phosphorylation 
of the major e-c coupling proteins using Western blots. The representative blots and 
summary plots are shown in Figure 2.5. We observed a similar, non-significant tendency 
for decreased RyR2 expression in both groups after MI (Figure 2.5 B). As expected, we 
did not observe phosphorylation of S2808 in mutant hearts. WT hearts, on the other hand, 




phosphorylation after MI (Figure 2.5 C). Among the other e-c coupling proteins studied, 
we only detected a significant increase in NCX expression after MI in both groups (Figure 
2.5 F), consistent with other models of HF. However, there were no differences between 
WT and S2808A in the abundance and phosphorylation of the proteins analyzed, 
suggesting both mice undergo similar remodeling of the e-c coupling apparatus after MI, 
and that S2808A does not prevent such changes.  
2.2.4. Cardiac Response to Adrenergic Stimulation 
To assess the response of S2808A mice to acute adrenergic stimulation, we used 
echocardiography and analyzed the cardiac function before and after i.p. injection of 2 
mg/kg Isoproterenol (Iso). Consistent with the data shown in Figure 2.3, there were no 
differences in the basal cardiac function between WT and S2808A mice. Following Iso 
injection, we observed a robust chronotropic and inotropic response in both groups (Table 
2.2), with a significant increase in HR (Figure 2.6 A), ejection fraction (EF; Figure 2.6 B), 
and fractional shortening (Figure 2.6 C). Interestingly, the stroke volume remained 
unchanged after Iso (Table 2.2). This was most likely due to insufficient ventricle refilling 
time, since we also observed a significant decrease of LV diameter and volume in diastole 
(Table 2.2). We did not observe differences between WT and S2808A mice injected with 
Iso. To complement these in vivo results, we used Langendorff perfusion of isolated 
hearts to assess the adrenergic response in the absence of neurohormonal and 
hemodynamic regulation (Table 2.3). Perfusion with 300 nM Iso produced a significant 
increase in HR (Figure 2.6 D), LV-developed pressure (LVDP; Figure 2.6 E), and dP/dt 




mice. Taken together, these data suggest that this phosphorylation site is not essential 
for the normal adrenergic response. 
2.2.5. Cellular Ca2+ Handling Kinetics 
Lastly, we measured the adrenergic response of isolated cardiac myocytes. We 
loaded the cells with fluo-4 and paced them at 1 Hz. When the Ca2+ transient amplitude 
was stable, 300 nM Iso was perfused for 1 minute, followed by a caffeine pulse to 
measure the SR Ca2+ load (Figure 2.7 A). As expected, Iso produced a significant 
increase in Ca2+ transient amplitude (Figure 2.7 B). This response, however, was identical 
in WT and S2808A cardiomyocytes. Additionally, we observed no differences in SR Ca2+ 
load (Figure 2.7 C) or in fractional release (percentage of SR Ca load released during 
pacing, Figure 2.7 D) between groups. These data are consistent with the isoproterenol 
stimulation observed in whole animals and isolated hearts, and further reinforce the notion 
that the S2808 phospho-site is not critical for adrenergic signaling. 
2.3. Discussion 
The notion that S2808 phosphorylation (1) is a marker of HF in humans and animal 
models,54 (2) is a critical mediator of the normal adrenergic response of the heart,53,55 and 
(3) that it greatly influences the progression and may actually exacerbate major signs of 
ischemic HF53 has been extensively documented by Marks et al. Since then, extensive 
research has focused on obtaining a better understanding of the underlying mechanisms. 
While the Marks group has produced elegant and comprehensive studies supporting their 
hypothesis53,55,56,134 and extended their central tenets to explain pathogenesis in some 
forms of Ca2+-dependent arrhythmias,22 muscular dystrophy,135 seizures,31 stress-




reproduce fundamental tenets of their model (reviewed in refs. 14,18,19) making this a 
highly controversial topic. One of the most remarkable aspects of this controversy is that 
RyR2-S2808A mice developed by the Marks laboratory show a blunted response to 
adrenergic stimulation53 and better outcomes after MI,55 while a different mouse model 
with the same mutation, generated independently by our laboratory, has a normal 
adrenergic response131 and normal progression to HF following TAC13 and MI.101 Beyond 
certain variations in the experimental approach followed by both groups, which have been 
addressed in previous studies, there are evident differences between both mouse 
models:13,53 (1) the targeting strategy utilized: Marks used a self-excising ACN vector 
(containing a NEO resistance cassette, Cre recombinase, and a testes-specific promoter, 
all flanked by loxP sites), while our laboratory employed the classic “floxed” NEO cassette 
approach, which requires breeding targeted mice with mice expressing Cre-recombinase 
to excise the cassette; (2) the embryonic stem cells targeted: Marks used MM13 cells 
from 129S/SvEv mice, we utilized R1 cells derived from (129X1/SvJx129S1/SvImJ)F1 
mice; and (3) the genetic background of the final mouse model: Marks backcrossed to 
the C57Bl/6 background for 10 generations, while we used a Sv129/C57Bl6 mixed 
background.  
Although the impact of the targeting strategies or embryonic stem cells on the final 
phenotypic outcome is difficult to assess, several instances support the idea that identical 
mutations expressed in mice of different strains may lead to diverse phenotypes.136,137 
Rubinstein et al.,138 for example, observed that C57Bl/6 mice with heterozygous Nav1.1 
deletion closely recapitulate the severe epileptic phenotype of human patients with Dravet 




phenotype. Moreover, mice with mixed genetic background have an intermediate 
phenotype. In a more dramatic example, mice with a mutant superoxide dismutase 
transgene on the mixed B6SJL background show abnormalities resembling human 
amyotrophic lateral sclerosis lesions that are not evident on the C57Bl/6 background.139 
Thus, the mouse strain can greatly alter the phenotype of a mutant mouse, likely because 
the targeted gene interacts substantially with background genes. Unfortunately, this sort 
of in-depth study has not been performed in the context of cardiac proteins. 
Some authors have suggested the variable beta-adrenergic response of the 
mouse strains used as a potential reason for divergent experimental results.140 Thus, in 
this study we aimed to determine whether the genetic background confers S2808A mice 
with a blunted adrenergic response and protection against HF. The experimental 
approach was straightforward: backcross the S2808A mice with mixed background 
(Sv129/C57Bl6) into a C57Bl/6 strain (the same strain used by the Marks Laboratory) and 
replicate several of the key experiments that have fueled this controversy. This approach 
allowed us to dissect a single variable (genetic background) that is potentially responsible 
for the conflicting results discussed above.  
Our initial mouse model has been characterized thoroughly and shared with 
several collaborators. Nevertheless, we performed gene sequencing of Ryr2 in the 
congenic mouse strain to validate the genetic integrity of the model. We identified a single 
missense mutation in exon 56, which introduces a serine to alanine substitution in codon 
2807 (S2807A). This codon corresponds to the human S2808. Classically, this site has 
been referred to as S2808 in the mouse nomenclature, but this changed when a revision 




continued using the same numbering to maintain consistency with previous literature and 
to avoid confusion. Also, both Benkusky et al.13 and Wehrens et al.53 reported targeting 
exon 55 of Ryr2 to generate their respective models. However, based on the most recent 
reference sequences available (accession numbers NM_023868.2 and NT_039578.8), 
this region corresponds to exon 56. Our sequenced amplicons align with this exon (Figure 
2.2) and show the missense mutation is at the expected codon, as discussed above. 
Following this genetic validation, we selected relevant experiments from previous 
reports to assess the response of our mice to acute and chronic stress (Iso injections and 
MI, respectively). If the genetic background were the cause of the conflicting results 
obtained with the two S2808A models, we expected (1) improved cardiac function after 
MI and (2) a blunted acute response to Iso, compared to WT. Each set of experiments 
produced the expected results in terms of the response to MI (LV dilation and deteriorating 
EF) and to adrenergic stimulation (positive chronotropism and inotropism), but S2808A 
mice behaved indistinguishably from WT controls. The only difference we detected was 
that S2808A mice showed a significant increase in HR compared to WT at one and four 
weeks post-MI. This observation was not reported by previous studies using our 
mouse,101 or by the Marks laboratory.7-53 We can only speculate about the potential 
mechanisms underlying this phenomenon: for example, chronic adrenergic stimulation of 
WT may reduce SR Ca2+ load in pacemaker cells and decrease HR due to decreased 
entrainment of Ca2+ signals and membrane potential;141 however, the absence of 
significant differences in cardiac output between genotypes after MI suggest that this 
increase in HR does not improve cardiac function and, therefore, is not protective against 




arrhythmias, potentially increasing — rather than decreasing — their vulnerability to MI. 
Still, the increase in HR after MI in S2808A mice is not logically derived from current 
models of RyR2 regulation by S2808 phosphorylation and remains to be understood; 
however, it appears from the multitude of other variables that are similar between the two 
groups (Table 2.1) that it does not affect the progression to HF.  
We also used Western blots to measure the expression of key e-c coupling before 
and after MI in both WT and S2808A hearts. There were no differences between WT and 
S2808A before or after MI in any of the proteins analyzed. Expression of RyR2 showed 
a tendency to be decreased 4 weeks after MI, but the difference did not reach statistical 
significance. The density of Cav1.2, SERCA2a, and PLB was unchanged after MI, 
whereas that of NCX increased by ~2.5-fold in both groups of mice. Hyperphosphorylation 
of S2808, a central process in the hypothetical model of Marks,53,54 had a modest trend 
to be increased in WT — but, again, the difference was not statistically significant. Lastly, 
phosphorylation of PLB-T17, a marker of CaMKII activation, trended to decrease but was 
not modified by MI. These observations agree with some — but not all — studies that 
report protein density after MI. There is considerable variability even in closely related 
models of HF. Hasenfuss130 and Houser et al.92 noted this variability in several reports 
from human HF. Nevertheless, our observations here agree with those of Zhang,101 who 
used our S2808A mice (in the Sv129/C57Bl6 background), suggesting that the transfer 
of the mutation to a different genetic background did not modify expression of other key 
proteins. More importantly, a side-by-side comparison of WT and S2808A mice shows 




c coupling before or after MI, as expected if the phospho-mutation had the profound 
changes in e-c coupling postulated by Marks.  
Concerning the physiologic response to acute stress, we also failed to detect 
differences between the two groups in mice in either isolated hearts or in isolated 
myocytes exposed to Iso. The lack of significant increase in stroke volume (SV) after 
adrenergic stimulation in both WT and S2808A mice was expected, considering that left 
ventricular volume at diastole (LVVd) and at systole (LVVs) were modified by 
Isoproterenol, since SV = LVVd–LVVs. However, fractional shortening (FS) and ejection 
fraction (EF), which directly reflect the inotropic response of the heart, were substantially 
increased by Isoproterenol in both groups (Table 2.2), thus indicating that the adrenergic 
response was fully installed in both groups of mice. Furthermore, the nearly-identical 
increase in LVDP in isolated hearts perfused with Iso (Table 2.3) supports the idea that 
both WT and S2808A mice show comparable response to acute stress. Again, these data 
are in agreement with all reports using our mouse model.101,131 Marks et al. previously 
proposed a dose-dependent effect of Iso, with only low doses (2 μg/kg) and 
concentrations (100 nM) producing blunted responses in S2808A mice. However, the 
idea of a dose-dependent effect on S2808 is not supported by previous reports that used 
a broad range of adrenergic agonist — as low as 10 nM Iso in isolated hearts131 and 
myocytes101 — and failed to observe differences in S2808A mice. In our whole-animal 
experiments we used 2 mg/kg Iso; for isolated-heart and cellular experiments we used 
300 nM Iso (a dose only 3-fold higher than that used by Shan et al.55) — yet there was 
no statistical difference between groups. All these data, taken together, argue against 




In summary, our data are in general agreement with all previous reports using our 
S2808A mice with mixed Sv129/C57Bl6 background. Therefore, the most logical 
conclusion is that the genetic background is not the cause of the conflicting results. This 
leaves the possibility open for other potential reasons, such as animal housing conditions 
and circadian rhythms, among others proposed by Dobrev & Wehrens.140 However, the 
studies using the mouse model generated in our laboratory include data obtained by four 
independent laboratories (ourselves,13 Houser,101,131 Niggli,133 and Gyorke132) located in 
five different academic institutions, which undermines the likelihood that animal housing, 
circadian rhythms, and animal handling are critical variables. Also, they have involved 
experiments at all integrating levels of physiology (in vivo, ex vivo, cellular, and molecular) 
and have encompassed a wide range of experimental approaches. The real causes of 
the discrepancy thus remain unsolved, but the complexity and variability of data that have 
become evident through this journey have prompted us to revise our current model of 
RyR2 regulation by phosphorylation. A deterministic model in which one site (S2808) 
controls the fight-or-flight response to stress and prevents ischemic cardiomyopathy, 
while another site (S2814) defines CaMKII-regulation of Ca2+ release and prevents non-
ischemic cardiomyopathy, appears now unsustainable and overly simplistic. Instead, it 
may be instructive to consider a more comprehensive model of RyR2 regulation that (1) 
includes all phospho-sites known to date (S2808, S2814 and S2030),18,61 (2) takes into 
account the interplay between these sites at baseline and under stress57,87 while 
acknowledging the great likelihood that other critical phospho-sites remain 
undiscovered,51 and (3) considers the effect of other post-translational modifications.18 




putative “phosphorylation hot spot” of RyR2,31 for example, strongly suggest that it is 
unlikely that these sites work independently. 
Finally, we consider that validation of experimental models by independent 
laboratories is paramount to resolving controversies. With this in mind, we make 
our S2808A mice, in either the mixed 129Sv/C57Bl6 or C57Bl/6 strains, available for 
distribution to all interested parties. 
2.4. Methods 
2.4.1. General Considerations 
All animal experiments were approved by the University of Michigan Institutional 
Animal Care and Use Committee. All experiments performed at institutional cores were 
single blind. Unless otherwise stated, all reagents were acquired from Sigma-Aldrich. 
2.4.2. Mouse Model 
The methods used to create the S2808A mouse model have been previously 
published.13 A congenic S2808A strain in the C57Bl/6 background was developed as 
follows (Figure 2.1): homozygous S2808A mice in a mixed Sv129/C57Bl6 background 
and with the floxed Neomycin resistance cassette were crossed with E2a-Cre transgenic 
mice (Jax Stock No. 003724). Heterozygous S2808A offspring with complete excision of 
the NEO resistance cassette were crossed with C57Bl/6J mice (Jax Stock No. 000664). 
S2808A offspring negative for the Cre recombinase were selected and backcrossed for 
6 additional generations with C57Bl/6J to create a mouse model with over 99% C57Bl/6 
genetic background.142 Backcrossing was conducted using a male C57Bl/6J and a female 




RyR2-S2808A colony was then maintained by breeding homozygotes. Age- and gender-
matched C57Bl/6J mice were used as WT controls. 
2.4.3. DNA Extraction, Sequencing and Genotyping 
DNA was extracted from tail biopsies using the GenElute Mammalian Genomic 
DNA MiniPrep kit (Sigma-Aldrich). Mouse genotyping was carried out with the following 
primers: 5’-GGTAGTCTGTTTCAGAAC-3’ and 5’-CTATATTCCCAAAGTTGGGT-3’, 
amplifying a region including part of Exon 56 and of the downstream intron. PCR products 
obtained during genotyping were purified using the QIAquick PCR Purification kit 
(Qiagen) and submitted to the Sequencing Core of the University of Michigan for direct 
Sanger sequencing, using the primers above. Sequences were compared, using 
Nucleotide BLAST143 to the region of the murine chromosome 13 containing the Ryr2 
(accession number NT_039578.8), as well as the corresponding mRNA (accession 
number NM_023868.2). In the current version of these sequences, the numbering of the 
amino acids in the translated mouse RyR2 protein (E9Q401) changed following the 
removal of the residue A2266; therefore, S2808 is now S2807. Here, we continued using 
the previous nomenclature, referring to this site as S2808 to avoid confusion. 
2.4.4. Myocardial Infarctions 
Myocardial Infarction (MI) surgeries using previously described methodologies144 
were performed by the Microsurgery Service of the Frankel Cardiovascular Center Animal 
Phenotyping Core at the University of Michigan. Briefly, 14–16-week-old mice were 
anesthetized using 1–5% isoflurane. A skin incision was made on the left side of the 
thorax, the pectoral muscle was retracted, and the third intercostal space was opened to 




approximately 2–3 mm from its origin. The thorax was closed immediately after ligation, 
followed by repositioning of the pectoral muscle and closing of the skin incision with 
surgical clips. Mice undergoing MI were evaluated with an echocardiogram one week 
prior to the surgery, and one and four weeks post-MI (Figure 2.1 B), and euthanized 
shortly thereafter (18-20 weeks of age). Hearts of control WT and S2808A mice were 
harvested at 18–20 weeks of age. 
2.4.5. Echocardiography 
Transthoracic echocardiography (Echo) was performed by the Echocardiography 
Service of the Frankel Cardiovascular Center Animal Phenotyping Core at the University 
of Michigan using a Vevo 2100 system with a 22–55 MHz transducer (MS550D; Visual 
Sonics), as described previously.89,145 Mice were anesthetized with 1–5% isoflurane and 
maintained on a heated platform. Two-dimensionally guided M-mode images of the left 
ventricle were acquired at the tip of the papillary muscles. Left ventricle diameter, septum 
wall and posterior wall thickness were recorded to determine the fractional shortening, LV 
volume, ejection fraction, and heart rate. To measure the adrenergic response, 
echocardiograms were performed in a different group of mice at basal conditions and 1 
min after a 2 mg/kg Iso IP injection, as previously described.131,146 All parameters were 
measured over at least three consecutive cycles. 
2.4.6. Tissue Homogenization 
Whole heart homogenates were prepared as previously described.13 Briefly, frozen 
hearts were pulverized in liquid nitrogen, suspended in homogenization buffer (0.9% 
NaCl, Tris-HCl 10 mM pH 6.8, 20 mM NaF, 2 µM leupeptin, 100 µM 




using a Teflon pestle, and centrifuged at 1000 x g for 10 minutes at 4 °C. Supernatants 
were aliquoted and stored at -80 °C until used. Protein concentrations were determined 
using the Bradford method (Bio-Rad).  
2.4.7. Western Blotting 
50 µg of tissue homogenate were suspended in Laemmlii buffer and separated by 
SDS-PAGE in 4-20% TGX or AnyKD precast gels (Bio-Rad). Proteins were then 
transferred to PVDF membranes using the iblot2 transfer system (ThermoFisher) or 
overnight wet transfer. Membranes were probed with the following primary antibodies: 
anti-RyR (1:2000; MA3-925, Thermo), pS2808-RyR (1:5000; A010-30, Badrilla), SERCA 
(1:1000; ab2861, Abcam), NCX (1:200; ab6495, Abcam), PLB (1:5000; A010-14, 
Badrilla), pS16-PLB (1:5000; A010-12, Badrilla), pT17-PLB (1:5000; A010-13, Badrilla), 
Cav1.2 (1:200; ACC-003, Alomone), anti-GAPDH (1:10000; MAB374, Millipore). 
Secondary antibodies, used as appropriate, were goat anti-mouse-HRP (1:1000; 31437, 
Thermo) or goat anti-rabbit-HRP (1:2000; 31463, Thermo). Membranes were developed 
using SuperSignal Femto ECL reagent (Thermo) and imaged with a ChemiDoc MP 
apparatus (Bio-Rad). Band intensity was quantified with the ImageLab software(Bio-Rad). 
2.4.8. Langendorff Perfusions 
Perfusion of isolated hearts was performed as previously reported.87,131 Mouse 
hearts were harvested and mounted on a Langendorff apparatus as indicated in section 
2.4.9, and perfused with Krebs-Henseleit Buffer (KHB) containing (mM) 118.5 NaCl, 4.7 
KCl, 1.2 KH2PO4, 1.2 MgSO4, 11 glucose, 25 NaHCO3, 1.8 CaCl2, aerated with 95% O2, 
5% CO2. The perfusion pressure was adjusted to 70–100 mmHg. A pressure-transducer 




6–15 mmHg. Following a baseline recording of 5 min, hearts were stimulated with 300 
nM Iso to record the adrenergic response for an additional 5 min. All parameters were 
acquired using a PowerLab 8/35 system (ADInstruments) and data were analyzed using 
LabChart 8 (ADInstruments). 
2.4.9. Isolation of Ventricular Myocytes 
Ventricular myocytes were isolated as previously described.89 Briefly, mice were 
heparinized (0.5 U/g IP, Sagent Pharmaceuticals) and anesthetized with urethane 
(1mg/kg IP). The heart was quickly excised, mounted on a Langendorff apparatus, and 
perfused with Perfusion Buffer (PB) containing (mM) 113 NaCl, 4.7 KCl, 1.2 MgSO4-
7H2O, 10 HEPES, 0.6 Na2HPO4, 12 NaHCO3, 0.6 KH2PO4, 10 KHCO3, 30 Taurine, 
500mM 2,3-Butanedione monoxime, 5.5 glucose, pH 7.46 at 37 ºC and 3 mL/min. The 
heart was then perfused with PB supplemented with 773.48 U/ml Collagenase Type II 
(Worthington), 0.14 mg/ml Trypsin (Gibco) and 12.5 µM CaCl2. Once fully digested (5–7 
min), the ventricles were minced in PB buffer containing with 10% FBS and 12.5 µM 
CaCl2. Tissue pieces were gently pipetted to dissociate cells. Ca2+ was reintroduced to 
1.8 mM step-by-step and cells were kept in Tyrode’s solution containing (mM) 135 NaCl, 
4 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, 1.2 NaH2PO4, and 10 glucose, pH 7.40, until used. 
2.4.10. Confocal Ca2+ Imaging.  
Ca2+ transients triggered by field stimulation were recorded from cardiac myocytes 
as previously described.89 Cells were incubated in 10 μM fluo-4 AM (ThermoFisher) with 
0.4% Pluronic F-127 (ThermoFisher) at 37 ºC for 5 min. Cells were then washed and kept 
in fresh Tyrode’s solution. Longitudinal line-scan images were recorded using a LSM510 




3.072 ms/line. Fluorescence was excited at 488 nm and recorded at >505 nm. Myocytes 
were first perfused with Tyrode’s solution and paced at 1 Hz using a Grass Stimulator. 
When a stable response was established, cells were perfused with Tyrode’s solution 
containing 300 nM Iso for 1 min. Finally, 20 mM caffeine was applied to measure the SR 
Ca2+ load. The last five Ca2+ transients under basal conditions and with Iso were averaged 
for each cell. The fractional release was calculated as a percentage of the SR Ca2+ load 
released during field stimulation.  
2.4.11. Statistical Analysis 
All data are presented as mean±SEM. Statistical significance was determined at p 
≤ 0.05 using survival logrank (survival rates), paired t-test (Echos pre- vs. post-MI, Echos 
pre- vs. post-Iso, Ca2+ transients basal vs. Iso, Langendorff perfusions vs. t = 0 of same 
genotype), one-tailed t-test (Ca2+ transients, Langendorff perfusions between genotypes 
at each time-point), or one-way ANOVA (all other comparisons). Analyses were carried 
out in SigmaPlot 12.5 (Systat Software). 
2.5. Acknowledgements 
This chapter previously published: Alvarado FJ, Chen X, Valdivia HH. Ablation of 
the cardiac ryanodine receptor phospho-site Ser2808 does not alter the adrenergic 
response or the progression to heart failure in mice. Elimination of the genetic background 








Figure 2.1. Experimental Model to Assess HF Progression in S2808A Mice.  
A. Backcrossing scheme used to produce a congenic mouse strain derived from the RyR2-S2808A mouse 
developed in our laboratory. B. Direct sequencing of a portion of exon 55 confirms the presence of the 
missense mutation in codon 2808 leading to the serine to alanine substitution. Two silent mutations are 
located in codons 2804 and 2805. C. General scheme used to assess cardiac function in mice undergoing 
myocardial infarction. In this model, each mouse acts as its own control at basal conditions. D. Kaplan-
Meier plot of survival after MI induction. Survival was slightly higher in S2808A than in WT controls, but this 






Figure 2.2. Direct Sequencing of the Region Ryr2 Containing S2808.  
Alignment of the murine chromosome 13 region containing Ryr2 (accession number NT_039578.8) and the 
sequence of the amplicon obtained from S2808A mice (SeqPCR). Ryr2 is in the opposite DNA strand to 
that contained in NT_039578.8, therefore the inverted, complementary sequence is shown as reference 
template (RefTemp). Exon 56 contains 2 silent mutations and a missense mutation corresponding to the S 
to A substitution at codon 2808. The downstream intron contains a short deletion within a non-complexity 
region and the remnant of the targeting vector containing a single loxP site from the Cre-mediated deletion 





Figure 2.3. Cardiac Function Post-MI in S2808A Mice.  
MI due to permanent LAD ligation produced a significant decrease in ejection fraction (A) and fractional 
shortening (B), and an increase in LV diameter in diastole (C). Septum wall thickness in diastole (D) and 
stroke volume (E) remained unaltered. Most parameters, measured at one and four weeks after MI, were 
comparable between S2808A and WT mice, except for heart rate (F) (n = 9 per genotype; * p < 0.05, ** p 
< 0.01 vs. same genotype basal; # p < 0.05, ## p < 0.01 vs. WT at same time-point). 
 
 
Figure 2.4. Tissue Remodeling post-MI in S2808A Mice.  
Heart weight (A), lung weight (B) and liver weight (C) as a percentage of body weight in control mice and 
4 weeks after LAD ligation. Only the heart weight was increased in both groups after MI (n = 7-9 per 






Figure 2.5. E-C Coupling Protein Expression and Phosphorylation in S2808A Hearts.  
A. Representative blots. B. Expression of RyR2 has a tendency to be decreased 4 weeks after MI. C. 
Phosphorylation level of RyR2-S2808 determined as a ratio between phosphorylated and total protein. 
Phosphorylation was absent in S2808A mice, and has a tendency to be increased in wild-type animals. D-
G. Expression level of excitation-contraction coupling proteins Cav1.2, SERCA2a, NCX and PLB. 
Expression of NCX was nearly 2.5-fold increased after MI. H. Phosphorylation level of PLB determined as 
described above (n = 6-8 per genotype per group; * p < 0.05, ** p < 0.01 vs. same genotype control; ^ 








Figure 2.6. Cardiac Response to Adrenergic Stimulation in S2808A Mice and Isolated Hearts.  
A-C. IP injection of isoproterenol (2 mg/kg) in anesthetized mice produces a significant increase in cardiac 
function, including heart rate (A), ejection fraction (B) and fractional shortening (C) (n = 6 per genotype; * 
p < 0.05, ** p < 0.01 vs. same genotype basal). D-E. Langendorff-perfused hearts stimulated with 300 nM 
Iso show a significant increase in heart rate (D), LV-developed pressure (LVPD, E) and dP/dt (F) (n = 5 per 







Figure 2.7. Ca2+ Transients and SR Ca2+ Load in S2808A Cardiomyocytes.  
A. Representative traces of field stimulation-triggered Ca2+ transients. After obtaining a stable basal 
response, Iso 300 nM was perfused for 1 min, followed by a pulse of 20 mM caffeine to measure the SR 
Ca2+ load. B. Quantification of Ca2+ transient amplitude at basal conditions and with Iso stimulation. Both 
groups showed a significant response to Iso. C-D. Quantification of the SR Ca2+ load and fractional release 
(Ca2+ transient amplitude/SR Ca2+ load) under Iso stimulation. (N = 2 WT, 3 S2808A; n = 16 cells per 






Table 2.1. Echocardiographic Parameters to Assess HF Progression in S2808A Mice.  
Structural and functional parameters measured in WT and S2808A mice at basal level and after induction 
of a myocardial infarction. 
 Basal 1 week Post-MI 4 weeks Post-MI 
 WT S2808A WT S2808A WT S2808A 
n 9 9 9 9 9 9 
BW (g) 22.3±0.7 24.6±1.2 22.2±1.0 24.4±1.4 23±1.2 25.3±1.5 
HR (bpm) 476±21 539±13 484±21 563±15 # 485±23 582±19 ## 
IVSd (mm) 0.73±0.04 0.73±0.04 0.71±0.06 0.66±0.05 0.75±0.05 0.75±0.05 
IVSs (mm) 1.05±0.06 1.06±0.06 0.94±0.07 0.93±0.09 1.02±0.07 1.05±0.05 
IVSth (%) 44.3±4.3 44.3±4.2 34.8±6.0 40.2±5.8 36.5±4.1 41.6±6.3 
PWd (mm) 0.76±0.04 0.75±0.04 0.67±0.04 0.62±0.06 0.73±0.04 0.75±0.07 
PWs (mm) 1.06±0.04 1.08±0.05 0.86±0.07 0.77±0.08 * 0.96±0.05 0.96±0.07 
PWth (%) 42.3±5.8 46.4±4.7 28.2±6.8 24.0±5.1 * 31.9±3.5 29.8±6.3 
LVDd (mm) 3.92±0.09 3.82±0.10 4.78±0.24 * 4.68±0.31 * 5.21±0.2 ** 5.21±0.29 ** 





FS (%) 27.0±2.9 25.2±1.5 14.9±2.0 * 13.9±2.0 ** 14.9±2.2 * 17.1±2.1 * 





LVVs (uL) 32.7±4.2 31.8±2.8 71.1±13.7 * 78.7±14.8 * 93.7±12.8 ** 
92.2±16.8 
** 
EF (%) 52.3±4.5 50.2±2.4 31.1±3.8 * 29.3±3.9 ** 30.8±4.1 ** 35.0±3.8 * 
SV (uL) 34.4±2.5 31.5±1.9 33.7±3.4 28.2±3.2 38.5±4.8 39.6±3.4 
CO 
(mL/min) 16.5±1.5 16.9±0.9 15.8±1.1 15.8±1.7 18.2±1.9 23.0±2.1 
LVmass 
(% of BW) 0.47±0.04 0.40±0.03 0.59±0.04 * 0.47±0.03 0.72±0.04 * 
0.65±0.06 
** 
BW: body weight; HR: heart rate; IVSd: interventricular septum thickness in diastole; IVSs: interventricular 
septum thickness in systole; IVSth: percent change in IVS between systole and diastole; PWd: posterior 
wall thickness in diastole; PWs: posterior wall thickness in systole; PWth: percent change in PW between 
systole and diastole; LVDd: left ventricle diameter in diastole; LVDs: left ventricle diameter in systole; FS: 
fractional shortening; LVVd: left ventricle volume in diastole; LVVs: left ventricle volume in systole; EF: 
ejection fraction; SV: stroke volume; CO: cardiac output; LVmass: left ventricle mass. 
*: p < 0.05, **: p < 0.01 vs. same genotype basal, paired t-test. 





Table 2.2. Echocardiographic Parameters to Assess the Adrenergic Response in S2808A Mice.  
Structural and functional parameters measured in WT and S2808A mice at basal level and after IP injection 
of 2 mg/kg of Iso. 
 Basal Iso 2 mg/kg 
 WT S2808A WT S2808A 
n 6 6 6 6 
BW (g) 24.0±1.8 25.8±1.6 - - 
HR (bpm) 504±18 542±14 572±13 * 584±10 * 
IVSd (mm) 0.81±0.04 0.78±0.03 0.99±0.05 ** 0.94±0.03 ** 
IVSs (mm) 1.20±0.04 1.16±0.05 1.60±0.05 ** 1.51±0.04 ** 
IVSth (%) 47.3±2.5 49.7±1.6 61.9±5.0 * 60.5±3.1 * 
PWd (mm) 0.83±0.02 0.85±0.05 0.95±0.03 ** 0.92±0.03 
PWs (mm) 1.12±0.03 1.14±0.07 1.47±0.07 ** 1.49±0.04 * 
PWth (%) 36.0±2.8 35.0±4.0 54.3±7.4 * 63.0±6.9 ** 
LVDd (mm) 3.77±0.10 3.86±0.09 3.00±0.10 ** 3.09±0.15 ** 
LVDs (mm) 2.71±0.11 2.86±0.11 1.43±0.05 ** 1.46±0.13 ** 
FS (%) 28.2±1.1 26.1±2.2 52.2±1.8 ** 53.1±2.4 ** 
LVVd (uL) 61.3±3.8 64.9±3.5 35.3±2.8 ** 38.4±4.9 ** 
LVVs (uL) 27.7±2.7 31.6±3.0 5.4±0.4 ** 6.1±1.5 ** 
EF (%) 55.2±1.8 51.5±3.5 84.5±1.4 ** 84.9±2.0 ** 
SV (uL) 33.5±1.2 33.3±2.7 29.9±2.7 32.4±3.6 
CO (mL/min) 16.9±0.9 18.0±1.5 17.3±1.9 19.0±2.3 
BW: body weight; HR: heart rate; IVSd: interventricular septum thickness in diastole; IVSs: 
interventricular septum thickness in systole; IVSth: percent change in IVS between systole and diastole; 
PWd: posterior wall thickness in diastole; PWs: posterior wall thickness in systole; PWth: percent 
change in PW between systole and diastole; LVDd: left ventricle diameter in diastole; LVDs: left 
ventricle diameter in systole; FS: fractional shortening; LVVd: left ventricle volume in diastole; LVVs: 
left ventricle volume in systole; EF: ejection fraction; SV: stroke volume; CO: cardiac output. 






Table 2.3. Cardiac Function Parameters in Langendorff-perfused S2808A Hearts.  
Functional parameters measured in isolated WT and S2808A hearts perfused in a Langendorff apparatus 
and stimulated with Iso 300 nM 
 Basal (t = 0) Iso 300 nM (t = 20 s) 
 WT S2808A WT S2808A 
n 6 6 6 6 
HR (bpm) 400±21 393±18 527±18** 539±20** 
ΔHR (%) - - 33.2±7.3 38.7±7.3 
LVDP (mmHg) 70.7±3.7 73.3±6.4 106.1±9.7** 121.3±17.2* 
ΔLVDP (%) - - 49.9±10.8 63.0±13.3 
+dP/dt (mmHg/s) 3485±154 3862±298 7261±640** 8196±1220** 
Δ+dP/dt (%) - - 106.5±10.5 108.9±23.2 
-dp/dt (mmHg/s) -2258±172 -2425±290 -4841±421** -4679±730* 
Δ-dP/dt (%) - - 113.6±7.6 100.1±27.2 
HR: heart rate; LVDP: left ventricle developed pressure (LV pressure max–end-diastolic pressure). 
*: p < 0.05, **: p < 0.01 vs. same genotype basal, paired t-test 
 
Table 2.4. Ca2+ Handling Parameters to Assess Adrenergic Response in isolated S2808A myocytes.  
Ca2+ transient amplitude and SR Ca2+ load measured in basal conditions and with 300 nM Iso stimulation. 
 WT S2808A 
Cells (n) 16 16 
Mice (N) 2 3 
[Ca2+]i transient amplitude 
basal (ΔF/F0) 3.72±0.29 3.47±0.29 
[Ca2+]i transient amplitude 
300 nM Iso (ΔF/F0) 7.45±0.31** 6.84±0.33** 
SR Ca2+ Load (ΔF/F0) 8.84±0.31 8.30±0.40 
Fractional release (%) 84.33±2.01 82.65±1.70 





CHAPTER 3  




Ryanodine Receptors (RyRs) are the largest ion channels known to date. RyR2, 
the cardiac isoform, releases Ca2+ from the sarcoplasmic reticulum (SR) after being 
activated by a small inward Ca2+ current (ICaL) mediated by L-type Ca2+ channels (LTCC). 
This is the underlying mechanism of excitation-contraction (e-c) coupling, the process that 
transduces action potentials into mechanical contraction in the heart. Ca2+ released from 
the SR via RyR2 binds to the myofilaments producing contraction. Relaxation is achieved 
when Ca2+ is re-sequestered into the SR through the SR Ca2+ pump (SERCA2a) or 
extruded out of the cell through the electrogenic Na+/Ca2+ exchanger (NCX).3  
Altered expression and function of many of these proteins have been observed in 
different forms of human heart disease.99,129 Increased expression of NCX and decreased 
expression of SERCA2a, for example, promote depletion of the Ca2+ stored in the SR 
during heart failure (HF).95 This, in turn, is associated with contractile dysfunction. 
Moreover, bursts of sympathetic activity due to physical and emotional stress can lead to 
SR overload and spontaneous Ca2+ release.97,147 Ca2+ is then extruded from the cell by 
NCX, depolarizing the cell and potentially leading to spontaneous APs during diastole 




because studies do not agree on whether its regulation by phosphorylation is important 
for the onset and progression of HF.58 Nevertheless, there is consensus that RyR2 
phosphorylation at S2814 by CaMKII increases SR Ca2+ leak and this can be pathogenic. 
Interestingly, several reports in the literature also indicate that expression of RyR2 is 
decreased in some forms of human heart disease,92,99,100,129,130 and in animal models of 
HF.121,148,149  
What is the contribution of decreased RyR2 expression to the pathology of heart 
disease? To date, there is no clear answer to this question due to the simple fact that no 
studies have addressed it thoroughly. Nevertheless, there is solid experimental support 
for the idea that RyR2 dysfunction due to specific mutations is deleterious to cardiac 
function. Gain-of-function RyR2 mutations are the culprits in catecholaminergic 
polymorphic ventricular tachycardia (CPVT), a severe inherited arrhythmia in which Ca2+ 
handling dysfunction is the underlying mechanism. On the other side of the spectrum, a 
loss-of-function RyR2 mutation recently characterized by our laboratory also produces 
Ca2+ mishandling and arrhythmia in mice.89 Therefore, RyR2 regulation in a cardiac 
myocyte requires a fine balance in which too much or too little RyR2 activity is deleterious. 
Interestingly, two studies reporting a constitutive decrease of RyR2 expression in mice — 
presumably leading to loss of RyR2 function — did not report harmful phenotypes.120,121 
Conditional knockout of RyR2 (cRyR2-KO) in adult mice, on the other hand, produces 
malignant ventricular arrhythmias and eventually death,150 while heterozygous cRyR2-
KO decreases glucose metabolism without grossly affecting cardiac function.151 These 
data suggest that RyR2 deficiency can be compensated in the heart without evident 




have been performed using a mouse model. However, cardiac e-c coupling is 
considerably different between mouse and human, with the SR contributing 90% and 70% 
of the total Ca2+ required for contraction, respectively.3 
In this study, we used a constitutive RyR2-KO rabbit model to determine the 
cardiac effects of decreased RyR2 channel expression. Using a rabbit model gives the 
important advantage of a species with cardiac physiology closer to human. We observed 
that homozygous RyR2 deletion in rabbits is embryonic lethal, as is the case in mice. 
Heterozygotes, on the other hand, show RyR2 haploinsufficiency without an overt 
phenotype. Further study of these animals allowed for the dissection of the mechanisms 
that compensate for the lower RyR2 expression. We found that when RyR2 expression 
is significantly decreased, channel activity is likely upregulated by reducing the basal 
phosphorylation of the S2031 site, which is mediated by increased association of RyR2 
with PP2A. Therefore, upregulation of channel function may offset the effect of lower 
expression of the protein. These results suggest that a decrease in RyR2 expression 
observed in different forms of heart disease is not likely pathogenic in and of itself. Most 
importantly, these data provide novel insights into the regulatory mechanisms of RyR2 
via phosphorylation of S2031. This poorly-studied site is often ignored in models of RyR2 
regulation; however, these data should prompt the development of more comprehensive 
models of RyR2 regulation involving all phosphorylation sites known to date and the 







3.2.1. Genetic Characterization of RyR2-KO Rabbits.  
For this work, we took advantage of an RyR2-KO rabbit model generated by 
Center for Advances Models and Translational sciences and Therapeutics (CAMTraST) 
at the University of Michigan.152 The model was developed using Crispr/Cas9 
endonuclease genome editing and contains a 16 bp deletion in exon 49. This KO allele 
encodes a normal RyR2 sequence until residue 2462, after which there are 34 scrambled 
amino acids followed by a termination codon (Figure 3.1 A, Figure 3.2). Several more 
termination codons appear downstream of this position (not shown). Since the PFD of the 
channel is located at the C-terminal end of the protein (residues 4486–4469), the mutant 
allele does not encode functional channels. Figure 3.1 B shows the offspring distribution 
obtained from mating heterozygous RyR2-KO rabbits. We have not detected 
homozygotes (χ2 = 39.96, p = 2.4x10-6, n = 118 kits), suggesting that complete lack of 
RyR2 is embryonic lethal. These data are consistent with previous studies using mice.153 
Hence, for all the experiments discussed in the following sections, we took advantage of 
the heterozygous RyR2-KO rabbits (Het), which we obtained in the expected Mendelian 
ratio.  
3.2.2. Assessment of RyR2 Expression and Phosphorylation 
The KO allele encodes a product of 2496 amino acids. This protein, which is unable 
to assemble functional channels, could associate with and destabilize channels properly 
assembled from the WT allele. We used Western blots (WB) to determine whether the 
KO allele was being translated into protein. The commercial antibody used for the RyR 




in the full-length but not the truncated RyR2. This antibody also reacts with th eother RyR 
isforms, RyR1 and RyR3. Hence, we took advantage of the S2031 phosphorylation site, 
present in both WT and KO proteins (Figure 3.3 A), to determine the fate of the product 
of the KO allele. Since the phosphorylation level of S2031 (pS2031) is low at basal 
conditions, we used an antibody that recognizes only the dephosphorylated (dpS2031) 
site. As shown in Figure 3.3 A, only a single band was detected with this antibody at the 
size of the full-length RyR2 (~500 kDa). This indicates that the product of the KO allele is 
probably absent in Het hearts likely because of premature degradation or because the 
mutant allele in silent. 
We observed a nearly 60% decrease in RyR expression in Het hearts, using RT-
PCR to measure RYR2 gene transcript level (WT 100.0±7.9% vs. Het 43.0±7.1%, p = 
0.0014; Figure 3.3 B) and WBs to detect total protein (WT 100.0±11.6% vs. Het 
38.6±6.8%, p = 0.0011; Figure 3.3 C). These data show that Het rabbits have RyR2 
haploinsufficiency. The close agreement between gene (RYR2) and protein (RyR) 
expression suggests that the KO allele is silenced and that other RyR isoforms do not 
compensate for RyR2 deficiency in Het KO hearts. Remarkably, the RyR2 level is well 
below the expected 50%, suggesting that a single functional allele is insufficient to provide 
half of the expected protein expression. Since phosphorylation is the best known post-
translational modification of RyR2, we also measured the phosphorylation level of the 
three characterized sites in RyR2 as a ratio of the level of phosphorylation to the total 
RyR2 expression. While pS2809 (Figure 3.3 F) and pS2815 (Figure 3.3 G) were not 
altered, we observed a 52% increase in the dpS2031 level (WT 100.0±8.3% vs. Het 




section 1.4.3), making it difficult to detect using a phospho-specific antibody; however, 
prolonged incubation with the antibody allowed us to quantify a ~60% decrease in basal 
phosphorylation (WT 100.0±22.4% vs. Het 39.8±13.9%, p = 0.045; Figure 3.3 E). 
Although the signal to noise ratio of this blot is low, it agrees with the dephosphorylation 
level of the residue. These data indicate that the phosphorylation of RyR2 is 
downregulated in Het KO hearts. This could be a possible compensatory mechanism for 
RyR2 deficiency.  
3.2.3. Cardiac Structure and Function 
Next, we tested whether Het rabbits develop a structural or functional cardiac 
phenotype because of the lower RyR2 expression. Macroscopically, there were no 
evident differences in the size and morphology of Het hearts (Figure 3.4 A, upper panel). 
Also, histological staining of left atrium and left ventricle (LV) sections of Het hearts did 
not show significant alterations in the microarchitecture of the cardiac tissue nor evidence 
of fibrosis, and display normal myocyte size and arrangement (Figure 3.4 A, middle and 
lower panels). M-Mode echocardiography in anesthetized rabbits showed no significant 
differences in functional parameters such as fractional shortening (FS; Figure 3.4 B) and 
ejection fraction (EF; Figure 3.4 C), or in structural parameters including posterior wall 
(Figure 3.4 D) and septal wall thicknesses (Figure 3.4 E). The heart rate (HR; Figure 3.4 
F) and LV mass (Figure 3.4 G) were also not altered. A more detailed analysis of 
additional echocardiographic parameters is shown in Table 3.1. Interestingly, we only 
observed a decreased septal wall thickness in Het rabbits. This change, which could 
indicate mild systolic dysfunction, also leads to a non-significant tendency toward lower 




observed normal EF, SV, and cardiac output (CO), we conclude that the overall cardiac 
function in Het rabbits is normal. Overall, these data suggest that both basal structure 
and function of the heart are preserved, even in rabbits with RyR2 deficiency. These data 
suggest that there is a considerable amount of non-essential RyR2 expressed in normal 
hearts and that cellular and sub-cellular compensatory mechanisms might be triggered to 
prevent the development of a whole-organ functional phenotype.  
3.2.4. Expression of E-C Coupling Proteins 
One possible compensatory mechanism could involve changes in the expression 
of proteins that participate in e-c coupling. These proteins contribute to Ca2+ handling 
during the cardiac cycle and functionally couple with RyR2 to produce the whole-cell Ca2+ 
transient required for contraction. We observed no differences in the expression of Cav1.2 
(pore-forming subunit of LTCC; Figure 3.5 B), NCX (Figure 3.5 C), or SERCA2a (Figure 
3.5 D) in Het KO rabbit hearts compared to WT. The expression of phospholamban (PLB), 
an inhibitor of SERCA2a, was also unchanged (Figure 3.5 E). Finally, no changes were 
observed in the phosphorylation level of PLB (Figure 3.5 F-G). These data suggest that 
Het hearts do not show significant changes in the expression or function of major Ca2+-
handling proteins other than RyR2. Furthermore, the unchanged phosphorylation level of 
PLB suggests that the basal adrenergic tone of Het rabbits is not significantly different 
than that of WTs. 
3.2.5. Assessment of RyR2 Activity 
As mentioned before, the assumption that lower RyR2 expression necessarily 
means lower RyR2 function could prompt a hypothesis suggesting that RyR2 deficiency 




we used [3H]ryanodine binding experiments to assess RyR2 activity in LV homogenates. 
The raw [3H]ryanodine binding was ~34% decreased in Het samples (WT 28.91±2.99 
fmol/mg of total protein vs. Het 19.14±2.02 fmol/mg of total protein, p = 0.0211; Figure 
3.6 A), as expected from the lower RyR2 expression. Remarkably, there is an evident 
discrepancy between the RyR2 expression level (~40% of WT) and the [3H]ryanodine 
binding (~66% of WT) in heterozygous hearts. We found that maximum [3H]ryanodine 
binding normalized to RyR2 density has a ~2-fold increase in Het samples (WT 
29.58±2.28 fmol/mg of total protein vs. Het 56.45±8.34 fmol/mg of total protein, p = 0.018; 
Figure 3.6 B). This suggests that, although RyR2 is less abundant, the activity of the 
remaining channels is increased in Het hearts. Interestingly, the corrected [3H]ryanodine 
binding had a significant linear relationship with dephospho-S2031 level (Figure 3.6 C), 
suggesting that phosphorylation of this site correlates with channel activity. Finally, we 
observed no change in RyR2 sensitivity to Ca2+, as shown by the superimposable curves 
normalized to 10 μM [Ca2+] (EC50: WT 1.05±0.03 μM vs. Het 1.05±0.09 μM, p = 0.95; 
Figure 3.6 D). Hence, RyR2 channels from Het rabbits have higher maximum response 
to activating [Ca2+] without a change in affinity. 
3.2.6. Association of RyR2 with Protein Phosphatases 
Two phosphatases are known to associate with RyR2: PP1 and PP2A.40 Recently, 
the binding of both enzymes to RyR2 channels from a transgenic rabbit model of long QT 
syndrome 2 (LQTS2) was found to be increased, thereby affecting the phosphorylation 
level of the channel.156,157 To gain a better understanding of the mechanisms underlying 
the lower phosphorylation level of S2031, we used WBs and co-immunoprecipitations to 




level of RyR2-bound phosphatases. The total expression of both PP1 and PP2A was not 
different between WT and Het rabbits (Figure 3.7 B-C); however, immunoprecipitated 
RyR2 channels had higher PP2A content than WT (WT 100.0±9.5% vs. Het 134.2±9.9% 
of WT, p = 0.03; Figure 3.7 D). In contrast to previous reports,157 we detected no PP1 
associated with RyR2 (Figure 3.7 A). Therefore, it is likely that PP2A is responsible for 
maintaining S2031 at a lower phosphorylation level in Het hearts and causing the 
channels to be more active. 
3.2.7. Adrenergic Response of Isolated Hearts 
To determine whether RyR2 haploinsufficiency affects the adrenergic response of 
the rabbit hearts, we used echocardiograms during IV infusion of 0.5 μg/kg/min Iso. To 
ensure a stable response, measurements were taken after 15 min of continuous IV 
infusion. In basal conditions, we did not observe significant differences between Het and 
WT rabbits in any of the parameters measured. As expected, we detected a significant 
increase in HR (Figure 3.8 A), EF (Figure 3.8 B), and FS (Figure 3.8 C) after Iso — all 
indicators of a strong inotropic and chronotropic response (Table 3.3). However, there 
was no difference between the response of WT and Het rabbits, suggesting that the latter 
have preserved adrenergic function in vivo. Furthermore, the basal difference we 
observed in septal wall thickness during diastole in Het rabbits (see section 3.2.3) was 
not evident during Iso. Moreover, the percent change in septal thickness between systole 
and diastole was significantly increased in Het rabbits after Iso compared to basal 





To complement these results and to remove neurohormonal and hemodynamic 
regulation of the heart — autonomous nervous system and preload, respectively — we 
used Langendorff perfusions of isolated hearts. After stabilization of the baseline 
recording at a constant maximum LV-developed pressure (LVDP), the hearts were 
perfused with 100 nM Iso. Both groups showed a rapid and significant increase in HR 
(Figure 3.8 D) and LVDP (Figure 3.8 E) with Iso stimulation. HR remained elevated 
throughout the experiment, while LVDP peaked within 10 seconds of the onset of the Iso 
response and stabilized at a lower value that was still significantly higher than baseline 
LVDP. Overall, the response to Iso was comparable between groups (Table 3.3), 
suggesting that RyR2 deficiency does not grossly impair the adrenergic response of the 
heart. Nevertheless, there is an overall non-significant tendency for decreased LVDP (the 
difference was only significant at two time-points). Furthermore, the velocity of contraction 
and relaxation (dP/dt; Figure 3.8 F, Table 3.3) was significantly lower in Het hearts at the 
onset of the Iso response, with the lower contraction velocity manifesting at several time-
points. These data indicate that, although LVDP is preserved, pressure development is 
slower in Het hearts perhaps due to a slower Ca2+ release or to a change in the Ca2+ 
affinity of the myofilaments. Also, the comparable baseline and Iso-stimulated LVDPs 
between Het and WT isolated hearts suggest that two possible compensatory 
mechanisms for RyR2 haploinsufficiency present in whole animals but not isolated hearts 
— (1) an increased basal adrenergic tone that normalizes contractility and (2) increased 
end-diastolic filling that normalizes contractile force in Het hearts via a Starling effect — 
are not likely responsible for normalizing cardiac function in Het rabbits. Lastly, the lack 




isolated hearts suggests that RyR2 haploinsufficiency may not affect the Ca2+-mediated 
component of the coupled clock regulating automaticity in the sinus node or the clock’s 
response to Iso stimulation. 
3.2.8. Cellular Ca2+ Handling 
Next, we assessed Ca2+ handling in isolated LV myocytes using confocal line 
scans of fluo-4AM-loaded cells paced at 0.5 Hz. After a train of 20 stimulations, a pulse 
of 20 mM caffeine was applied to measure SR load (Figure 3.9). First, the Ca2+ transient 
amplitude was comparable between WT and Het myocytes in basal conditions and with 
50 nM Iso (Figure 3.10 A). This result is in agreement with the results described above 
from whole animals and isolated hearts undergoing Iso treatment. Remarkably, the time 
to reach the peak of the Ca2+ transient was prolonged in Het cells stimulated with Iso 
(Figure 3.10 B), suggesting that the increased dP/dt we measured in isolated Het hearts 
is a result of slower Ca2+ release rather than a change in the Ca2+ sensitivity of the 
myofilaments. This also suggests that, while theCa2+ transient amplitude release is 
apparently preserved, haploinsufficiency seems to affect the recruitment of RyR2 
channels during Iso stimulation. Based on the comparable expression of SERCA2a, NCX, 
and PLB, as well as the similar phosphorylation level of PLB between WT and Het (section 
3.2.4 and Figure 3.5), we did not expect differences in cytosolic Ca2+ removal. Indeed, 
the 50% decay time of the Ca2+ transient was not different between genotypes (Figure 
3.10 C). We also determined that the SR load was not significantly different WT and Het 
cells; yet, Iso did not induce an increase in SR load in either group (Figure 3.10 D). This 
observation is at odds with previous literature using rabbit myocytes20,157 and with the 




explanation is that our studies were carried out at room temperature, while other groups 
have measured the Iso response at 37 ˚C.157 It is important to consider, however, that the 
increase in transient amplitude (Figure 3.10 A), decrease in time-to-peak (Figure 3.10 B), 
and transient decay acceleration (Figure 3.10 C) confirm the adrenergic response to Iso. 
Then, the increase in ICaL produced by Iso — which we have yet to quantify — may be 
driving the surge in Ca2+ release without overloading the SR. Indeed, we observed that 
the fractional release of Ca2+ is significantly increased in both WT and Het myocytes 
during Iso stimulation (Figure 3.10 E). Interestingly, this value was slightly but significantly 
lower in Het cells.  
3.2.9. Arrhythmia Susceptibility 
Up to this point, we have established that heterozygous KO of RyR2 in rabbits 
does not produce a deleterious phenotype under basal conditions, and that higher RyR2 
activity likely compensates for the observed decrease in expression. Next, we studied the 
response of RyR2-KO rabbits to adrenergic stress. We began by testing the susceptibility 
of anesthetized rabbits to ventricular arrhythmia. Initially, we tried a less aggressive 
protocol than that used in mice (see section 4.4.5), using only 2 mg/kg epinephrine IP; 
however, WT rabbits died after episodes of ventricular tachycardia followed by severe 
bradycardia and apnea (not shown). Decreasing the dose of epinephrine or changing the 
administration route to intravenous (IV) produced variable results, ranging from short 
adrenergic responses to high mortality in WT animals (not shown). The powerful 
vasoconstriction effect of epinephrine was always evident, as rabbits became cyanotic 
shortly after injection. Because dobutamine is used in human patients during 




inotropic and weak vasoactive effects. We tested different IV infusion rates and settled 
upon 80 μg/kg/min: a dose two-fold higher than the maximum used in humans.158 This 
dose was well-tolerated in WT rabbits and provided enough resolution between 
heartbeats to measure ECG parameters accurately (Figure 3.11). A higher dose of 100 
μg/kg/min produced fusion of the T wave with the following P wave (not shown). 
Caffeine has been reported to potentiate arrhythmias in rabbits exposed to 
hazardous chemicals;159 therefore, we added it to the arrhythmia protocol. Considering 
the pharmacokinetics of caffeine (half-life 3.8 h, clearance of 0.2 L/kg/min and distribution 
volume of 0.82 L/kg160), we surmised that it would take approximately 27 h for caffeine to 
reach a steady plasma concentration during IV infusion, assuming caffeine follows single-
compartment pharmacokinetics. To overcome this issue, we used the following protocol: 
a loading dose of 9 mg/kg caffeine IV, followed by infusion of 28 µg/kg/min caffeine and 
80 μg/kg/min dobutamine. The half-life of dobutamine is as short as 2 min; thus, it would 
take approximately 15 min to reach a steady plasma concentration. We observed a 
maximum increase in HR within 30 min of initiating treatment. After this, the IV infusion 
was maintained for 30 additional minutes to test arrhythmia susceptibility. During this 
time, the ECG showed little change and neither WT nor Het rabbits developed ventricular 
arrhythmia. Furthermore, all ECG parameters measured at baseline and at the peak HR 
response were comparable between WT and Het rabbits (Table 3.2). From these 
experiments, we can conclude that RyR2 haploinsufficiency is not expected to predispose 





In this study, we report a thorough characterization of the first rabbit model with 
genetic targeting of the RYR2 gene, specifically a constitutive gene knock out created by 
Yan et al.152 using CRISPR/Cas9 technology. The rabbit is a classical model to study 
cardiac pathophysiology, but targeted genome editing in this species is a recent 
breakthrough. Until recently, genetic manipulation of rabbits was limited to transgenic 
overexpression of exogenous genes, such as human HERG channels with a dominant-
negative mutation associated with long QT syndrome (LQTS).156,157 The newly-developed 
technique to manipulate endogenous genes in rabbits, on the other hand, offers the same 
versatility as in the mouse but in a species with cardiac Ca2+ handling and 
electrophysiology more similar to that of the human. To create the rabbit model used in 
this study, Yan et al. introduced a 16 bp deletion in exon 49 of RYR2, changing the 
reading frame of the gene and truncating RyR2 synthesis before the pore-forming 
domain. Hence, the mutant allele works as a knock-out allele. 
RyR2-KO animals have been the subject of a handful of studies since 1998, when 
Takeshima et al.153 described that constitutive RyR2-KO in mice is also embryonic lethal. 
In that report, the authors detected contractions of the developing heart at embryonic day 
E9.5 — suggesting that RyR2 is not essential for the embryonic heart to contract — but 
RyR2-KO embryos showed vacuolization of the SR and died after embryonic day E10.5. 
These ultrastructural abnormalities resembled those observed in the skeletal muscle of 
RyR1-KO and RyR1/RyR3 double-KO mice.161,162 However, these animals died 
perinatally due to respiratory failure, rather than in utero. Later, Zou et al. reported lower 




et al., on the other hand, showed that conditional knockout (cKO) of RyR2 in adult mice 
results in a progressive decline of cardiac function and eventually death,150 while 
heterozygous cKO mice only showed reduced heart rate and oxidative metabolism.163 
Hence, complete lack of RyR2 is lethal, while haploinsufficiency is well-tolerated. Indeed, 
we determined that homozygous RyR2-KO is also embryonic lethal in rabbits and 
heterozygous animals have significantly lower expression of RyR2 in the left ventricle 
(~40% of WT). Then we used a multi-level approach to determine whether RyR2 
haploinsufficiency alters cardiac function in rabbits, and the possible underlying 
mechanisms. 
We determined that in basal conditions (1) Het rabbits have normal cardiac 
structure and function; (2) Het hearts develop the same contractile force as WT hearts; 
and (3) Ca2+ homeostasis is not altered in Het cardiomyocytes. To explain the lack of an 
abnormal phenotype, we looked at the possible compensatory mechanisms involved. 
Remarkably, while Het KO hearts showed ~60% lower RyR2 expression — suggesting 
that a single functional allele is unable to provide half of the protein expression — the 
remaining RyR2 channels had ~2-fold higher activity than in WT hearts. Therefore, RyR2 
deficiency is possibly compensated, at least partially, by an upregulation of channel 
function. Our data indicate that this is most likely mediated by decreased phosphorylation 
of S2031 due to enhanced association of PP2A with RyR2. It is important to note that, 
even though PP1 is also reported to co-immunoprecipitate with RyR2, we did not detect 
it in our experiments possibly due to a weaker association disrupted during the procedure. 





Interestingly, the mechanism above represents the exact opposite of that 
described in the LQTS rabbits, where lower association of phosphatases with RyR2 
increased RyR2 phosphorylation, resulting in abnormal Ca2+ release and enhanced 
arrhythmogenesis.157 This mechanism agrees with the prevalent idea in the field: more 
RyR2 phosphorylation promotes increased channel activity, a notion coming from nearly 
two decades of reports arguing that increased phosphorylation of the two main sites in 
RyR2 — S2809 and S2815 — produces “leaky” channels that contribute to different forms 
of heart disease including heart failure,53,60 hypertrophic cardiomyopathy,99 and even 
diabetic cardiomyopathy.164 Nevertheless, there is evidence in the literature suggesting 
that dephosphorylation of RyR2, as we observed in Het hearts, also increases channel 
activity. Lokuta et al. showed that dephosphorylation of cardiac SR vesicles using acid 
phosphatase increases the maximum [3H]ryanodine binding and open probability of single 
RyR2 channels.65 Also, Terentyev et al. showed that perfusion of permeabilized rat 
cardiomyocytes with PP1 increases Ca2+ spark frequency and depletes SR Ca2+, a 
reliable indicator of RyR2 activity.66 Moreover, ablation of both S2809 and S2815 
phosphorylation sites in a mouse model (S2808A/S2814A, as per the mouse 
nomenclature), increases Ca2+ leak and promotes arrhythmia,165 probably due to higher 
RyR2 activity. Together, these reports suggest that both phosphorylation and 
dephosphorylation of RyR2 may increase channel activity. 
At the single channel level, the increase in RyR2 activity we detected using 
[3H]ryanodine binding experiments must translate into increased open probability. While 
we did not test this hypothesis, the study by Lokuta et al. reported that dephosphorylated 




frequency.65 Hence, the population of RyR2 channels in Het hearts would be able to 
maintain a normal Ca2+ release upon activation by ICaL by decreasing the inactivation time 
within the timeframe of SR Ca2+ flux (up to ~150 ms after activation166), thus decreasing 
the refractory period. Indeed, we observed normal Ca2+ transient amplitude in Het 
cardiomyocytes. Previous studies showed that acute pharmacological modulation of 
RyR2 activity only produces transient changes in Ca2+ release with the SR load having a 
prominent compensatory role.167-169 Hence, if RyR2 channel activity is acutely reduced — 
e.g. using tetracaine — systolic Ca2+ release will decrease transiently and will recover 
after the SR load stabilizes at a higher level. Following the same logic, a higher SR Ca2+ 
load could compensate for a lower RyR2 expression, hindering the appearance of a 
deleterious whole-organ phenotype. Since we measured a comparable basal SR load in 
WT and Het myocytes, we conclude that modulation of the SR load does not contribute 
to maintain Ca2+ homeostasis in haploinsufficient hearts. 
Our results indicate that decreased S2031 phosphorylation may contribute to 
compensate for RyR2 deficiency in Het rabbits by increasing channel activity, while the 
phosphorylation level of S2809 and S2815 remains unchanged. S2031 is a 
phosphorylation site often ignored in the overall scheme of RyR2 regulation.51 The low 
basal phosphorylation of this site and initial reports suggesting it is not phosphorylated by 
PKA — making it irrelevant for the adrenergic response53 — relegated this site to a lower 
tier than S2809 and S2815. However, S2031 is readily phosphorylated by PKA in vitro 
and upon adrenergic stimulation with a high dynamic range (~16-fold increase).13,61,62 
Correspondingly, S2809, regarded by many researchers as the only PKA site in RyR2 




stimulation.13 We cannot overlook the fact that S2031 phosphorylation level is low. Then, 
how does decreasing it further increase channel activity? To fully answer this question, 
we need more information from animal models with amino acid substitutions ablating 
(S2031A) or mimicking phosphorylation (S2031D). Interestingly, preliminary data 
generated in our laboratory show that S2030A mice (as per the mouse nomenclature) 
develop severe hypertrophy, confirming that phosphorylation of this site, albeit low, is 
necessary to maintain normal heart homeostasis. The underlying mechanisms for the 
phenotype of the S2030A mouse model have yet to be elucidated. 
We have established so far that the heterozygous ablation of RyR2 does not 
induce a deleterious basal phenotype. Now, we must consider the response of RyR2 
haploinsufficient rabbits to acute adrenergic stimulation. Overall, the adrenergic response 
was preserved in Het rabbits. Iso induced a comparable increase in ejection fraction and 
fractional shortening in anesthetized animals, pressure development in isolated hearts, 
and Ca2+ transient amplitude in isolates ventricular myocytes. Stimulation of β-adrenergic 
receptors (β-ARs) with Iso prompts activation of protein kinase A (PKA), which 
phosphorylates several targets, including LTCC, PLB (a regulator of SERCA2a) and, 
most importantly for this discussion, RyR2. This creates an apparent paradox, because 
PKA phosphorylates S2031 upon activation of β-AR but we postulate that decreased 
phosphorylation compensates for the lower RyR2 expression. One possible explanation 
is that the increase in ICaL produced by Iso because of LTCC phosphorylation offsets the 
overall effect of RyR2 phosphorylation under Iso. Indeed, Ginsburg and Bers determined 
that the main drivers for the augmented Ca2+ release during Iso stimulation are ICaL and 




Interestingly, isolated Het hearts showed slower pressure development immediately after 
Iso (Figure 3.8) and isolated myocytes showed delayed Ca2+ transient time-to-peak 
compared to WT (Figure 3.10). Altogether, these data suggest that a ~40% RyR2 
expression is enough to sustain normal Ca2+, but affects the rate of release during Iso 
stimulation. Finally, Fu et al. recently reported that RyR2 phosphorylation prompts 
reorganization of the channels within the dyadic cleft.170 Unfortunately, we have not 
performed ultrastructural studies to determine the extent to which RyR2 deficiency affects 
the number of Ca release units (CRUs) or the content of RyR2 within the CRU. Still, we 
hypothesize that the microdomain reorganization proposed by Fu et al. is preserved 
because RyR2 channels from Het rabbits can be phosphorylated in the three 
phosphorylation sites. Nevertheless, the issue would be with the number of channels 
recruited. 
To conclude, we must consider the pathophysiological relevance of decreased 
RyR2 expression. Our data suggest that lower RyR2 expression is not a trigger for overt 
cardiac dysfunction, even in the presence of acute adrenergic stimulation; hence, it is 
unlikely to contribute to the pathology of HF and HCM. The Genome Aggregation 
Database (gnomAD)83 — which contains data from over 123,000 human exomes — 
reports 27 RYR2 variants (allele frequency of ~1x10-4) that introduce termination codons 
before the pore-forming domain of RyR2. Since these variants are equivalent to our rabbit 
model, it is reasonable to hypothesize that these individuals have lower RyR2 expression 
as well. Our data provides strong experimental support to classify these truncation 
variants as benign. Exon 3 deletion in RYR2, on the other hand, a mutation potentially 




produces haploinsufficiency in a mouse model. Lui et al. argued that the lack of abnormal 
phenotype was because the mutant allele was silenced, and mouse hearts only 
expressed the WT allele.120 If exon 3 deletion is indeed pathogenic in humans, our data 
indicate that this is unlikely a result of haploinsufficiency. 
In summary, our data show that RyR2 haploinsufficiency — which likely involves 
fewer RyR2 channels per CRU, fewer CRUs overall or a combination thereof — is 
compensated at basal conditions, at least partially, by decreasing the phosphorylation 
level of S2031 and upregulating channel activity (Figure 3.12). This prevents the 
appearance of deleterious phenotypes. Furthermore, the adrenergic response is 
preserved in these animals, but the Ca2+ release kinetics is significantly slower with low 
RyR2 expression. Het rabbits showed RyR2 expression levels ranging from 15–69% of 
the average expression in WT animals, in which the range was 63–150%. Since we also 
established that complete lack of RyR2 is lethal, then how much RyR2 expression is 
enough and how much it too little? These are tantalizing questions that will require further 
study. 
3.4. Methods 
3.4.1. General Considerations 
All animal experiments were approved by the University of Michigan Institutional 
Animal Care and Use Committee. All experiments performed at institutional cores were 
single blind. Unless otherwise stated, all reagents were acquired from Sigma-Aldrich. 




RyR2 knockout rabbits (RyR2-KO) were generated by the Center for Advanced 
Models and Translational Sciences as previously published.152 Two KO founders carrying 
different genetic mutations in RYR2 were initially used: Founder 6 with a 16 bp deletion 
(KO allele) and a 12 bp insertion, each in a different allele, and Founder 7 with an 11 bp 
deletion. These founders were mated and several preliminary experiments were 
conducted with the offspring. Figure 3.1B summarizes the offspring yield of this mating, 
in which rabbits carrying both KO alleles were never identified (defined as homozygous 
KO rabbits or Homo). It is important to note that following Mendel’s Law of Segregation, 
the 12 bp insertion from Founder 6 was inherited by all rabbits labeled as “WT” in Figure 
3.1 B, as well as those heterozygotes that inherited the KO allele from Founder 7. This 
12 bp insertion results from an in-frame insertion of 4 amino acids into RyR2. Therefore, 
we carefully selected only those rabbits carrying the KO allele from Founder 6 and a WT 
allele (data not shown). These rabbits were further mated with New Zealand White rabbits 
to continue the colony and provide the experimental animals. All data shown in this 
chapter, except for Figure 3.1 B were gathered using Het rabbits carrying the KO allele 
from Founder 6. 
3.4.3. Tissue Homogenization 
Rabbits were heparinized (1000 U/kg, Sagent Pharmaceuticals), sedated with 30 
mg/kg ketamine (VETOne) and 5 mg/kg xylazine (Akorn Animal Health), and fully 
anesthetized with 10 mg/kg propofol (Abbott). The heart was quickly excised, cleaned, 
section into major regions and flash frozen in liquid nitrogen. Left ventricle homogenates 
were prepared as described in section 2.4.6 using 1 mL of homogenization buffer per 200 




3.4.4. Co-immunoprecipitations and Western Blotting 
Western blots were carried out as described in section 2.4.7. The following primary 
antibodies were also used: anti-pS2814 (1:1000, custom13), pS2030 (1:1000, custom13), 
dpS2030 (1:1000, custom13), PP1 (1:1000; ab150782, Abcam), PP2A (1:250; 610555, 
BD Biosciences).  
RyR2 was immunoprecipitated from LV homogenates as previously described.86 
Briefly, 5 mg of protein from LV homogenates were diluted in modified RIPA buffer 
containing 0.9% NaCl, 10 mM Tris pH 6.8, 0.1% Triton X-100, 20 mM NaF, 2 µM 
leupeptin, 100 µM phenylmethylsulphonyl fluoride, 500 µM benzamidine, 100 nM 
aprotinin. Samples were incubated for 2 hours at 4 ˚C with protein-G Dynabeads 
(ThermoFisher) crosslinked with 5 μg of anti-RyR2 antibody (MA3-925, ThermoFisher). 
Crosslinking was done using BS3 (ThermoFisher) following the manufacturer’s 
instructions. Beads were then washed three times with RIPA buffer and incubated with 
Laemlii buffer at 55 ̊ C for 10 min to elute the protein. Supernatants were used for Western 
blots as described above. 
3.4.5. Gene Expression Analysis 
Total RNA was extracted from WT and KO LV samples. Briefly, tissue was 
homogenized in TRIzol reagent (ThermoFisher) following the manufacturer’s instructions. 
After addition of an appropriate amount of chloroform, mixing, incubation, and 
centrifugation, the RNA-containing aqueous phase was collected and treated with DNase 
I (Qiagen) for one hour. RNA was subsequently purified using the RNeasy mini kit 
(Qiagen), following the manufacturer’s protocol. First strand cDNA synthesis was 




first strand cDNA synthesis, samples were incubated for 90 minutes at 50 ˚C prior to heat 
inactivation of the reverse transcriptase at 70 ˚C for 15 minutes. 
Expression levels of RYR2 (Oc03398553_m1) and GAPDH (Oc03823402_g1) 
were subsequently assessed using TaqMan gene expression assays (ThermoFisher). 10 
ng of cDNA were used as template reaction, together with TaqMan gene expression 
Master Mix (ThermoFisher). Thermal cycling and fluorescence measurements were 
performed in a StepOnePlus Real-Time PCR System (ThermoFisher). Data were 
analyzed using OnePlus software (ThermoFisher). RYR2 expression levels were 
calculated using the ΔCT-method, normalized to GAPDH expression and calculated as 
percentage of WT. 
3.4.6.  [3H]Ryanodine Binding Assays 
Binding assays were carried out following a modified version of a protocol 
previously described.87,164 Binding mixtures were prepared containing 100 μg of protein 
LV homogenate, 0.2 M KCl, 20 mM Na-HEPES pH 7.4, 6.5 nM [3H]ryanodine (NET950, 
PerkinElmer), and enough CaCl2 to set free [Ca2+] between 100 nM to 100 μM. 1 mM 
EGTA was used to buffer Ca2+. The Ca2+/EGTA ratio for these solutions was determined 
using MaxChelator (WEBMAXCLITE v1.15, http://maxchelator.stanford.edu/). The 
binding reactions were incubated for 2 h at 37°C, then filtered through Whatman GF/B 
filters and washed three times with 5 mL of distilled water in a Brandel M24-R Harvester. 
Non-specific binding was determined in the presence of 20 μM unlabeled ryanodine 
(2153770, MP Biomedicals). [3H]ryanodine binding was measured by liquid scintillation 
using Bio-Safe II counting cocktail (RPI Research). Corrections for RyR2 expression were 




from Western blots, relative to WT. Hill’s equation was used to determine the maximum 
[3H]ryanodine binding and the EC50 in Origin 9 (Origin Lab). 
3.4.7. Histological Staining 
LV and left atrium samples were fixed in 10% neutral buffered formalin and 
processed by the Pathology Core of the Unit for Laboratory Animal Medicine at the 
University of Michigan. An expert pathologist analyzed the samples looking for alterations 
of the micro-architecture of the tissue, including hypertrophy, myocyte disarray, and 
fibrotic infiltrations. 
3.4.8. Langendorff Perfusions 
Perfusion of isolated hearts was performed as described in section 2.4.8 and in 
the literature.171 Rabbits were heparinized  and anesthetized as indicated in section 3.4.3. 
The chest was opened and the heart exposed. The aorta was cannulated in situ and the 
heart was excised and mounted on a Langendorff apparatus. A latex balloon (Harvard 
Apparatus) as introduced in the LV to measure developed pressure. Hearts were 
perfused with modified Tyrode’s solution containing (mM) 130 NaCl, 4 KCl, 1 MgCl2, 1.2 
NaH2PO4, 24 NaHCO3, 5.6 glucose, 1.8 CaCl2, pH 7.4, aerated with 95% O2, 5% CO2. 
The perfusion pressure was adjusted to 50–70 mmHg (30–45 mL/min). Hearts were 
stimulated with 100 nM Iso to record the adrenergic response. LV pressure traces were 
analyzed using the Blood Pressure module of LabChart 8 (ADInstruments) to calculate 






Transthoracic echocardiography (Echo) was performed by the Echocardiography 
Service of the Frankel Cardiovascular Center Animal Phenotyping Core at the University 
of Michigan as described in section 2.4.5, using a MS200 transducer. Rabbits were lightly 
sedated with ketamine/xylazine (10 mg/kg and 1 mg/kg, respectively) and anesthetized 
with 2% isoflurane. The adrenergic response was also determined after 15 minutes of 
continuous IV infusion of 0.5 μg/kg/min Iso. All parameters are the average of three 
consecutive cardiac cycles. 
3.4.10. Electrocardiography 
Rabbits were anesthetized as indicated in section 3.4.9. Surface electrodes were 
placed on the limbs to record the ECG in Lead-I and Lead-II configurations using a 
PowerLab 8/35 system (ADInstruments). After 10 minutes of stabilization and baseline 
recording, a loading dose of caffeine 9 mg/kg was injected IV followed by IV infusion of 
dobutamine and caffeine (80 μg/kg/min and 28 μg/kg/min, respectively). After reaching a 
steady HR, the infusion was maintained for 30 min and the ECG was monitored for 
arrhythmia events. Lead-II ECG traces were analyzed using ECG Analysis module of 
LabChart 8 (ADInstruments) and averaged over 2 min of basal recording or at the peak 
HR response 
3.4.11. Isolation of Cardiac Myocytes 
Cardiac myocytes were isolated as previously described.97,98,171 Briefly, rabbits 
were anesthetized as indicated in section 3.4.9, hearts were mounted on a Langendorff 
apparatus as described in section 3.4.7 and perfused for 5–10 min (30–40 mL/min, 37 
˚C) with normal Tyrode’s (NT) solution containing (mM) 138 NaCl, 4.4 KCl, 1 MgCl2, 24 




completely removed, perfusion was switched to nominally-free Ca2+ Tyrode’s solution for 
5–10 min until the heart stopped contracting. At this point, the perfusion was changed to 
nominally-free Ca2+ Tyrode’s solution supplemented with 200 U/mL collagenase type 2 
(Worthington), 1 mg/mL BSA and 36 µM Ca2+, for 20–30 min until the heart became 
flaccid. The LV was then removed and minced in collagenase solution. Myocytes were 
dispersed by gentle pipetting. The supernatant was collected and the remaining tissue 
was further digested in fresh collagenase solution. This process was repeated, every 2–
3 min, six times. After gently dispersion, the cell-containing supernatants were centrifuged 
(100 x g, 1 min) and the myocytes were resuspended in Tyrode’s solution containing 1 
mg/mL BSA and 36 µM Ca2+. The solution was replaced every 10–15 min to raise [Ca2+] 
to 1.8 mM in five steps: 80 µM, 250 µM, 500 µM, 1 mM and, finally, 1.8 mM. 1 mg/mL 
BSA was added to the first two solutions. Cells were maintained in NT solution until used. 
3.4.12. Cellular Ca2+ Imaging 
Ca2+ transients and SR load were recorded as described in 2.4.10 and in the 
literature.89 Cells were plated on laminin-coated glass-bottom dishes with NT solution and 
in the presence of 50 nM Iso. Longitudinal line-scans were recorded during field 
stimulation at 0.5 Hz. After 20 pulses 20 mM caffeine was perfused to measure the SR 
Ca2+ load (Figure 3.9). 
3.4.13. Statistical Analysis 
All data are presented as mean ± SEM. Statistical significance was determined at 
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Figure 3.1. Generation of the RyR2-KO Rabbit Model. 
A. Strategy to develop the RyR2-KO rabbit. Exon 49 of RYR2 was targeted using the Crispr/Cas9 
technology, which generated a 16 bp deletion. Sequence analysis shows a stop codon downstream, which 
terminates translation after residue 2496. The PFD is not part of the truncated protein, hence the knock-
out. The only phosphorylation site present in the truncated protein is S2031. The arrowhead indicates a 
DpnII restriction site present only in the WT allele B. Propagation of KO rabbits upon mating heterozygotes. 






Figure 3.2. RyR2 Sequence Alignment of the WT and KO Allele Products. 
Alignment of the WT RyR2 (accession number NP_001076226.1) and the product of the KO RYR2 allele. 
The amino acid sequence is identical until residue 2462. After this point, the KO allele encodes 34 
scrambled amino acids followed by a first termination codon in the position 2497. Several stop codons are 







Figure 3.3. RyR2 Expression and Phosphorylation in LV Samples. 
A. Representative blots. B-C. Expression of RyR2 is decreased in the left ventricle of KO rabbits, as 
measured by RT-PCR (B) and WB (C). D-F. Phosphorylation levels of the three major RyR2 phospho-sites 
(dp: dephospho; p: phospho): S2031 (D,E), S2809 (F), and S2814 (G). Basal phosphorylation of S2031 is 
decreased in heterozygous rabbits. Phosphorylation levels calculated as the ratio between phospho-band 
and total RyR2 band intensity, expressed as percentage of control (n = 7 per genotype; * p < 0.05, ** p < 






Figure 3.4. Cardiac Structure and Function In Vivo. 
A. Representative images of whole hearts fixed in formalin (first row), high-magnification micrographs of 
H&E-stained tissue section (third row), and high-magnification micrographs of Masson’s Trichrome-stained 
tissue sections (fourth row). B-G. M-Mode echocardiography measurements of heart rate (B), LV Mass (C), 
fractional shortening (D), ejection fraction (E), and posterior wall (F) and septum (G) thickness in diastole 





Figure 3.5. Expression of E-C Coupling Proteins in LV Samples.  
A. Representative blots. B-D. Expression level of excitation-contraction coupling proteins Cav1.2, 
SERCA2a, NCX, and PLB (n = 5-7 per genotype, two-tailed t-test comparison). F-G. Phosphorylation level 







Figure 3.6. Assessment of RyR2 Activity Using [3H]Ryanodine Binding Assays. 
A. [3H]ryanodine binding curves quantified in LV homogenate samples. B. [3H]ryanodine binding curves 
corrected for RyR2 expression (Western blot data from Figure 3.3 C). Each sample was normalized to its 
RyR2 level, determined as the ratio between normalized band intensity and the WT average. C. Linear 
fitting of S2031 dephosphorylation level vs. maximum [3H]ryanodine binding corrected for RyR2 expression 
determined from B. D. [3H]ryanodine binding curves normalized to 10 μM [Ca2+] showing a comparable 





Figure 3.7. RyR2 Association with Protein Phosphatases in LV Samples. 
A. Representative blots of PP1 and PP2A expression and association with RyR2 determined through co-
immunoprecipitation (co-IP). B-C. Quantification of expression of PP1 and PP2A in LV homogenates. D. 
Quantification of RyR2-bound PP2A showing a significant increase in heterozygous LV (n = 7 per genotype; 






Figure 3.8. Cardiac Response to Adrenergic Stimulation in KO Rabbits.  
A-C. IV infusion of isoproterenol (0.5 μg/kg/min) in anesthetized rabbits produced a significant increase in 
cardiac function, including heart rate (A), ejection fraction (B), and fractional shortening (C) (n = 6 per 
genotype; ##: p < 0.01 vs. same genotype basal, paired t-test). D-E. Langendorff-perfused hearts stimulated 
with 100 nM Iso show a significant increase in heart rate (D), LV-developed pressure (LVPD, E), and dP/dt 






Figure 3.9. Representative Ca2+ transient and SR load trace. 
Representative line-scan image (top panel) and intensity profile (bottom panel) of a WT rabbit myocyte 
paced 20 times at 0.5 Hz with field stimulation (black double arrows) under 50 nM Isoproterenol 
stimultion. A pulse of caffeine to measure the SR Ca2+ load (red double arrow). 
 
 
Figure 3.10. Cellular Ca2+ Handling in Rabbit Myocytes. 
A-C. Quantification of Ca2+ transient amplitude (B), time-to-peak (C) and 50% transient decay time (D) 
during 0.5 Hz field stimulation (Basal WT: N = 4, n = 47-49; Het: N = 5, n = 45-47. Iso WT: N = 3, n = 34-
36; Het: N = 3, n = 35-36). E-G. Quantification of SR load (E) and fractional release of Ca2+ (F) (Basal WT: 
N = 3, n = 35; Het: N = 3, n = 32. Iso WT: N = 3, n = 33-34; Het: N = 3, n = 34). * p < 0.05 vs. WT, same 





Figure 3.11. Representative ECG Traces from Rabbits Undergoing Arrhythmia Challenge. 
Following a 15 min of basal recording, rabbits were challenged with a dobutamine/caffeine cocktail for 30 








Figure 3.12. Scheme of Functional Compensation in RyR2-KO Rabbits. 
Heterozygous knock-out of RyR2 (panels on the right) decrease channel expression, thereby decreasing 
the number of RyR2s per Ca2+ release unit (CRU) or the number of overall number of CRU. Hence, in basal 





Table 3.1. Echocardiographic Parameters to Assess Cardiac Structure and Function in RyR2-KO 
Rabbits. 
Structural and functional parameters measured in WT and Het rabbits at basal level and after IV infusion 
of 0.5 μg/kg/min of Iso. 
 Basal Iso 0.5 μg/kg/min 
 WT Het WT Het 
n 6 6 6 6 
BW (g) 2.5±0.1 2.6±0.1 - - 
LV Mass  
(% of BW) 0.149±0.004 0.145±0.009 - - 
HR (bpm) 205±13 208±9 354±8## 361±5## 
IVSd (mm) 2.27±0.12 2.25±0.11 3.44±0.14## 3.34±0.13## 
IVSs (mm) 3.38±0.14 2.88±0.15* 5.44±0.21## 5.11±0.08## 
IVSth (%) 50.3±6.7 29.3±9.5 59.0±5.5 54.0±5.0# 
PWd (mm) 2.00±0.15 2.22±0.08 3.48±0.12## 3.63±0.12## 
PWs (mm) 3.34±0.2 3.43±0.28 5.23±0.27## 5.66±0.25## 
PWth (%) 68.6±9.8 54.7±12.8 51.6±10.0 56.1±5.6 
LVDd (mm) 14.44±0.62 13.94±0.36 9.14±0.59## 8.84±0.37## 
LVDs (mm) 10.31±0.45 9.92±0.40 4.57±0.27## 4.43±0.22## 
FS (%) 28.5±1.4 28.9±1.5 49.8±2## 49.3±3.4## 
LVVd (uL) 1265.5±113.9 1165.8±63.5 475.8±70.6## 434.7±39.5## 
LVVs (uL) 610.9±57.6 561.2±48.9 98.1±12.7## 90.9±10.7## 
EF (%) 51.6±2.0 52.2±2.3 78.9±2## 78.1±3.4## 
SV (uL) 654.6±69.0 604.6±31.4 377.7±62.4# 343.8±42.9## 
CO (mL/min) 130.7±9.4 125.3±6.5 132.9±20.7 124.5±16.5 
BW: body weight; HR: heart rate; IVSd: interventricular septum thickness in diastole; IVSs: 
interventricular septum thickness in systole; IVSth: percent change in IVS between systole and diastole; 
PWd: posterior wall thickness in diastole; PWs: posterior wall thickness in systole; PWth: percent 
change in PW between systole and diastole; LVDd: left ventricle diameter in diastole; LVDs: left 
ventricle diameter in systole; FS: fractional shortening; LVVd: left ventricle volume in diastole; LVVs: 
left ventricle volume in systole; EF: ejection fraction; SV: stroke volume; CO: cardiac output. 
*: p < 0.05, vs. WT, t-test 





Table 3.2. Electrocardiographic Parameters in RyR2-KO Rabbits Undergoing Arrhythmia Challenge. 
Average ECG parameters from Lead-II determined as the average of 2 min of recording in basal conditions 
and at the peak HR response. 
 Basal Dobutamine + Caffeine 
 WT Het WT Het 
n 4 8 3 3 
HR (bpm) 207±15 211±9 329±5## 320±14## 
delta HR - - 109.0±6.7 114.8±14.1 
RR (ms) 294.0±22.1 288.5±12.9 182.6±3.0## 188.2±8.7## 
QRS (ms) 27.8±2.6 29.3±1.9 24.0±0.5 26.8±1.7 
PR (ms) 57.5±3.7 58.3±2.0 51.7±1.8 52.4±1.2# 
QT (ms) 138.4±3.9 138.4±5.2 122.1±2.8 121±8.1 
QTc (ms) 155.9±2.4 156.5±5.6 150±3.0 147.7±8.6 




















Table 3.3. Cardiac Function Parameters in Langendorff-perfused RyR2-KO Hearts. 
Average parameters of cardiac function measured in isolated rabbit hearts perfused in a Langendorff 
apparatus. 
 Basal (t = 0) Iso 100 nM (t = 10 s) Iso 100 nM (t = 300 s) 
 WT Het WT Het WT Het 
n 5 7 5 7 5 7 
HR (bpm) 194±14 180±9 238±16## 258±8## 285±14## 295±13## 
ΔHR (%) - - 23.8±7.8 43.5±7.8 48.6±7.0 68.1±7.5 
LVDP 




## 117.3±8.7# 96.6±6.6# 
ΔLVDP (%) - - 157.7±24.5 141.5±22.3 32.8±10 17.1±7.0 
+dP/dt 







(%) - - 572.0±90.6 408.8±81.1 194.9±31.6 135.2±31.5 
-dp/dt 
(mmHg/s) -1362±139 -1115±92 -4782±368
## -3312±313*,## -2976±286## -2266±174## 
Δ-dP/dt (%) - - 269.7±52.1 188.9±22.9 120.5±14.4 89.4±13.8 
HR: heart rate; LVDP: LV-developed pressure (LV pressure max–end-diastolic pressure). 
*: p < 0.05, vs. WT, t-test. 





CHAPTER 4  
A Novel RyR2 Mutation Associated with Hypertrophic Cardiomyopathy Induces 
Hypertrophy and Arrhythmia in Mice 
 
4.1. Introduction 
Hypertrophic cardiomyopathy (HCM) is the most common congenital cardiac 
disease, affecting 1 out of every 500 individuals (0.2% of the general population).108 HCM 
is characterized at the tissue level by myocyte hypertrophy and disarray, and interstitial 
fibrosis; while the clinical features involve thickening of the left ventricle (LV) wall, diastolic 
dysfunction, heart failure, and increased risk of life-threatening arrhythmias that may lead 
to sudden cardiac death.172-174 More than 1400 mutations109 affecting over 24 genes175 
have a strong correlation with HCM, with the most commonly affected genes encoding 
for sarcomeric proteins. HCM patients have the highest prevalence of mutations in are 
MYH7 and MYPBC3, accounting for approximately 50% of the cases with a positive 
genetic diagnosis. However, approximately half of the patients who meet the diagnostic 
criteria of HCM and undergo genetic testing do not carry mutations in the genes included 
in commercial screening tests.109 As genetic testing has become more common, and the 
gene panel has expanded, new HCM-associated mutations have been identified in a 
plethora of genes within the myofilaments and beyond. While rare, there are reports 




such as SRI, CASQ2 and RYR2.110 None of these mutations has been thoroughly 
characterized. 
RYR2 encodes ryanodine receptor type 2 (RyR2), the major Ca2+-release channel 
in the heart. During an action potential in cardiac myocytes, a small inward Ca2+ current 
trough L-type channels activates RyR2 on the membrane of the sarcoplasmic reticulum, 
triggering more Ca2+ release. RyR2 provides most of the Ca2+ required for this process 
— ~70% in humans2 — called excitation-contraction (e-c) coupling. Tight regulation of 
Ca2+ release in the heart, and thus of RyR2 function, is essential because the same 
calcium used for e-c coupling can induce Ca2+-dependent arrhythmias,69 or modulate 
signaling pathways involved in structural remodeling.126  
Over the last 20 years, nearly 200 RyR2 mutations have been identified in patients 
with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), a disorder 
involving severe ventricular arrhythmias triggered by stress, but without structural 
alterations of the myocardium. The mechanisms underlying this disorder have been the 
subject of extensive research, uncovering a variety of molecular and cellular alterations 
producing Ca2+ mishandling and, ultimately, arrhythmia. More recently, the first HCM-
related RyR2 mutation — T1107M — was reported by a Japanese group.113 This mutation 
generated considerable interest in the field, as it was the first RyR2 variant associated 
with a structural — HCM — rather than an entirely functional disorder — CPVT. 
Interestingly, A1107M, the mouse analog, behaved considerably different in a 
heterologous expression system when compared to other CPVT mutations, suggesting a 
different pathogenic mechanism.119 Furthermore, it produces disruption of the SPRY2 




sequencing (WES)176 and cohorts of CPVT patients,81 weakening its pathogenic potential. 
Altogether, these data indicated that RyR2 mutations can produce a wide range of cardiac 
alterations, but the link between RyR2 mutations and structural cardiomyopathy remains 
elusive. 
In this study, we performed a thorough characterization of the novel mutation 
P1124L, recently identified in a patient with HCM. Remarkably, P1124L is in the same 
domain as T1107M. Nonetheless, four criteria support the pathogenicity of P1124L in the 
context of HCM: (1) the patient is negative for other potential mutations associated with 
HCM as screened in the clinical test; (2) the patient has a family history of HCM; (3) we 
provide compelling evidence showing that this mutation produces disruption of RyR2 
structure and function; and (4) mice harboring P1124L develop hypertrophy and cardiac 
arrhythmia. Still, we have yet to identify the specific signaling pathways responsible for 
the hypertrophic phenotype. Hence, while P1124L represents a new paradigm for the 
emerging field of RyR2-mediated cardiac remodeling and Ca2+-dependent HCM, a 
detailed elucidation of all the pathogenic mechanisms associated with the mutation will 
require further investigation. 
4.2. Results 
4.2.1. Identification of RyR2-P1124L in a Human Patient 
The patient harboring the heterozygous RyR2-P1124L mutation was diagnosed at 
17 years of age with HCM after a syncopal episode and demonstrated concentric LV 
hypertrophy most prominent in the lateral and inferolateral walls. Despite beta blocker 
therapy, he remained symptomatic, experiencing chest tightness and paroxysmal 




dual-chamber pacemaker (right atrium + right ventricle) placed 4 months later. He has a 
positive family history of two maternal cousins having HCM, without reported cases of 
sudden cardiac death. His mother was phenotypically negative for HCM, while his father 
and three siblings have not been screened. The patient tested negative for the equivalent 
of the clinical HCM genetic test (sarcomeric genes including MYBPC, MYH7, TNNT2, 
TNNI3, TNNC1, TPM1, ACTC, MYL2, and MYL3). The only relevant variant identified 
was the heterozygous RyR2-P1124L. Since DNA samples from immediate relatives were 
not available, it is not possible to determine co-segregation of the mutation and HCM 
phenotype within the patient’s family. 
At a subsequent visit to Mayo Clinic at age 18, he had a 24 mm mid-ventricular 
septal thickness (basal septum 16 mm) and LVOT obstruction (88 mmHg with Valsalva, 
46 mmHg baseline, and systolic anterior movement of the mitral valve) with mitral valve 
regurgitation. Because of these symptoms, he underwent an extended surgical 
myectomy. Figure 4.1 shows the complete electrocardiograms recorded before and after 
the surgery. Pre-surgery, Figure 4.1 A shows significant widening of the QRS complex 
and an elevated heart rate (95 bpm) maintained by firing of the pacemaker (pacing artifact 
most evident in leads II and V5). After the surgery (Figure 4.1 B), sinus rhythm was re-
stablished, and the widening of the QRS complex was significantly decreased. 
For the final publication of this chapter in a scientific journal, the Ackerman group, 
which identified the mutation, must provide additional information including the 
echocardiograms from previous visits to Mayo, to offer a stronger clinical foundation for 





4.2.2. Localization of P1124L in the Three-dimensional Structure of RyR2 
RyR2 mutations are clustered in four regions of the protein (Figure 4.2): CPVT-I is 
contained within the N-terminal domain (NTD), CPVT-II is formed by the second helical 
domain (HD2), CPVT-III and CPVT-IV involve the carboxy-end and comprise the central 
and pore-forming domains, respectively (CD and PFD). P1124L is a highly conserved 
residue (Figure 4.3) located outside of these regions in close proximity to T1107M, the 
only other HCM-associated mutation in RyR2.113 P1124 is part of SPRY2, one of the three 
SPRY domains in RyR2.33,177 The crystal structure of SPRY2 from RyR2 was recently 
solved to a resolution of 1.34 Å.31 P1124 belongs to a flexible linker connecting β-strands 
β2 and β3 that was not included in the initial SPRY2 model due to poor electron density. 
We did further refinement of the crystal structure of the wild type SPRY2 and crystalized 
the domain with the P1124L mutation (Figure 4.4). These new data suggest that the loop 
containing P1124 is located at the SPRY2-SPRY3 interface (Figure 4.5). Introducing the 
P to L substitution produces a substantial conformational change that affects neighboring 
residues, most notably C1122 and D1125, which are now directly facing SPRY3 (Figure 
4.5 D). While high-resolution structures of SPRY3 are not available yet, modeling of the 
SPRY2-SPRY3 interface shows that the new position of D1125 facilitates the formation 
of a salt bridge with R1599 of SPRY3. Therefore, this new inter-domain interaction might 
promote protein stability. Also, a new salt bridge forms between R1119 and D1132, 
located in opposite ends of the β2-β3 flexible linker. This could also provide rigidity to the 






4.2.3. Molecular Phenotype of P1124L Channels 
To determine the molecular phenotype of RyR2 channels harboring the P1124L 
mutation, we introduced the mutation into the mouse RyR2 cDNA and expressed the WT 
or mutant protein in HEK293 cells. 48 hours after transfection, we lysed the cells and 
performed functional studies. First, we found that P1124L mutant RyR2 expression is 
significantly reduced in transfected HEK 293 cells compared to the expression of WT 
RyR2 (49.4±3.4% of WT expression, n = 6, p < 0.01; Figure 4.6 A,B). This is an 
uncommon observation, as mutation-harboring RyR2 channels are often expressed to 
the same level as WT channels in this heterologous system.119 Next, we performed 
[3H]ryanodine binding assays to assess RyR2 channel activity. Ryanodine, the alkaloid 
which provided the name to RyR2, only binds to the open state of the channel. Hence, 
ryanodine binding is suitable to evaluate RyR2 activity in a population of channels at 
varying [Ca2+] exposed to the cytosolic side of the channel. After correcting for RyR2 
expression levels by Western blot, we determined that P1124L behaves as a loss-of-
function mutation, with lower maximum [3H]ryanodine binding than WT (BMax = 
0.44±0.02 vs. 0.60±0.03 pmol/mg of protein, n = 7, p < 0.01; Figure 4.6 C,D) and requiring 
higher [Ca2+] for activation (EC50 = 362.9±74.5 vs. 190.6±9.8 nM, n = 7, p = 0.04; Figure 
4.6 E,F). 
4.2.4. Spontaneous Ca2+ Oscillations in HEK Cells Expressing RyR2 
Using an assay involving heterologous expression of RyR2 in HEK293 cells and 
monitoring of intra-endoplasmic reticulum (ER) [Ca2+]. Tang et al.119 previously 
determined that some RyR2 mutations induce abnormal termination of spontaneous Ca2+ 




understanding of the possible mechanisms underlying the pathogenicity of P1124L. 
HEK293 cells stably expressing RyR2 were transfected with the FRET-based 
endoplasmic reticulum (ER) Ca2+ sensor D1ER. Then, cells were perfused with 2 mM 
Ca2+ to fill the ER and induce luminal [Ca2+] oscillations due to RyR2 activation. In this 
experiment, luminal Ca2+ oscillations are observed as a decrease in the FRET ratio. 
Figure 4.7 A shows representative FRET traces measured in cells expressing WT and 
P1124L channels. From these recordings, we determined the FRET level at which Ca2+ 
oscillations are triggered (FAct) and terminated (FTermi). Then, we perfused the cells with 
tetracaine to inhibit RyR2 and determine the FRET level at maximum store capacity 
(FMax), followed by caffeine to empty the ER and determine the residual FRET signal 
(FMin). In both groups, Ca2+ oscillations activated at ~80% the maximum ER store capacity 
(Figure 4.7 B). However, P1124L showed a significant reduction in the termination 
threshold for [Ca2+] oscillations (Figure 4.7 C), resulting in a larger fractional release 
(Figure 4.7 D). Interestingly, the ER store capacity was also decreased in the cells 
expressing P1124L channels (Figure 4.7 E). Similar to HEK293 cells with transient 
transfection of P1124L, cells with stable expression of these channels also showed lower 
RyR2 expression (Figure 4.8), which could account for the change in store capacity. This 
observation was not reported by Tang et al.119, who did not observe changes in RyR2 
expression among the variants they tested. 
Ultimately, these data suggest that P1124L channels have impaired luminal 
regulation and, upon activation, release more Ca2+ than WT channels. In the context of a 
myocyte, the implication may be that upon reaching a threshold SR load, P1124L 




subcellular [Ca2+] potentially leading to activation of entire clusters of RyR2 that propagate 
as Ca2+ waves. 
4.2.5. Single Channel Recordings 
Recombinant RyR2 from a heterologous system is expressed in the absence of 
other important regulatory co-factors. Therefore, we prepared SR-enriched microsomal 
fractions from pooled WT or homozygous P1124L mouse hearts to assess RyR2 activity 
from native channels reconstituted in artificial planar lipid bilayers. Knock-in P1124L mice 
were generated following the strategy summarized in Figure 4.9 A. Using homologous 
recombination, we introduced three mutations in exon 28 of Ryr2 (Figure 4.9 B): a silent 
A to G substitution in codon 1123, creating a PvuII restriction site; and two substitutions 
in codon 1124, accounting for the P to L change. P1124L mice have Mendelian 
propagation (Figure 4.9 C), and show heart rate (Figure 4.9 D) and RyR2 expression 
(Figure 4.9 E) comparable with WT controls. 
Figure 4.10 A shows representative current traces and histograms normalized to 
the average current of the open state obtained from single RyR2 channels from SR 
microsomes. We observed that P1124L channels have lower open probability than WT 
channels (Po = 0.113±0.046, n = 3 channels vs. 0.515±0.143, n = 5 channels, p < 0.01; 
Figure 4.10 B) at nominally-free [Ca2+] (~3-5 μM). These data agree with the 
[3H]ryanodine binding assays and support the idea that P1124L shows a cytosolic loss-
of-function at physiologically-relevant cytosolic [Ca2+]. The average conductance of WT 
and P1124L was not different, as determined based on the single channel currents 




sensitivity of P1124L channels to luminal [Ca2+], to confirm our findings on the termination 
threshold of SCR presented in the previous section. 
4.2.6. Cardiac Structure of Mice Harboring P1124L 
We determined that P1124L mice develop mild hypertrophy at 12-months of age 
(Figure 4.11, Table 1.1). This phenotype is evident in both homozygous (Homo) and 
heterozygous (Het) mice, and involves thickening of the posterior wall (Figure 4.11 B) 
and septum (Figure 4.11 C), without deterioration of the ejection fraction (Figure 4.11 D). 
In Het and Homo mice we also observed a significant increase in heart weight as 
percentage of body weight (Figure 4.11 E). However, we did not observe microscopic 
alterations of the cardiac muscle or fibrotic infiltrations (fibrosis quantification; WT: 
4.54±0.57%, Het: 5.21±0.74%, Homo: 4.19±0.57%; p > 0.05). At this age, we did not 
detect differences in the expression and phosphorylation of RyR2 (Figure 4.12) or other 
e-c coupling proteins (Figure 4.13). However, there was significant variability within 
samples of the same genotype, and tendencies, such as an increase in NCX expression, 
were not significant (Figure 4.13 B). Nevertheless, GAPDH expression showed little 
variability suggesting that the variability in in the e-c coupling proteins is not due to 
inadequate normalization (Figure 4.13 I). 
To complement these results, we isolated and measured ventricular myocytes 
from P1124L mice. Figure 4.14 A shows representative transmitted-light images of these 
cells. We observed that Homo myocytes were significantly longer than WT and Het 
myocytes, and wider than WT cells (Figure 4.14 B). This results in Homo myocytes having 
a significantly larger surface area than WT (Figure 4.14 C). Het myocytes, on the other 




length and surface area. Finally, we measured the cardiac expression of three 
hypertrophy marker genes using RT-PCR: atrial natriuretic peptide (Nppa), brain 
natriuretic peptide (Nppb), and β-myosin heavy chain (Myh7). Consistent with the mild 
hypertrophy we observed in Homo mice, we only measured a significant increase in Nppa 
expression in Homo mice (Figure 4.15). 
Taken together, these data suggest that P1124L produces mild cardiac 
hypertrophy in mice. This phenotype is detectable in both Homo and Het mice, as 
determined at the whole-heart and cellular level. Overall, the number of significant 
differences in indexes of hypertrophy were greater in Homo mice. To our knowledge, 
P1124L mice are the first animal model harboring a clinically-relevant RyR2 mutation that 
induces structural remodeling of the cardiac muscle. 
4.2.7. Signaling Pathways Associated with Cardiac Hypertrophy 
To determine the mechanisms by which P1124L might induces hypertrophy, we 
used Western blots to measure the expression and phosphorylation of relevant signaling 
molecules in 12-month-old hearts. First, we looked at the two Ca2+-dependent signaling 
pathways: CaM-CaMKII-HDAC and CaM-CaN-NFAT. In both cases, Ca2+ binds to 
calmodulin (CaM), which in turn activates either the Ca2+/CaM-dependent kinase II 
(CaMKII) or the serine/threonine phosphatase calcineurin (CaN). Downstream, each 
pathway follows a different signaling cascade that ultimately activates hypertrophic 
genes.178 We did not detect a difference in the expression of CaMKII between genotypes 
(Figure 4.16 B), although there was a tendency for an increase in Homo mice. Upon 
activation CaMKII auto-phosphorylates at residue T287 which confers it with Ca2+/CaM-




phosphorylation indicates pathologic activity, as occurs in human HCM.99,100 After several 
trials adjusting the blotting conditions and using different lots of antibody, we did not detect 
phosphorylation of T287 in any of the three genotypes (data not shown). This is unlikely 
due to an issue with the antibody, since we have successfully used it with samples from 
younger mice, atrial tissue, and other species. We also measured the expression of CnA, 
the catalytic subunit of CaN (Figure 4.16 B). Again, there was no significant difference 
between WT, Het, and Homo mice.  
Yamaguchi et al. also failed to detect differences in Ca2+-dependent signaling while 
studying a mouse model expressing RyR2 channels unable to bind CaM.43,111. Hence, 
they looked at other pathways also related to cardiac hypertrophy:111 Erk1/2 — 
extracellularly responsive kinases part of the MAPK family — and Akt — also known as 
protein kinase B, part of the PI3K/Akt/GSK-3 cascade.178 We tested the same signaling 
molecules by Western blotting, but did not observe significant differences in expression 
or phosphorylation (Figure 4.16 C,D). Altogether, these data suggest (1) that the mild 
cardiac hypertrophy of P1124L mice is likely not mediated by Ca2+-dependent signaling 
pathways, and (2) Erk1/2 and Akt do not appear to be responsible for the cardiac 
hypertrophy. Hence, we have yet to determine the specific link between the RyR2 
dysfunction produced by P1124L and the cardiac hypertrophy developed in 12-month-old 
mice. 
4.2.8. Arrhythmia Susceptibility of P1124L Mice. 
RyR2 mutations are commonly associated with cardiac arrhythmia in the absence 
of gross remodeling of the heart. Therefore, we tested whether P1124L is sufficient to 




epinephrine 2 mg/mg and caffeine 120 mg/kg87) during surface ECG recording, to 
determine the susceptibility of P1124L mice to develop ventricular arrhythmia. We 
performed this test in 8-month-old mice because at this age they do not show signs of 
cardiac hypertrophy. Figure 4.17 A shows representative 2-seconds long lead-II ECG 
recordings. Most of the arrhythmias we quantified were ventricular bigeminy (alternated 
premature and sinus beats, Figure 4.17 Aiii) and ventricular tachycardia (3 or more 
consecutive premature beats, Figure 4.17 Aiv). The effect of the arrhythmogenic cocktails 
was minimal in WT mice, which only showed premature ventricular beats (PVB, Figure 
4.17 Aii) and non-sustained arrhythmias lasting less than 5 seconds (Figure 4.17 C). 
P1124L mice exhibited a non-significant tendency to develop more PVBs than WT (Figure 
4.17 B), which coalesced into significantly more episodes of arrhythmia in Homo mice 
during 30 min post-challenge (Figure 4.17 C-D), including bidirectional ventricular 
tachycardia (BDVT, Figure 4.17 E), the pathognomonic sign of RyR2-induced arrhythmia. 
Again, Het mice had an intermediate phenotype between WT and Homo. While the 
difference in the number of episodes of sustained arrhythmia and incidence of BDVT was 
not statistically different between WT and Het mice, WT animals did not show these types 
of events, consistent with the literature. This suggests that the phenotype of Het mice is 
significant. 
In summary, P1124L predisposes 8-month-old mice to develop cardiac arrhythmia 
before the onset of the structural remodeling at 12 months of age. This suggests that the 






4.2.9. Cellular Ca2+ Handling in Ventricular Myocytes 
To understand the cellular mechanisms for the cardiac arrhythmia, we measured 
the kinetics of Ca2+ handling in isolated myocytes. We first paced at the cells at 1 Hz to 
quantify the properties of the cellular Ca2+ transient at basal conditions and then during 
300 nM Isoproterenol (Iso) perfusion. Figure 4.18 summarizes these data, which show no 
differences in Ca2+ release, Ca2+ removal, or SR content between WT and P1124L mice. 
Next, we studied the propensity for spontaneous Ca2+ release using a different protocol: 
cells were paced at 3 Hz for 30 s, followed by a resting period of 30 s. During this time, 
we monitored the cells for episodes of spontaneous Ca2+ release (SCR), manifested as 
Ca2+ waves (Figure 4.19). The incidence of SCR was higher in Homo myocytes at basal 
conditions, compared to WT and Het. This difference dissipated with Iso; however, the 
frequency of SCR was significantly higher in Homo myocytes treated with Iso than WT. 
Het myocytes displayed an intermediate phenotype, with a non-significant tendency for 
higher SCR frequency under Iso compared to WT. Incidentally, SCR frequency was not 
statistically different between Het and Homo under Iso. These data suggest that the 
cellular mechanism for the ventricular arrhythmias in P1124L mice is SCR during diastole. 
4.3. Discussion  
Since HCM was first described by Teare in 1957,179 and the identification of the 
first associated mutation affecting β-myosin heavy chain in 1990 (MYH7-R403Q),180 the 
number of genes and genetic variants related to the disease continues to grow steadily. 
Most of these mutations affect components of the contractile machinery of the heart, 
commonly MYH7 of the thick filaments and myosin-binding protein C of the intermediate 




but also hypertrophic signaling, it is quite surprising that genetic mutations in Ca2+-
handling proteins are rare among HCM patients. In 2006, Fujino et al. reported, for the 
first time, an RyR2 mutation occurring in a family with HCM — T1107M.113 While in vitro 
studies suggested this is a loss-of-function mutation119 that alters the SPRY2 domain of 
RyR2,30 T1107M is not a good tool to study the mechanisms by which RyR2 dysfunction 
and any associated Ca2+ mishandling produces cardiac hypertrophy for two main 
reasons. On the one hand, Medeiros-Domingo et al. identified this mutation in patients 
with CPVT, the inherited arrhythmia already strongly associated with RyR2 dysfunction,81 
weakening its association with HCM. Yet, at least two studies question the pathogenicity 
T1107M altogether,176,181 since it appears with high frequency in whole-exome 
sequencing (WES) cohorts. Hence, Landstrom et al. demoted T1107M from disease-
causative to variant of unknown significance (VUS).176 
In this report, we thoroughly characterized the novel mutation P1124L in RyR2. 
P1124L was detected in a patient with severe HCM, who underwent surgical myectomy 
to relieve an LVOT obstruction producing symptoms of HF. Among all the RyR2 mutations 
reported to date (over 200), this is the first with a strong correlation with structural 
cardiomyopathy rather than cardiac arrhythmia. P1124L also appears in the gnomAD, a 
WES database, albeit with significantly lower frequency than T1107M — i.e. ~2 in 100,000 
vs. ~4 in 10,000 for T1107M.83 Hence, to our knowledge this is the first comprehensive, 
multi-level study — from molecule to whole animal — of an RyR2 mutation strongly 
associated with structural remodeling of the heart.  
First, we show that P1124L, a highly conserved residue among RyR isoforms and 




where it produces structural disturbances affecting the arrangement of a flexible linker 
and the interface between the SPRY2 and SPRY3 domains. P1124L is one of a handful 
of mutations that fall outside of the canonical mutation “hotspots” of RyR2 (Figure 4.2). 
These regions, which contain ~95% of the disease-causing RyR2 mutations, involve the 
N-terminal domain (CPVT-I), the helical domain 1 (CPVT-II), the central domain (CPVT-
III) and the pore-forming domain (CPVT-IV). Recent high-resolution studies of RyR1 and 
RyR2 described in detail the movement of the central domains during RyR activation and 
gating;36,37 unfortunately, the resolution of the peripheral domains does not allow such a 
detailed analysis. Nevertheless, our model of the SPRY2/SPRY3 interface suggests that 
P1124L creates an inter-domain ionic bridge that could provide stability to this region of 
the channel. Ultimately, the consequence of these structural alterations is a cytosolic loss-
of-function of the channel, as we determined using two complementary assays — 
[3H]ryanodine binding with recombinant protein and single channel recordings with mouse 
SR microsomes — and a luminal gain-of-function, which we measured in the SCR assay 
in HEK293 cells. While these experiments were carried out using homozygous P1124L 
channels, in the heterozygous condition — as in the patient — any phenotype will be the 
result of a heterogeneous population of channels containing anywhere between zero and 
four mutant subunits. We have previously discussed this issue for two CPVT related 
mutations.87,89 
Second, we show that mice expressing P1124L channels develop cardiac 
hypertrophy at 12 months of age. This phenotype, albeit mild, involves an increase in LV 
wall thickness, myocyte size and ANP expression in homozygous mice. Het hearts, on 




myocyte width. There are two possible reasons for the discrepancy in the phenotypic 
penetrance in mice compared to the human patient. For one, there are significant 
differences between mouse and human cardiac physiology3 that can hamper the 
expected phenotype. An example of this in the HCM field is for mutations that truncate 
the myosin-binding protein C (MyBP-C), which only produce hypertrophy in homozygous 
mice.182 The same occurs in MyBP-C knockout mice.145,183 It is possible that the patient 
carries specific epigenetic markers or modifiers that enhance the pathogenicity of 
P1124L. This could also explain the report of P1124L in WES cohorts, in which carriers 
devoid of these markers might have a mild, sub-clinical phenotype.184 Further study of 
carriers of the mutation can strengthen this idea. Nevertheless, the presence of 
hypertrophy in mice supports the pathogenicity of P1124L, which is a not a dominant 
negative mutation — i.e. the phenotype increases with the P1124L content. 
To our knowledge, this report is the first instance in which a clinically-relevant 
RyR2 mutation produces cardiac hypertrophy in mice. Previously, the Meissner laboratory 
reported a mouse model with three amino acid substitutions in RyR2 
(W3587A/L3591D/F3603A, ADA), impairing the association with calmodulin (CaM), a 
regulatory partner.43 Cardiomyocytes from homozygous ADA mice showed aberrant Ca2+ 
handling, and mice developed severe cardiac hypertrophy and died within 13–15 days of 
birth. Interestingly, none of the two Ca2+-dependent signaling pathways (CaM-CaN-NFAT 
and CaM-CaMKII-HDAC) was required for these mice to develop the hypertophy.111 
Instead, the authors observed increased phosphorylation of GSK-3β, most likely 
mediated by early activation of Erk1/2 kinase signaling but not Akt.111 These pathways 




phosphorylation levels of CaMKII, Akt and Erk1/2 are unchanged in mice harboring 
P1124L, suggesting these pathways do not mediate the hypertrophic phenotype we 
observed. It is also possible that, since we only detected mild hypertrophy, these 
mediators are not significantly altered yet. Hence, further studies will be required to 
determine the specific signaling pathways necessary to trigger cardiac hypertrophy due 
to RyR2 dysfunction. Yet, our results provide concrete evidence that a clinically-relevant 
RyR2 mutation can trigger cardiac hypertrophy in mice, in the absence of other 
experimental manipulations. 
Third, we observed cardiac arrhythmia — particularly BDVT — in 8-month-old 
P1124L mice undergoing a challenge with epinephrine and caffeine. In HCM, arrhythmia 
often develops because of the extensive structural and electrophysiological 
remodeling.99,100 Interestingly, P1124L mice show both structural (hypertrophy) and 
functional (arrhythmia) phenotypes independently, with the latter occurring at younger 
ages. Hence, these animals develop arrhythmia solely due to RyR2 dysfunction induced 
by the mutation. Unlike hypertrophy though, it is not surprising that an RyR2 mutation 
produces cardiac arrhythmia, since more than 200 mutations have been found in patients 
with CPVT. Commonly, these RyR2 gain-of-function mutations sensitize channels to 
luminal [Ca2+], triggering spontaneous Ca2+ release during diastole, delayed 
afterdepolarizations and, ultimately, arrhythmia.69 The only other described loss-of-
function mutation, on the other hand, produces bursts of Ca2+ during systole, leading to 
early afterdepolarizations and arrhythmia.89 In myocytes expressing P1124L we observed 
stable Ca2+ handling during stimulation and SCR during resting periods, which is more 




mutations.69,185 Hence, from the molecular phenotypes we uncovered for P1124L 
channels — i.e. cytosolic loss-of-function and luminal gain-of-function — the latter seems 
to drive the arrhythmia: spontaneous activation of P1124L channels in conditions of high 
SR load will produce a larger Ca2+ signal that can diffuse to neighboring clusters, and 
propagate as Ca2+ waves. These events would activate NCX during diastole and produce 
triggered activity due to delayed afterdepolarizations. As shown in Figure 4.17, Homo 
mice have higher incidence of arrhythmia than Hets. It is important to underline that even 
though the difference in BDVT incidence between Het and WT mice is not statistically 
significant, none of the latter developed episodes of sustained arrhythmia. Therefore, the 
phenotype of Het mice cannot be overlooked. In these animals, permutation analysis 
predicts that most RyR2 channels should contain at least one P1124L subunit, and ~6% 
of the channels should contain four P1124L subunits.87,89 In the cellular mechanism 
described above, these are the channels that would likely promote larger SCR and Ca2+ 
waves. 
 Overall, P1124L represents a new paradigm for the emerging field of RyR2-
mediated cardiac remodeling and Ca2+-dependent HCM, as the first RyR2 mutation able 
to induce cardiac hypertrophy in a mouse model. Although we did not determine the 
signaling pathways underlying the hypertrophic phenotype, this is not discouraging. 
Similar to the reports by the Meissner laboratory using the ADA mouse, the lack of 
involvement of Ca2+-dependent pathways foresees a more complex panorama that will 
require further investigation. Hence, at this point it is difficult to assess which of the 
molecular mechanisms we identified for P1124L — cytosolic loss-of-function and luminal 




arrhythmia, on the other hand, seem to be consistent with previously-studied CPVT 
mutations, and are expected to originate because of the luminal gain-of-function. 
4.4. Methods 
4.4.1. Identification of P1124L in a Human Patient 
P1124L was identified in a patient with HCM referred to Mayo Clinic for evaluation. 
Michael Ackerman’s groups at Mayo did the clinical evaluation and genetic testing that 
identified P1124L. In the final version of this chapter before publication as a scientific 
paper, we will include a section detailing the relevant work by Dr. Ackerman’s laboratory 
that lead to the identification of P1124L. 
4.4.2. Generation of the RyR2-P1124L Targeted Mice 
The RyR2-P1124L-KI targeting vector was constructed using a combination of 
traditional cloning techniques and “recombineering”, a highly efficient phage-based 
Escherichia coli homologous recombination system.186,187 The RyR2- P1124L-KI 
targeting vector was linearized by digestion with NotI and electroporated into murine 
SV/129 AB2.2 embryonic stem cells.188 ES cells that integrated the targeting vector either 
by homologous or random integration were selected by growth on G418. The presence 
of gancyclovir (GANC) selected against clones that contained the HSV-TK cassette, thus 
enriching for clones that integrated the Neo cassette by homologous recombination. 472 
Neor, GANCr colonies were selected, replicated and expanded. DNA was isolated from 
192 replica ES clones, digested with BamHI restriction endonuclease, electrophoresed 
on agarose gels, transferred to charged nylon membranes and hybridized to radiolabeled 




in addition to the 21.7 kb native band. DNA from 19 clones that appeared to be correctly 
targeted on the 3’ side were digested with Nco1 electrophoresed on agarose gels, 
transferred to charged nylon membranes and hybridized to radiolabeled 5’ probe. 
Nineteen positive clones were identified. Six clones (2B2, 2C3, 2E5, 2B9, 2C9 and 2G9 
1F2) were thawed from the master plate and fully expanded. The remaining 13 clones 
were partially expanded and cryopreserved. The expanded clones were genotyped using 
both the 5’ and 3’ probes. Correctly targeted clones were identified by the presence of a 
21.7 kb native band and a 17.2 kb altered band when digested with BamH1, transferred 
to a charged nylon membrane and hybridized to the 3’ probe, and the presence of a 15.2 
kb native band and an 8.7 kb altered band when digested with Nco1 and hybridized with 
the 5’ probe. DNA sequence analysis was used to identify the correctly targeted clones 
and to confirm the presence of the floxed Neo cassette and the P to L substitution at 
position 1124. The chromosomes of 2 Ryr2-P1124L clones were counted and both clones 
were found to be euploid. Clones RyR2-P1124L 2E5 and RyR2-P1124L 2B2 were 
microinjected into C57Bl/6 blastocyst to produce chimeric founders. Highly chimeric 
males were crossed with C57Bl/6J females (000664, Jackson Laboratory). Agouti pups 
carrying the P1124L chromosome were identified by PCR. The floxed Neo cassette was 
excised by mating heterozygous RyR2-P1124L mice with EIIa-Cre transgenic mice 
(003724, Jackson Laboratory). Pups with complete excision of the Neo cassette were 
identified by PCR and then backcrossed with C57Bl/6J mice. RyR2-P1124L pups 
negative for the Cre recombinase gene were further backcrossed for 7 additional 
generations to obtain a 99%+ congenic strain.142 Direct sequencing of the region of Ryr2 




following primers: 5’-CGCATCTTCAGGGCAGAG-3’ and 5’-
GAGTGAAGCGGGAATGTC-3’. The sequences obtained were compared with the 
targeting vector, to the region of the murine chromosome 13 containing the Ryr2 
(accession number NT_039578.8), as well as the corresponding mRNA (accession 
number NM_023868.2) using Nucleotide BLAST.143 The translated protein was compared 
to the mouse RyR2 (accession number E9Q401). 
4.4.3. Experimental Animals 
All animal experiments were approved by the University of Michigan Institutional 
Animal Care and Use Committee. All experiments performed at institutional cores were 
single blind. Age- and gender-matched littermates and C57Bl/6J mice were used as WT 
controls. 
4.4.4. Echocardiography 
Transthoracic echocardiography (Echo) was performed by the Echocardiography 
Service of the Frankel Cardiovascular Center Animal Phenotyping Core at the University 
of Michigan as described in section 2.4.5. 
4.4.5. Electrocardiography 
Surface electrocardiograms were recorded as described previously.87 Mice were 
anesthetized with isoflurane (2–5%) and maintained on a heated pad. Needle electrodes 
were placed under the skin to record in Lead-I and Lead-II configurations, using a 
PowerLab system (ADInstruments). After 5–10 minutes of stabilization and baseline 
recording, epinephrine (2 mg/mg) and caffeine (120 mg/kg) were applied through 




of arrhythmic events (typically ventricular bigeminy and ventricular tachycardia) defined 
as 3 or more ventricular ectopic beats, consecutive or alternated with normal beats. These 
events were further classified as non-sustained (lasting less than 5 seconds) or sustained 
(lasting 5 seconds or longer). 
4.4.6. Histological Staining 
Hearts were explanted, perfused with PBS, and fixed in 10% neutral buffered 
formalin. The tissue was processed by the Pathology Core of the Unit for Laboratory 
Animal Medicine at the University of Michigan. Briefly, hearts were cut transversely, 
embedded in paraffin and stained with hematoxylin/eosin and Masson’s trichrome stains. 
A blinded veterinary pathologist performed the tissue assessment and fibrosis scoring. 
4.4.7. Transient Expression of RyR2 in HEK293 Cells 
HEK293 cells were grown in DMEM supplemented with 10% FBS, 100 U/mL 
penicillin and 100 μg/mL streptomycin on 100 mm tissue culture dishes. Cells were 
transfected with a plasmid containing the mouse Ryr2 cDNA using the Xtreme-DNA 
reagent (Roche Laboratories), following the instructions of the manufacturer. Cell lysates 
were prepared from transfected cells as previously described.89 24 h after transfection, 
cells were washed twice with PBS, then scraped from the plate and solubilized in 200 μL 
of lysis buffer, containing 25 mM Tris/50 mM HEPES (pH 7.4), 137 mM NaCl, 1% CHAPS, 
0.5% soybean phosphatidylcholine, 2.5 mM DTT, and protease inhibitors (2 µM leupeptin, 
100 µM phenylmethylsulphonyl fluoride, 500 µM benzamidine, 100 nM aprotinin). The 
cells were incubated on ice for 1 h and lysates were obtained by centrifuging at 16,000 × 
g at 4 °C for 10 min to remove insoluble material. Protein concentrations were determined 




4.4.8. Spontaneous Ca2+ Release in HEK293 Cells 
Stable inducible HEK293 cells lines expressing WT or P1124L-RyR2 were cultured 
as described in section 4.4.7. Spontaneous Ca2+ release was measured using the FRET 
endoplasmic reticulum Ca2+ sensor D1ER (Addgene, 36325), as previously described.119 
After 18-24 hours of subculture on 35 mm glass-bottom dishes, D1ER was transfected as 
described in section 4.4.7. 18–24 post-transfection, RyR2 expression was induced by 
adding culture medium supplemented with tetracycline 1 μg/mL. For imaging (performed 
18–24 h after induction), cells were continually perfused with Krebs-Ringer-HEPES buffer 
containing (mM): 125 NaCl, 5 KCl, 1.2 KH2PO4, 1.2 MgCl2, 6 glucose, 25 HEPES, pH 7.4. 
2 mM CaCl2, 1 mM tetracaine and 20 mM caffeine were added as indicated. Images were 
captured at room temperature on an Olympus FV-100 confocal microscope with a 40X 
objective at 405 nm excitation, and 535-565 (YFP) and 430-470 (CFP) emission. Images 
were collected every 1.644 seconds. FRET was calculated as the YFP/CFP ratio. The 
maximum store capacity, fractional release, and activation and termination thresholds 
were calculated using the following equations. The parameters for these equations were 
defined as described in Figure 4.7. 
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4.4.9. Tissue Homogenization 





4.4.10. Western Blotting 
Western blots were carried out as described in section 2.4.7. In addition, we used 
primary antibodies for the following targets: CaMKII (1:1000; 4436, Cell Signaling), 
pT286-CaMKII (1:1000; 12716, Cell Signaling), p44/42 MAPK (Erk1/2) (1:1000; 9102, 
Cell Signaling), pT202/Y204-p44/42 MAPK (Erk1/2) (1:1000; 9101, Cell Signaling), Akt 
(1:1000; 9272, Cell Signaling), pS473-Akt (1:1000; 9271, Cell Signaling). 
4.4.11. [3H]Ryanodine Binding Assays 
[3H]Ryanodine binding assays were performed as described in section 3.4.5. 
Binding reactions contained 50–100 μg of cell lysates. Whatman GF/B filters were pre-
soaked in 5% polyethyleneimine to maximize protein retention. 
4.4.12. Single Channel Recordings 
Cardiac SR-enriched microsomes for single channel recordings were prepared 
from mouse hearts using differential centrifugation, as previously described.89 10–15 
pooled mouse hearts were homogenized as described in section 2.4.6. Homogenates 
were centrifuged a second time at 8000 x g for 20 minutes at 4˚C. Supernatants were 
further centrifuged at 100,000 x g for 35 minutes at 4˚C. The pellets containing SR-
enriched microsomes were resuspended in homogenization buffer supplemented with 0.3 
M sucrose. 
RyR2 from cardiac microsomes were incorporated into planar lipid bilayer to record 
single channel activity as previously reported.89 The trans (1000 µl) and the cis (1000 µl) 
chambers (corresponding to the luminal and cytoplasmic side of the channel, 
respectively) contained 300 and 50 mM CsCH3SO3 (cesium methanesulfonate), 




bilayer of phosphatidylethanolamine : phosphatidylserine : phosphatadylcholine 
(1.0:0.8:0.2 ratio dissolved in n-decane to 20 mg/ml) was "painted" with a glass rod across 
an aperture of ~200 µm diameter in a Delrin cup. The trans chamber was the voltage 
control side connected to the head stage of a 200-A Axopatch amplifier, while the cis side 
was held at virtual ground. Channel activity was recorded after filtration with an 8-pole 
low pass Bessel filter set at 1.5 kHz, and digitized at a rate of 4 kHz using a Digidata 1200 
AD/DA interface. Data acquisition and analysis was performed with Axon Instruments 
hardware and software (pClamp 10). 
4.4.13. Confocal Ca2+ Imaging in Isolated Myocytes 
Ventricular myocytes were isolated as described in section 2.4.9. Ca2+ transients 
triggered by field stimulation were recorded as described in section 2.4.10. To determine 
the susceptibility of developing spontaneous Ca2+ release, cells were paced at 3 Hz for 
30 s at basal conditions and in the presence of 300 nM Iso. Following this train of 
stimulation, cells were monitored for 30 seconds for spontaneous Ca2+ waves. 
4.4.14. Crystallization of SPRY2 
Mouse RyR2 (residues 1080–1253) including the P1124L substitution were 
cloned, expressed and purified according to a similar strategy previously used for wild 
type RyR2 SPRY2 domain.30 Protein crystals were grown using hanging drop method at 
20°C. P1124L (5 mg/mL) was crystallized in 0.1 M potassium thiocyanate, 25-35% 
PEG2000MME with seeding of wild type crystals. Crystals were harvested and flash 
frozen in the original growth condition supplemented with 25-30% glycerol. Diffraction 




processed with HKL2000. The wild type RyR2 SPRY2 structure (PDB ID 4P9I) was used 
as a search model for molecular replacement to solve the RyR2 SPRY2 P1124L mutant 
structure. The statistics for data collection and refinement is shown in Table 4.1. 
Coordinate and structure factor for P1124L is available in the PDB with accession code 
5VSN. 
4.4.15. Gene Expression Analysis 
Total RNA extraction, cDNA synthesis and gene expression analysis were carried 
out as described in section 3.4.5. Expression levels of Nppa (Mm01255748_g1, 
ThermoFisher), Nppb (Mm01255770_g1, ThermoFisher), Myh7 (Mm00600555_m1, 
ThermoFisher), and Actb (4352933E, ThermoFisher) were assessed using TaqMan gene 
expression probes (ThermoFisher). 
4.4.16. Statistical Analysis 
Data are presented as mean±SEM. Statistical significance was determined at p ≤ 
0.05 using t-test, one-way ANOVA with Holm-Sidak’s post-hoc or two-way ANOVA with 
Holm-Sidak’s post-hoc. Data without normal distribution are shown in box-plots with 
whiskers indicating a 1.5 inter-quartile range. These data were compared using one-way 
ANOVA on Ranks followed by Dunn’s post-hoc. Analyses were carried out in SigmaPlot 
12.5 (Systat Software). 
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Figure 4.1. Electrocardiogram Recordings from the Patient Harboring the P1124L Mutation. 
A. 12-lead ECG recorded upon admission at Mayo Clinic before undergoing surgery. Heart rate is normal, 
but rhythm is maintained by firing of the dual-chamber pacemaker previously implanted to alleviate 
symptoms of heart failure. Stimulation artifact is visible in all leads. B. ECG recording 1 day post- surgical 






Figure 4.2. Location of P1124L in the Context of the RyR2 Mutation “Hotspots.” 
A. Linear representation of an RyR2 subunit indicating the three mutation “hotspots.” B. Chromatograms 




Figure 4.3. Amino Acid Sequence Alignment of RyR Isoforms from Various Species. 
Sequence alignment of residues 1100–1134 of the human RyR2 with RyR isoforms from other species. 
Shaded residues are different from the human template. P1124 is conserved in all RyR isoforms from all 
the species compared. Accession numbers and protein sequences from UniProt.128 *: Pig RyR2 sequence 






Figure 4.4. Structure of the SPRY2 Domain at 1.44 Å resolution. 
A. Crystal structures of the WT SPRY2 domain. B. Crystal structure of the P1124L SPRY2. C. Overlap the 
structures from panels A and B. Numbers indicate β-sheets as defined by Lau et al.30 Asterisk indicates the 





Figure 4.5. Location of P1124L Within the SPRY2 Domain of RyR2. 
A. Electron density map of RyR2.36 Subunits are delimited by black lines and the three SPRY domains area 
colored as indicated in B. B. Modeled interface between the three SPRY domains of RyR2. The position of 
the two HCM-associated mutations, A1107 and P1124, is indicated. C-D. Superimposed crystal structures 
of the WT and P1124L SPRY2 domains. Asterisk indicates positions of residue 1124 within the β2-β3 linker. 
Blue arrows indicate movement of four residues between WT and P1124L structures. Most notably: D1125 
rotates and becomes exposed into the SPRY1-3 interface, D1132 rotates away from R1133 breaking a salt 










Figure 4.6. RyR2-P1124L Activity Measured with [3H]Ryanoding Binding Assays. 
A. Representative Western blot of P1124L and WT RyR2 expression in transiently-transfected HEK 293 
cells. B. P1124L expression is lower than WT expression (n = 6 transfections, **: p < 0.01). C. Ca2+-
dependent [3H]ryanodine binding curve corrected for RyR2 expression. D. Maximum binding (BMax) 
calculated from the curves in C using Hill’s equation. P1124L has lower Bmax than WT (0.44±0.02 vs. 
0.60±0.03 pmol/mg of protein, p < 0.01). E. Ca2+-dependent [3H]ryanodine binding curve normalized to 10 
µM [Ca2+]. F. P1124L required higher [Ca2+] for activation than WT (EC50 = 362.9±74.5 vs. 190.6±9.8 nM, 
p = 0.04). Overall these data suggest P1124L is a loss-of-function mutation (n = 7 bindings. *: p < 0.05, ** 








Figure 4.7. Abnormal Termination of Spontaneous Ca2+ Release in HEK293 Cells Expressing RyR2. 
A. Representative traces of the intra-ER FRET signal using D1ER, from HEK cells with stable expression 
of RyR2. The [Ca2+] in the perfusion solution was increased to 2 mM to induce oscillations of intra-SR [Ca2+] 
due to spontaneous activation of RyR2 (spontaneous Ca2+ release, SCR). Tetracaine (1 mM) and caffeine 
(20 mM) were perfused to measure the store capacity and calculate other parameters. B-C. Activation and 
termination thresholds for SCR, as percentage of store capacity. D. Percentage of the store capacity 
release during SCR events. E. Store capacity, determined as FRETTetracaine–FRETCaffeine. Data expressed 










Figure 4.8. RyR2 Expression in Stable HEK Cells. 
Representative Western blot and quantification of RyR2 level in HEK cell with stable expression induced 






Figure 4.9. Generation of the P1124L Mouse Model. 
A. Strategy for the generation of the mouse model by homologous recombination. Numbers indicate Ryr2 
exons. B. Direct sequencing of the WT and mutant allele of a heterozygous mouse. C. Offspring proportions 
of heterozygous mice mating (n = 160 pups, 25 litters). D. Heart rate measured during echocardiography 







Figure 4.10. Single RyR2 Recordings from Cardiac Microsomes. 
A. Left. Representative single RyR2 channel recordings from cardiac microsomes prepared WT and Homo 
P1124L hearts. Right. Overlapped histograms of normalized current calculated from two representative 
channels. B. Average open probability (PO) recorded at nominally free [Ca2+] (~3-5 μM). C. Average single 
channel current calculated from single channel current recorded in with a 50/500 mM Cs+ gradient. (n = 3 






Figure 4.11. Cardiac Hypertrophy in 12-month-old P1124L Mice. 
A. Representative pictures of whole hearts fixed in formalin (first row), H&E-stained coronal sections at low 
magnification of paraffin-embedded tissue (second row), high-magnification micrographs of H&E-stained 
tissue section (third row) and high-magnification micrographs of Masson’s Trichrome-stained tissue 
sections (fourth row). B-D. M-Mode echocardiography measurements showing an increase in posterior wall 
(B) and septum thickness (C), and normal ejection fraction in homozygous mice (D) (n = 8 WT, 7 Het, 8 
Homo. *: p < 0.05 vs WT). E. Heart weight normalized by body weight is also increased in homozygous 





Figure 4.12. RyR2 Expression and Phosphorylation in 12-month-old Mice. 
A. Representative blots. B. Quantification of RyR2 expression normalized to GAPDH. C-F. C-F. 
Phosphorylation levels of the three major RyR2 phospho-sites (dp: dephospho; p: phospho): S2031 (C,D), 






Figure 4.13. Expression of E-C Coupling Proteins in 12-month-old Mice. 
A. Representative blots. B-F. Quantification of expression normalized to GAPDH of the e-c coupling 
proteins Cav1.2 (catalytic subunit of LTCC, B), NCX (C), SERCA2a (D), Casq2 (E) and PLB (F). G. 
Phosphorylation level of PLB at the CaMKII site, T17, normalized to total PLB expression. H. Ratio between 
the normalized expression of SERCA2A and PLB. I. Quantification of GAPDH expression (n = 4–5 per 







Figure 4.14. Ventricular Myocyte Size. 
A. Representative transmitted light images of ventricular myocytes. Cells are delineated and colored green 
(measured cells) or purple (out of focus or out of frame). B. Average cell length and width measured from 
confocal images. C. Distribution of cell surface area per genotype (n = WT 75, Het 81, Homo 84, N = 3. * p 
< 0.05, ** p < 0.01 vs WT). 
 
 
Figure 4.15. Expression of Hypertrophic Genes in 12-month-old Mice. 
Box plots with data overlap expression level showing of three hypertrophic genes: atrial natriuretic peptide 
(Nppa), brain natriuretic peptide (Nppb), and β-myosin heavy chain (Myh7). Data normalized to actin 





Figure 4.16. Hypertrophic Signaling Pathways. 
A. Representative blots. B-D. Quantification of the expression and phosphorylation of proteins involved in 
three hypertrophic signaling pathways: CaMKII and CnA, the catalytic subunit of CaN (B); Erk1/2 and 







Figure 4.17. Susceptibility to Ventricular Arrhythmia in P1124L Mice Challenged with 
Epinephrine/Caffeine. 
A. 2-second representative lead-II ECG traces from mice undergoing IP injection of 2 mg/kg of epinephrine 
and 120 mg/kg of caffeine (Epi/Caff). i- sinus rhythm in a WT mouse before treatment; ii- premature 
ventricular beats in a WT mouse; iii- non-sustained ventricular bigeminy in a Homo mouse; iv- bidirectional 
VT in a Homo mouse. B. Premature ventricular beats quantified after injection. C-D. Average number of 
episodes of non-sustained (lasting ≤ 5 s) and sustained arrhythmias (lasting > 5 s). E. Incidence if sustained 
bidirectional VT. F-G. Duration of non-sustained and sustained arrhythmia events. (n = 7 per genotype. * p 







Figure 4.18. Ca2+ Transients and SR Load. 
A. Representative traces of Ca2+ fluorescence produced by fluo-4, at control conditions (i), in the presence 
of 300 nM isoproterenol (ii) and upon rapid perfusion of 20 mM caffeine (iii, perfusion indicated by arrow). 
B-D. Quantification of Ca2+ transient amplitude (B), time-to-peak (C) and 50% transient decay time (D) 
during 1 Hz field stimulation (Basal WT: N = 5, n = 56; Het: N = 3, n = 15; Homo: N = 6, n = 47. Iso WT: N 
= 3, n = 22; Het: N = 3, n = 19; Homo: N = 3, n = 18). E-G. Quantification of SR load (E), 50% caffeine 
transient decay time (F) and fractional release of Ca2+ (G) (Basal WT: N = 5, n = 22; Het: N = 3, n = 15; 
Homo: N = 6, n = 25. Iso WT: N = 3, n = 21; Het: N = 3, n = 19; Homo: N = 3, n = 18. For all genotypes, p 







Figure 4.19. Susceptibility to Spontaneous Ca2+ Release in Ventricular Myocytes. 
A. Representative traces of WT and Homo ventricular myocytes stimulated with 300 nM Isoproterenol (Iso), 
paced at 1 Hz for 30 s and monitored at rest for 30 s. B. Percentage of cells showing spontaneous Ca2+ 
release (SCR) during the monitoring period. SCR incidence is increased in Homo mice in basal conditions. 
C. Average number of SCR events (Ca2+ waves) during in 30 seconds. Homo myocytes show significantly 
more waves under Iso stimulation (Basal WT: n = 17; Het: n = 16; Homo: n = 16. Iso WT: n = 12; Het: n = 




Table 4.1. X-ray crystallography data collected and refinement statistics. 
Parameters P1124L 
Wavelength (Å) 1.00 
Resolution range (Å) 23.55 - 1.439 (1.491 - 1.439) 
Space group P 2 21 21 
Unit cell 36.29 66.23 66.98 90 90 90 
Total reflections 29741 
Unique reflections 29697 (2662) 
Multiplicity 6.7 (5.2) 
Completeness (%) 98.88 (89.81) 
Mean I/sigma(I) 12.97 (1.96) 
Wilson B-factor 21.94 
R-merge (%) 0.109 (0.830) 
R-meas 0.118 (0.918) 
R-pim (%) 0.045 (0.384) 
Reflections used in refinement 29665 (2643) 
Reflections used for R-free 1480 (129) 
R-work 0.1736 (0.2979) 
R-free 0.1926 (0.2986) 
Number of non-hydrogen atoms 1518 
 Macromolecules 1400 
 Ligands 7 
 Solvent 111 
Protein residues 169 
RMS(bonds) 0.005 
RMS(angles) 0.76 
Ramachandran favored (%) 97.01 
Ramachandran allowed (%) 2.99 
Ramachandran outliers (%) 0.00 
Rotamer outliers (%) 0.00 
Clash score 2.94 
Average B-factor 31.74 
 Macromolecules 30.96 
 Ligands 49.03 
 Solvent 40.45 





Table 4.2. Echocardiographic Parameters in 8-month-old P1124L Mice. 
 WT Het Homo ANOVA t-test WT vs Homo 
n 6 6 7 - - 
BW (g) 26.00±1.88 25.83±1.66 27.43±1.76 NS NS 
HR (bpm) 534±13 552±11 495±11 
WT vs Homo  
p = 0.056 
Het vs Homo  
p = 0.008 
p = 0.040 
IVSd (mm) 0.78±0.02 0.81±0.03 0.82±0.02 NS NS 
IVSs (mm) 1.07±0.03 1.20±0.08 1.29±0.03 WT vs Homo  p = 0.023 p < 0.001 
IVSth (%) 37.88±5.94 47.35±7.00 58.2±3.75 WT vs Homo  p = 0.056 p = 0.019 
PWd (mm) 0.78±0.02 0.8±0.04 0.86±0.03 NS p = 0.062 
PWs (mm) 1.06±0.03 1.05±0.07 1.22±0.05 
WT vs Homo  
p = 0.072 
Het vs Homo  
p = 0.062 
p = 0.016 
PWth (%) 35.56±5.01 31.83±5.04 42.08±2.81 NS NS 
LVDd (mm) 3.99±0.13 3.97±0.14 4.25±0.11 NS NS 
LVDs (mm) 2.96±0.15 2.98±0.19 3.03±0.13 NS NS 
FS (%) 26.09±1.63 25.04±2.63 28.73±2.06 NS NS 
LVVd (μL) 70.3±5.52 69.58±6.12 81.48±4.88 NS NS 
LVVs (μL) 34.54±4.52 35.45±5.6 36.57±3.81 NS NS 
EF (%) 51.53±2.84 50.06±4.1 55.33±3.13 NS NS 
SV (μL) 35.76±2.49 34.13±2.7 44.9±3.47 
WT vs Homo  
p = 0.087 
Het vs Homo  
p = 0.061 
p = 0.057 
CO (ml/min) 19.13±1.5 18.83±1.49 22.04±1.38 NS NS 
LVMass 
(% of BW) 0.44±0.02 0.45±0.02 0.51±0.03 NS NS 
BW: body weight; HR: heart rate; IVSd: interventricular septum thickness in diastole; IVSs: 
interventricular septum thickness in systole; IVSth: percent change in IVS between systole and diastole; 
PWd: posterior wall thickness in diastole; PWs: posterior wall thickness in systole; PWth: percent change 
in PW between systole and diastole; LVDd: left ventricle diameter in diastole; LVDs: left ventricle 
diameter in systole; FS: fractional shortening; LVVd: left ventricle volume in diastole; LVVs: left ventricle 







Table 4.3. Echocardiographic Parameters in 12-month-old P1124L Mice. 
 WT Het Homo ANOVA t-test WT vs Homo 
n 8 7 8 - - 
BW (g) 28.25±1.31 31.14±1.78 30.75±1.80 NS NS 
HR (bpm) 539±13 553±14 566±19 NS NS 
IVSd (mm) 0.75±0.03 0.9±0.06 0.88±0.02 
WT vs Het 
p = 0.058 
WT vs Homo 
 p = 0.050 
p = 0.005 
IVSs (mm) 1.11±0.04 1.28±0.08 1.28±0.06 NS p = 0.041 
IVSth (%) 48.34±4.89 43.49±3.37 44.13±4.30 NS NS 
PWd (mm) 0.78±0.02 0.94±0.05 0.91±0.03 
WT vs Het  
p = 0.013 
WT vs Homo 
p = 0.021 
p = 0.004 
PWs (mm) 1.14±0.05 1.32±0.07 1.27±0.05 NS p = 0.079 
PWth (%) 46.22±5.54 41.79±4.13 39.8±4.04 NS NS 
LVDd (mm) 3.93±0.1 3.99±0.12 4.00±0.10 NS NS 
LVDs (mm) 2.89±0.12 2.84±0.11 2.84±0.11 NS NS 
FS (%) 26.56±1.42 28.8±1.3 29.12±1.53 NS NS 
LVVd (μL) 67.91±4.36 70.19±5.13 70.70±4.36 NS NS 
LVVs (μL) 32.73±3.25 31.17±2.99 31.17±2.98 NS NS 
EF (%) 52.38±2.34 55.87±2.05 56.24±2.37 NS NS 
SV (μL) 35.18±1.87 39.02±2.74 39.53±2.38 NS NS 
CO (ml/min) 18.93±1.05 21.77±2 22.3±1.36 NS NS 
LVMass 
(% of BW) 0.38±0.02 0.47±0.05 0.45±0.01 NS p = 0.003 
BW: body weight; HR: heart rate; IVSd: interventricular septum thickness in diastole; IVSs: 
interventricular septum thickness in systole; IVSth: percent change in IVS between systole and diastole; 
PWd: posterior wall thickness in diastole; PWs: posterior wall thickness in systole; PWth: percent change 
in PW between systole and diastole; LVDd: left ventricle diameter in diastole; LVDs: left ventricle 
diameter in systole; FS: fractional shortening; LVVd: left ventricle volume in diastole; LVVs: left ventricle 







Table 4.4. Ca2+ Handling Parameters in Isolated P1124L Myocytes.  
Ca2+ transient amplitude and SR Ca2+ load measured in basal conditions and with 300 nM Iso stimulation. 
 WT Het Homo 
Cells (n) 21–56 15–36 18–47 
Mice (N) 3–5 3 3–6 
[Ca2+]i transient amplitude 
basal (ΔF/F0) 3.72±0.16 3.64±0.24 3.82±0.17 
SR Ca2+ Load basal (ΔF/F0) 8.17±0.34 7.70±0.44 7.52±0.22 
Fractional release basal (%) 41.02±2.14 50.68±3.99 48.29±2.42 
[Ca2+]i transient amplitude 
Iso (ΔF/F0) 8.57±0.28 7.91±0.32 8.13±0.38 
SR Ca2+ Load Iso (ΔF/F0) 10.02±0.30 9.50±0.33 9.52±0.31 
Fractional release Iso (%) 86.95±2.25 83.21±1.79 84.82±2.23 




CHAPTER 5  
Conclusions and Perspectives 
 
5.1. Summary of Key Findings 
In this dissertation, we examined different aspects of RyR2 regulation to obtain a 
better understanding of the role of this ion channel in the healthy and diseased heart. To 
follow this aim, we took advantage of three animal models with point mutations in RyR2. 
While each chapter of this dissertation focused on one specific question regarding RyR2’s 
role in the regulation of cardiac function — channel phosphorylation in CHAPTER 2, 
haploinsufficiency in CHAPTER 3, and involvement in structural remodeling in CHAPTER 
4 — this final chapter highlights key pieces of information that thread the dissertation 
together. The following sections provide a summary of the most important findings from 
each chapter, while the other sections provide technical, physiological, and clinical 
context to these data. This chapter contains references to the human RyR2 
nomenclature, unless otherwise stated; however, sections 5.1.1, 5.1.2 and 5.1.3 refer to 
the nomenclature of the specific animal model used in the chapter summarized. 
5.1.1. The Genetic Background of RyR2-S2808A Mice  
In CHAPTER 2, we determined that the genetic background of S2808A mice does 
not affect their overall response to acute adrenergic stimulation, nor does it improve their 




the inconsistent results obtained with S2808A generated by two different laboratories — 
Andrew Marks’ at Columbia University and Héctor Valdivia’s at the University of Michigan. 
Since the pioneering studies on this subject were published in 2000, the issue evolved 
into a contentious controversy. Until now, several investigators in the field have 
recognized the difference in the results of both groups,14,140 but no studies have been 
devoted to determining the causes for the discrepancy. There are several differences in 
the approach used to characterize the mice from each lab, but the most striking one is 
the mouse strain, which could have profound effects on the phenotypic presentation of a 
specific mutation138,189 or experimental manipulation.190 Hence, the data presented in 
CHAPTER 2 are complementary to similar studies performed by our laboratory and 
several collaborators, but the novelty resides in the use of a congenic mouse strain in the 
C57Bl/6 background. This new line was derived for the specific purpose of performing all 
experiments in mice with the same genetic background used by the Marks laboratory — 
as opposed to the Sv129/B6 mixed strain originally developed by the Valdivia laboratory. 
Using an approach that involved some of the fundamental experiments that fueled the 
controversy, we demonstrated that the genetic background is an unlikely cause for the 
divergence between the results of both laboratories. In our hands, S2808A mice were 
indistinguishable from WT in most experiments. There was only a single exception: 
S2808A mice showed a significantly higher HR after MI than WT animals. Since this 
unexpected observation was not reported by any of the previous studies on S2808A mice, 
elucidating the underlying mechanisms will deserve further investigation. Nevertheless, 




RyR2-S2808 Phosphorylation Does Not Alter the Adrenergic Response or the 
Progression to Heart Failure in Mice.” 
5.1.2. RyR2 Haploinsufficiency is not Deleterious in Rabbits 
CHAPTER 3 looked at the compensatory mechanisms that preserve cardiac 
function and structure in a rabbit model of RyR2 haploinsufficiency. We showed that Het 
RyR2-KO rabbits have ~60% decrease in RyR2 expression but lack an obvious abnormal 
phenotype. The data presented in CHAPTER 3 suggest that this may be due to an 
upregulation of RyR2 function by decreasing the basal phosphorylation level of the S2031 
phosphorylation site. Furthermore, our data indicated that increased association of RyR2 
with PP2A may be responsible for maintaining the S2031 site at a lower phosphorylation 
level in Het animals. In basal conditions, this response was perhaps sufficient to 
compensate for the lower RyR2 expression. Under acute adrenergic stimulation, Het 
RyR2-KO rabbits responded similarly to WT animals; however, data from isolated hearts 
and Ca2+ imaging in cardiomyocytes suggested that this level of RyR2 expression could 
be insufficient to maintain a normal Ca2+ release flux during Iso stimulation. Hence, Het 
rabbits showed slower force generation and delayed Ca2+ transient time-to-peak during 
adrenergic stimulation. As stated in the title of CHAPTER 3, our conclusion is that “RyR2 
Haploinsufficiency is Compensated by Fine-tuning Channel Activity Through 
Phosphorylation.” To determine whether decreased RyR2 expression affects the 







5.1.3. RyR2 Mutations Can Induce Structural Remodeling of the Heart 
Finally, in CHAPTER 4 we performed a multi-level characterization of the novel 
P1124L mutation, identified in a patient with HCM. We determined that this mutation 
induces structural alterations in the SPRY2 domain of RyR2, likely affecting an 
interdomain interface with the neighboring SPRY3 domain. Functionally, P1124L 
channels show decreased cytosolic sensitivity to Ca2+, but we also observed that when 
P1124L channels are activated by luminal Ca2+ they release a larger fraction of the store 
Ca2+ content compared to WT. In a mouse model, these alterations translated into a mild 
hypertrophy and increased susceptibility to arrhythmia. For the former phenotype, we 
attempted to identify the underlying signaling pathways; however, after probing three 
signaling cascades we have yet to determine the hypertrophic signaling acting in P1124L 
mice. As for the latter, we hypothesize that upon luminal activation, the larger mass of 
Ca2+ released by P1124L channels might coordinate isolated SCR events into 
arrhythmogenic Ca2+ waves and, hence, lead to ventricular arrhythmia. As stated in the 
title of CHAPTER 4, P1124L is “A Novel RyR2 Mutation Associated with Hypertrophic 
Cardiomyopathy [that] Induces Hypertrophy and Arrhythmia in Mice.” Therefore, these 
data suggest that it may be the disease-causing mutation in the patient with HCM where 
it was identified. A full elucidation of the pathogenic mechanisms induced by P1124L will 
require further investigation. 
5.2. Genetically-Engineered Rabbit Models to Study Cardiac Physiology 
For two of the chapters of this dissertation we took advantage of knock-in mouse 
models to study point mutations in RyR2. However, in terms of novelty, one of the most 




in CHAPTER 3 were generated in one of only a handful of genetically-engineered rabbit 
models available today, and, to our knowledge, the first specifically targeting RYR2. This 
section gives brief technical context to the use of larger mammals, like the rabbit, for the 
study of cardiac physiology. 
Mus musculus, the house mouse, is the animal species most widely used in 
biomedical research. Mice are small, reproduce quickly, reach adulthood in only a few 
months, have a relatively short lifespan, and exist as inbred strains of genetically identical 
animals. But these characteristics offer no clear advantage over smaller and simpler 
organisms, such as Drosophila melanogaster — the fruit fly — and the worm 
Caenorhabditis elegans. Instead, the reasons the mouse is the number one species used 
to model human disease are simple: mice and humans are genetically very similar, and 
mice are, to date, the only mammal in which any gene can be targeted through genetic 
engineering.191 While this genetic versatility makes the mouse the most powerful tool for 
biomedical research, this species is not the best to model human disease.  
In the field of cardiac research, the characteristics that make the mouse an often-
unsuitable model are particularly evident, as shown in Figure 5.1. Mice have a heart rate 
of ~500 bpm requiring short cardiac cycles and fast action potentials, while humans have 
significantly lower heart rate and a cardiac action potential (AP) with a completely different 
waveform. The phase-2 plateau observed in the human cardiac AP — formed by a 
transient balance between outward K+ currents and ICaL — is largely absent in mice.192 
Because of the small role of ICaL in shaping the mouse cardiac AP, e-c coupling must rely 
primarily on SR rather than extracellular Ca2+. This explains why in the mouse heart the 




and RyR2/SERCA2a on the SR is ~10% and ~90% respectively, while in the human heart 
they account for ~30% and ~70,% respectively (Figure 5.1).3,193 Furthermore, the 
repolarization phase of the mouse AP relies on transient outward currents (Ito), while in 
the human and rabbit this is mediated by delayed rectifier K+ currents (IKr and IKs).194 
Unfortunately, larger mammals such as the rabbit (Figure 5.1), the sheep, or the 
pig, that have cardiac physiology that better resembles that of the human,195 are 
significantly more difficult to genetically engineer than the mouse. Transgenic expression 
of exogenous genes due to random insertion of DNA constructs is possible in these 
species,196 but the lack of suitable embryonic stem cell lines has hindered the 
development of knock-in and knock-out strains.197 Indeed, several transgenic rabbits 
overexpressing human genes are available198,199 — including the LQTS model mentioned 
in CHAPTER 3156,157 — but any study that requires manipulation of endogenous genes 
— such as the characterization of disease-causing mutations without protein 
overexpression — must be performed in mice (e.g. in CHAPTER 2 and CHAPTER 
4).87,89,102 On the other hand, those studies requiring healthy animals or the use of 
experimental manipulations to induce heart disease are often performed in larger species 
(examples in refs. 8,147,200). Rabbits are commonly preferred because their small size (2–
4 kg adults), rapid sexual maturation (5–6 months), short gestational period (~30 days), 
and large litter size (4–12 kits/litter) make them convenient laboratory animals.201 
Lately, new gene editing techniques have been applied to create gene knock-outs 
in rabbits152,202,203 and pigs,204,205 overcoming a historic hurdle by microinjecting the 
targeting vectors into healthy pronuclear embryos that are then implanted into surrogate 




carefully-designed RNA probes derived from the bacterial CRISPR system (clustered, 
regularly interspaced, short palindromic repeats) to recruit the nuclease Cas9 to the 
genomic region of interest. Cas9 then creates a double-stranded DNA cut, which the cell 
repairs by employing non-homologous end joining — introducing insertions or deletions 
that change the reading frame of the gene and, in some cases, knock out protein 
expression — or homology-directed repair — when the cell restores the DNA using a 
donor template provided to that effect.206 Adding specific mutations to this donor template 
is, theoretically, the means to create knock-in animals. While using this approach to 
create gene knock-out animals is relatively easy, introducing a DNA donor template to 
create knock-in animals is more challenging.  
In 2014, Yang et al. published the first report of knock-out rabbits created using 
CRISPR/Cas9.152 The RyR2-KO rabbit model discussed in CHAPTER 3 is one of seven 
RyR2-KO founders reported in that publication, along with several KOs of three other 
genes — CD36, APOE, and LDLR.152 Since the DNA restoration performed by the cellular 
machinery is variable, each Cas9-damaged allele is repaired differently and founders are 
unique. Furthermore, two different types of repair can occur within the same cell on each 
gene allele, and if the targeting materials injected into the embryo are transmitted to the 
daughter cells, a second round of Cas9 targeting/DNA repair could result in mosaicism 
— i.e. animals containing more than two different alleles for each gene. Indeed, Yang et 
al. described 20 founders with at least two different mutations in the gene of interest, and 
three of those founders were mosaics with three different alleles for the gene.  
While studying the RyR2-KO model in CHAPTER 3 we dealt with this issue: one 




a 12 bp insertion in the second allele accounting for four additional residues in RyR2. This 
second mutation remained unnoticed for nearly two years because it behaved as a WT 
allele in the genotyping protocol. Hence, most of the animals we initially classified as WT 
littermates were not. When we changed the breeding pairs and observed inconsistent 
genotyping in the offspring, we performed an extensive genetic characterization and 
identified the 12 bp insertion. Then, using Punnett’s diagrams we determined which 
animals carried this mutation without the need to perform additional genetic screening. 
Ultimately, the lesson is that, when using CRISPR/Cas9 to develop mutant animals and 
regardless of the species, a careful genetic characterization of the founders and the F1 
offspring is paramount to avoid costly mistakes. Ultimately, the screening, selection, and 
breeding of the offspring carrying only the knock-out allele took over one year and 
required to purge all datasets from inadequate samples and repeat several experiments. 
Finally, there is one piece of information we did not discuss in CHAPTER 3: the 
site of the mutation in the RyR2-KO allele. RYR2 is formed by 105 exons and Cas9 was 
purposely targeted to exon 49 (Figure 3.1, Figure 3.2), a rather unusual choice to make 
a knock-out. Exon 49 encodes 56 residues from 2448 to 2504 in the middle of the protein. 
Our laboratory previously characterized the CPVT mutation V2475F in mice;87 hence, the 
targeting site is in fact quite obvious: every single RyR2-KO founder generated by the 
Chen laboratory and described by Yang et al.152 was obtained while attempting to knock-
in this mutation into RYR2. Fortunately, the fortuitous creation of the knock-outs allowed 
us to address important questions regarding cardiac function, Ca2+ homeostasis, and 
RyR2 regulation when lower RyR2 expression occurs. After several years of trial-and-




RyR2-V2475F rabbit founders. The characterization of these animals and the comparison 
with the mouse results already published will be exciting new projects for the Valdivia 
Laboratory in coming years. 
5.3. Mouse vs. Rabbit Cardiac Electrophysiology and Ca2+ Handling 
The similarity in Ca2+ handling between the rabbit and human hearts makes RyR2 
mutant rabbits particularly exciting to study in our field. One would expect that if the mouse 
heart relies mostly on the SR Ca2+ for contraction, RyR2 dysfunction might have a more 
deleterious effect in the mouse than in the rabbit, which requires a larger sarcolemmal 
Ca2+ contribution. With the RyR2-KO rabbit model we indirectly tested this hypothesis. 
Interestingly, both heterozygous RyR2-KO mice121 and rabbits have lower RyR2 
expression but lack a basal abnormal phenotype. Hence, regardless of the specific 
contributions of the SR and the sarcolemma to Ca2+ homeostasis, both species maintain 
a normal cardiac function even with lower RyR2 expression. Nonetheless, this may not 
be the case for other types of mutations. We discussed in section 1.5.1 that the most 
accepted mechanism of CPVT involves extemporaneous release of Ca2+ that produces 
either DADs or EADs as this Ca2+ is extruded from the cell by the electrogenic NCX. Since 
the role of NCX is more prominent in the rabbit heart than in the mouse (Figure 5.1), it is 
reasonable to hypothesize that a rabbit model of CPVT may be more susceptible to 
arrhythmia. Indeed, inducing arrhythmia in a CPVT mouse model requires an extremely 
large, non-physiologic dose of epinephrine mixed with an even larger dose of caffeine 
(Figure 4.17). Hence, a systematic side-by-side comparison between rabbit and mouse 
models of CPVT will be an interesting experimental approach now that our laboratory has 




differences between the mouse, rabbit and human heart physiology. Since we discussed 
Ca2+ handling in the previous section, here we will make a brief comparison of specific 
parameters in the three species.  
Evidently, mouse and rabbit cardiac physiology is significantly different from 
human; yet, the rabbit is typically an intermediate between the two. One of the most 
evident differences in cardiac physiology among the three species is the heart rate (HR): 
the resting human HR is 60–100 bpm and the parasympathethic/vagal tone, which 
restraints cardiac function, prevails over the sympathetic/adrenergic tone, which 
enhances cardiac function (section 1.3).207 Conscious mouse HR is significantly higher 
(450–750 bpm), and the rabbit HR, although lower than the mouse, is still significantly 
higher than that of the human (180–350 bpm).208 Remarkably, isolated mouse hearts, 
devoid of hemodynamic and neurohormonal regulation of cardiac function, have a HR 
significantly lower than anesthetized animals (396.5±13.2 bpm vs. 522.9±12.3 bpm, 
respectively; Figure 5.2 A), while in rabbits both anesthetized and isolated-heart HR are 
nearly-identical (186.6±7.0 bpm vs. 206.3±7.4 bpm; Figure 5.2 A). Similarly, small studies 
of human hearts explanted from organ donors have found either a slight decrease209 or 
no difference210 in HR compared to the value before pre-explantation. This suggests that 
mice have a significantly higher adrenergic tone than rabbits and humans. Upon 
adrenergic stimulation, human HR can increase nearly 2-fold during exercise,211 whereas 
mice and rabbits respond to Iso stimulation with a ~10% and ~1.7-fold increase, 
respectively (Figure 5.2 B). Other functional parameters such as the EF and FS are more 
similar: the normal human EF is between 50–70%,212 and both mouse and rabbit EF 




modest rise in EF (~15%),211 but Iso stimulation in anesthetized mice and rabbits 
produces a more robust increase: ~1.5 fold in EF and ~1.8 fold in FS (Figure 5.2 C-D). 
Therefore, the higher adrenergic tone in mice seems to be restricted to the sinus node. 
At the ventricle, the three species seem to have a similar sympathetic reserve. This is not 
the case for isolated hearts, because the mouse and rabbit HR have the same response 
to Iso (Figure 5.2 E), and rabbits show a larger increase in LVDP (Figure 5.2 F); 
unfortunately, LVDP measurements are difficult to obtain in isolated human hearts. 
Finally, it is important to note that the HR and EF measurements in exercising humans 
discussed above are likely to underestimate the maximum effect of adrenergic 
stimulation.  
At the cellular level, the differences between species are empirically less obvious 
but equally striking. As shown in figure Figure 5.1 B and discussed in section 5.2, some 
of the ionic currents that form the mouse AP are different from those that shape the rabbit 
and human AP. Similarly, the source/sink contribution of specific e-c coupling 
components to Ca2+ homeostasis is similar between rabbit and human, and significantly 
different in the mouse (Figure 5.1 C, section 5.2). Figure 5.3 shows a comparison between 
Ca2+ transients and action potentials in mouse and rabbit ventricular myocytes. As 
previously shown by Maier & Bers,213 rabbit myocytes show post-rest potentiation of Ca2+ 
release — i.e. Ca2+ transient amplitude increases progressively during pacing as the SR 
is loaded214 — while in mouse myocytes Ca2+ transient amplitude decreases with pacing 
as the SR is progressively unloaded (Figure 5.3 A,B). The SR load in quiescent cells is a 
result of two factors: the balance between SERCA2a and NCX, and the resting SR Ca2+ 




powerful contribution of SERCA2a to Ca2+ reuptake and low resting leak. Interestingly, 
healthy human myocardium shows post-rest decay (like the mouse), while failing 
myocardium shows post-rest potentiation (like the rabbit).215 Considering the similarity in 
SERCA2a/NCX balance between rabbit and human, the different response of the Ca2+ 
transients to stimulation suggests that human myocytes have lower basal SR Ca2+ leak 
compared to rabbit myocytes. Finally, the kinetics of Ca2+ release is slower in rabbit than 
in mouse myocytes (Figure 5.3 C). While a mouse Ca2+ transient peaks within ~40 ms 
(Figure 4.18 C), rabbit transients peak within ~200 ms (Figure 3.10 B). This is likely a 
result of the AP waveform (Figure 5.3 D) and underlying ionic currents.192 At 1 Hz 
stimulation rate, a rabbit AP lasts ~300 ms and ICaL is active during a large fraction of this 
time producing the phase 2 of the AP.192 A mouse AP, on the other hand, lasts ~150 ms; 
hence, the kinetics of activation and inactivation of ICaL are compressed in a shorter 
period, as is RyR2 recruitment and activation. Furthermore, the overall contribution of ICaL 
to AP waveform is more prominent in rabbit myocytes (as it is in human); therefore, Ca2+ 
transients are slower. To determine whether the responsiveness of RyR2 to ICaL is also 
playing a role in the kinetics of Ca2+, it would be interesting to make a systematic 
comparison of the kinetics of Ca2+ transients while controlling ICaL with voltage clamp — 
i.e. e-c coupling gain. Interestingly, while isoproterenol stimulation clearly enhances Ca2+ 
flux in both species, it decreases the time-to-peak of rabbit Ca2+ transients (Figure 3.10 
B) but has the opposite effect in the mouse (Figure 4.18 C). The reason for this 
observation difference is unclear, but it might be associated to the overall contribution of 




In conclusion, the mouse is not human and the rabbit is not human. The selection 
of any species to model human cardiac pathophysiology will be inherently affected by the 
characteristics of such species at all levels — whole-organ, cellular and molecular. 
Hence, it is important to interpret the results carefully. Finally, while the use of genetically-
engineered rabbits is hindered by the novelty of the technique, it is expected that, in the 
future, mutant rabbit models will be more frequently used in the field of cardiac physiology. 
5.4. RyR2 Regulation by Phosphorylation 
Two of the chapters in this dissertation looked at RyR2 phosphorylation as a 
regulatory mechanism of Ca2+ release during e-c coupling. In CHAPTER 2 we revisited 
the idea that S2808 phosphorylation is essential for the adrenergic response and critical 
for HF progression, while in CHAPTER 3 we identified a decrease in basal 
phosphorylation of S2031 as a possible compensatory mechanism for RyR2 
haploinsufficiency. This section provides a brief experimental context for these findings. 
Early work by Takasago et al. showed that at least four kinases — PKA, PKG, 
PKC, and CaMKII — phosphorylate RyR2 using 32P incorporation studies.68 Identifying 
the relevant phosphorylation targets of these kinases is, however, a difficult issue to 
tackle. We discussed before that the human RyR2 (hRyR2) contains 353 serine and 222 
threonine residues (section 1.4.3). From these, ~40 residues are predicted 
phosphorylation sites based on computational analysis of consensus sequences.51,216 
Therefore, a simple permutation analysis shows that there are ~1.1x1012 possible 
different phosphorylation states for a single RyR2 subunit — ~1.5x1048 for a fully-
assembled channel. Thus, in physiological conditions there will be a heterogeneous 




on several factors, including the association of the channel with kinases and 
phosphatases, and the location of any given channel within the myocyte’s SR network. In 
any case, it is unlikely that all these sites are essential for the regulation of the channel, 
especially because the access of any given kinase to some sites is likely limited by steric 
hindrance, and the phosphorylation of many of these sites will prevent or enchance the 
phosphorylation of others. Still, according to the experiments by Takasago et al., CaMKII 
phosphorylates at least four residues for every PKA, PKG or PKC site.68 Considering only 
the two currently-known PKA sites (S2031, S2808) there should be at least six more for 
CaMKII — in addition to S2808 and S2814. Therefore, even as we argue to create a more 
comprehensive model contemplating the three phosphorylation sites known to date 
(S2031, S2808 and S2814; sections 2.3 and 3.3), such model may also be too simplistic. 
Indeed, Lau and Van Petegem31 showed that two additional putative phosphorylation 
sites — T2810 and S2811, phosphorylated by CaMKII and PKA in vitro — are part of the 
same “phosphorylation hotspot” loop of the P2 domain containing S2808 and S2814. To 
date, there are no published studies focusing on these novel sites. Most of the discussion 
regarding RyR2 phosphorylation has focused on S2808 and S2814 for historical reasons. 
S2808 is a controversial phosphorylation site that we discussed at length in 
previous chapters. Since we have already discussed the studies that have fueled this 
controversy, it is not necessary to relitigate this issue here. Nevertheless, it is important 
to consider that a study reported slight differences in the velocity of Ca2+ wave 
propagation and luminal Ca2+ sensitivity between cardiac myocytes from WT and S2808A 
mice,133 which do not affect the overall cardiac function of animals harboring the mutation. 




section 5.1.1, it is reasonable to conclude that this site is not essential for RyR2 regulation 
in physiologic or pathologic conditions. It is fascinating, however, that this is not the case 
for S2814: while this site is not required for the cardiac adrenergic response and the 
phospho-mimetic mutation S2814D does not produce an overt basal phenotype,217 
S2814A animals are resistant to non-ischemic HF,60 ventricular arrhythmia,217 atrial 
fibrillation,218 and CaMKII-induced SR Ca2+ leak.15,217 Hence, despite the proximity 
between S2808 and S2814, both sites transduce different regulatory signals to the 
channel. One reason for this may be the specific location of the sites within the P2 domain: 
while both are contained within the same flexible linker,31 S2814 is closer to the C-
terminus end of the loop and might have fewer structural constraints to convey 
conformational changes to rest the domain and the central tower scaffold. Since S2814 
is a CaMKII phosphorylation site, CaMKII phosphorylation of RyR2 is branded as 
deleterious,58,219 and this idea also suggests that overall increased phosphorylation of 
RyR2 is detrimental to cardiac function.51 Hence, more phosphorylation would produce 
hyperactive channels, as seen in some forms of heart disease such as HF60 and HCM99 
— following the same line of thought initially proposed by Marks et al. for S2808. 
Nevertheless, there is experimental support for the idea that dephosphorylation of RyR2 
also increases channel activity: Lokuta et al. showed that dephosphorylation of rabbit 
cardiac SR vesicles with acid phosphatase increases [3H]ryanodine binding, and the open 
probability of channels embedded in artificial lipid bilayers;65 Terentyev et al. 
demonstrated that perfusion of permeabilized rat myocytes with PP1 increases Ca2+ 
spark frequency and depletes the SR load;66 Camors et al. proposed that the double 




leak and arrhythmia;165 and in CHAPTER 3 we showed that a lower S2031 
phosphorylation level in RyR2-KO rabbits may be responsible for increasing RyR2 activity 
to compensate for the lower expression (Figure 3.3 and Figure 3.6). Altogether, these 
data suggest that the relationship between RyR2 phosphorylation and channel activity is 
not a straight line but a parabola (Figure 5.4): from the lowest point of the curve, an 
increase or decrease in phosphorylation will activate RyR2. Different populations of 
channels, or models with specific genetic mutations that hamper or mimic phosphorylation 
will fall within an “optimal phosphorylation” range that will not produce deleterious 
phenotypes — such as the S2808A, S2814A, and RyR2-KO models. Extremes on both 
sides of the curve beyond the optimal range, however, will produce RyR2 dysfunction — 
as in the S2808A/S814 mouse on the left, and HF and HCM on the right. 
So far, most of this discussion relies on the generalization of data from two of the 
three known phosphorylation sites and on reports that study global channel 
phosphorylation. Hence, it is difficult to assess where a normal human patient or 
experimental animal subject would fall on the phosphorylation-activity curve (Figure 5.4). 
To continue improving our understanding of this issue, similar in-depth studies of the 
S2031 site are required. Our laboratory has developed a mouse with genetic ablation of 
this site — S2030A as per the mouse nomenclature. To date, the only data available on 
this model suggests that the site regulates the sensitivity of RyR2 channels to Ca2+ during 
e-c coupling and CICR.220 These data are consistent with the idea that the low basal 
phosphorylation of this site provides a wide dynamic range during adrenergic stimulation 
— 16-fold, as opposed to 50% increase for S2808 and S2814. Further studies of the 




least two fundamental questions: is S2031 phosphorylation essential for the normal 
adrenergic response, and does genetic modification of this site lead to an overt basal 
phenotype? With this information, we can continue building a more comprehensive model 
of RyR2 regulation. Together with our data from CHAPTER 3 indicating that changes in 
S2031 phosphorylation potentially compensates for RyR2 deficiency, the limited data 
available from the S2030A mouse model suggest that this site is more relevant than 
previously anticipated. 
5.5. Clinical Significance of RyR2 Variants and Polymorphisms 
In 1999, Swan et al. used genetic linkage analysis of two unrelated families with 
clinical history of sudden cardiac death to map the underlying arrhythmogenic disorder to 
chromosome 1q42-43.221 Shortly after, this region was narrowed to RYR2, when Priori et 
al. reported four specific mutations in a same number of probands with CPVT,73 the 
syndrome studied by Swan et al.221 One of these mutations, R4497C, was later 
introduced in mice (R4496C) and heterozygous animals recapitulated the most relevant 
clinical signs of CPVT: polymorphic ventricular tachycardia and ventricular fibrillation in 
response to catecholamines and exercise.222 Hence, the research field devoted to 
elucidating the mechanisms of RyR2-mediated inherited cardiac disease was born. 
Today, there is enough evidence in the literature to assert beyond doubt that some RyR2 
mutations produce CPVT. However, the spectrum of possible phenotypes induced by 
RyR2 dysfunction continues to grow. P1124L, the novel HCM mutation discussed in 
CHAPTER 4, is one example; but the Human Gene Mutation Database (HGMD)127 — a 
resource compiling studies of potentially pathogenic mutations — also incorporates 




arrhythmogenic right ventricular cardiomyopathy (ARVC), and even colorectal cancer and 
intellectual disability. Altogether, this information is stimulating to the field, but it deserves 
careful consideration. Landstrom et al. recently reported that 7.5% of individuals 
undergoing whole-exome sequencing (WES) carry RYR2 variants, but only 1.2% of those 
were pathogenic based on clinical information.176 Overall, RyR2 appears to be highly 
tolerant to variability: gnomAD — a public database containing WES and genome 
sequencing information from more than 120,000 individuals — reports 1422 residues 
susceptible to 1751 missense variants. These mutations are equally distributed 
throughout the protein, while those associated with CPVT cluster in three regions of the 
channel, as we discussed before (Figure 1.5, section 1.5.1). Remarkably, the 31 specific 
mutations summarized in Table 5.1 appear in gnomAD and HGMD. Then, what is the 
overall clinical significance of novel RyR2 mutations? If a patient carries any given RyR2 
mutation and shows an abnormal phenotype, should this be labeled as the disease-
causing mutation? 
Ackerman recently addressed this issue arguing that, hierarchically, the phenotype 
must prevail over the genotype.82 Hence, if the clinical diagnosis is inconclusive, any rare 
mutation identified in a patient is likely a false-positive — i.e. a variant of unknown 
significance (VUS). But even with a robust phenotype, any RyR2 mutation could be 
merely coincidental. This is evident from Table 5.1: for many mutations compiled in 
HGMD, the original clinical report does not provide detailed information of the patients’ 
phenotype (e.g. S1765C and R2359C), and considers a mutation as “pathogenic” even 
when the patient carries variants in other relevant genes (e.g. L73V found with mutations 




tests (e.g. T1223A, the patient only had one episode of syncope). For other mutations, 
this issue is compounded by the high allelic frequency in the general population. Such is 
the case of T1107M (Table 5.1), reported in cases of CPVT81 and HCM,113 but occurring 
in approximately 4 of every 10,000 alleles in gnomAD (Table 5.1). Hence, T1107M is 
probably not disease-causing — as recognized by Landstrom et al.176 — and in patients 
carrying this mutation, other epigenetic or environmental factors likely contribute to the 
phenotype. This residue is also subject to inter-species variation (Figure 4.3), and the 
functional and structural studies were performed with A1107M, the mouse analog.30,119  
Ultimately, the genetic variability in RYR2 should not discourage the study of rare 
mutations from patients with phenotypes other than CPVT, since determining the 
pathogenic potential of any genetic variant, whether in RYR2 or any other gene, needs 
confirmation at different levels. P1124L, for example, also appears in gnomAD (Table 
5.1), but this residue is conserved in all species and RyR isoforms (Figure 4.3), and we 
provide experimental evidence in support of its pathogenicity, including the marked 
hypertrophic phenotype in the human patient (section 4.2.1), a molecular characterization 
showing structural and functional alterations in RyR2 (sections 4.2.3), and a mouse model 
showing cardiac hypertrophy (section 4.2.6) and arrhythmia (section 4.2.8). Nevertheless, 
the lack of segregation data within the patient’s family and the mild phenotype in the 
animal model undermine the disease-causality of P1124L, even with our thorough 
characterization. Therefore, the data discussed in CHAPTER 4 might be insufficient to 
include RYR2 in the clinical HCM panels — as suggested by a colleague at a conference 
— but it validates the hypothesis of a wider spectrum of RyR2-caused disease deserving 




hence, the field of RyR2-mediated HCM and structural remodeling is at the same 
developmental stage as the RyR2-mediated CPVT field was when Cerrone et al. reported 
the first CPVT mouse model nearly 12 years ago.222 
Finally, there is another category of RyR2 mutations in gnomAD deserving 
discussion: 29 RYR2 genetic variants produce premature termination of RyR2 synthesis, 
collectively accounting for ~1 of every 10,000 alleles. Overall, these truncations are 
compatible with that of the RyR2-KO rabbit model discussed in CHAPTER 3 (Figure 3.1). 
Like the rabbit model, these individuals are heterozygous; hence, it is conceivable that 
they have RyR2 haploinsufficiency as well. As we discussed earlier, our data suggest that 
lower RyR2 expression is readily compensated and does not trigger a deleterious 
phenotype. Therefore, even though these mutations produce significant disturbance of 
the RYR2 gene, there is an insignificant effect on the e-c coupling apparatus. This may 
explain why no truncation mutations are currently associated with heart disease. If a 
report identified one of such mutations in a patient with a cardiac disease, like is the case 
of T1107M, our data would provide strong experimental evidence suggesting that this is 
likely a false-positive, i.e. not the disease-causing mutation. 
5.6. RyR2-Associated Structural Cardiomyopathy 
The attempt to study structural cardiomyopathy because of RyR2 dysfunction is 
not entirely new. Even before Fujino et al.113 presented at the 2006 American Heart 
Association Scientific Sessions the abstract reporting T1107M in a family with HCM, there 
were already reports of RyR2 mutations in patients with arrhythmogenic right ventricular 
cardiomyopathy (ARVC, section 1.5.3) — formerly ARVD2, for dysplasia. Rampazzo et 




years before Swan et al. mapped CPVT to the exact same locus.221 Later, Tiso et al. 
narrowed this region to RYR2 when they reported four missense mutations in five families 
with ARVC.117 So far, the story of ARVC is very similar to that of CPVT (previous section), 
but the reason both have not received the same recognition is simple: instead of 
producing structural cardiomyopathy, three of the mutations described by Tiso et al. 
predisposed mice to stress-induced arrhythmia, the CPVT phenotype — L433P,223 
N2386I,223 and R176Q.224 To our knowledge, the fourth mutation, T2504M, has not been 
expressed in mice but was found in the same allele as R176Q in the family described by 
Tiso et al;117 hence, the R176Q mouse model is not representative of the clinical report. 
Ultimately, these mutations are likely pathogenic — they induce RyR2 channel 
dysfunction,225 produce a phenotype in mice and none of them appear in gnomAD — but 
their link with structural cardiomyopathy is weak. Therefore, a clear association between 
RyR2 mutations and ARVC remains unproven, even as the number of such mutations 
continues to grow. 
As we discussed in previous sections, the relationship between other types of 
cardiomyopathy such as HCM and LVNC with RyR2 mutations also remains, at best, 
tantalizing. For exon 3 deletion the mouse model does not develop cardiomyopathy nor 
stress-induced arrhythmia, and for T1107M there are no animal models available. Still, 
both mutations appear in CPVT patients as well, which obscures any association. 
Nevertheless, there is a reasonable link between RyR2 dysfunction and cardiomyopathy: 
any mutation that produces a constitutive diastolic leak of SR Ca2+ might activate the two 
Ca2+-dependent hypertrophic signaling pathways — CaM-CaN-NFAT and CaM-CaMKII-




channel activity at diastolic [Ca2+] (100 nM), even though heterozygous mice only show 
arrhythmia.87 The characterization of P1124L in CHAPTER 4 addressed this issue, but 
we were not able to identify the link between the molecular phenotype of RyR2 channels 
and the hypertrophy in mice. Nevertheless, the fact that mice harboring the mutation 
develop hypertrophy is supportive of two hypotheses: (1) P1124L is the disease-causing 
mutation in the patient; and (2) that RyR2 dysfunction can indeed produce structural 
cardiomyopathy. In any case, we must also consider the possibility that any of these 
mutations could fail to trigger the expected phenotype just because of the cardiac 
physiology of the mouse, which we have addressed before. 
Lastly, we must consider the possible signaling pathways underlying the 
development of hypertrophy due to RyR2 mutations. If CaM-CaN-NFAT and CaM-
CaMKII-HDAC are not the culprits, the number of other possible hypertrophic cascades 
is overwhelming.178 In CHAPTER 4 we selected two specific ones mediated by AKT and 
ERK based on the work by the Meissner laboratory with the RyR2-ADA mouse which 
expresses CaM-binding deficient RyR2.43,111 Until P1124L, this mouse model was the 
only one to develop cardiac hypertrophy as a result of an RyR2 mutation. However, the 
ADA mutation is not clinically relevant — i.e. not from a patient — and the phenotype is 
very severe: homozygous mice die 10–15 days after birth. At this stage, there are clear 
signs of activation of Ca2+-dependent hypertrophic signaling: increased HDAC43 and 
NFAT111 activity, but none of these molecules is altered in embryos before the onset of 
hypertrophy. In P1124L we did not observe indications of increased Ca2+, Erk1/2 or Akt-
dependent signaling pathways; hence, these pathways are not likely involved in the 




cardiomyopathy remains elusive; but the association between RyR2 mutations and HCM 
seems promising. 
5.7. Future Directions 
5.7.1. S2808A Mouse Models and the Never-Ending Controversy 
One of the reviewers of our article describing the results of CHAPTER 2102 
commended us for addressing the issue of the genetic background in the S2808 
phosphorylation controversy, but suggested to perform a side-by-side comparison with 
the S2808A mouse from the Marks Laboratory. Indeed, such study would likely solve this 
long-standing controversy. Since this has not been possible to date, we made our S2808A 
mouse models available to the entire scientific community. Recently, Dobrev and 
Wehrens140 provided an extensive list of potential reasons for the divergent results that 
have fueled the S2808 debate. Environmental conditions (diet, microbiome, water quality) 
and circadian rhythms (light/dark cycles and time-of-day of the experiments) stand out 
among those possibly accounting for the opposite phenotypes of S2808A mice. It is 
unlikely, however, that all these factors selectively affect S2808A mice to assign 
diametrically different properties to this site depending on the laboratory. Hence, 
independent validation of all these experimental results is critical. This controversy will 
hardly be solved until a side-by-side comparison between the Mark and Valdivia S2808A 
mice is performed by an independent group. 
5.7.2. The Three Phosphorylation Sites and Their Role in RyR2 Regulation 
Complete ablation of S2808 and S2814 phosphorylation does not seem to affect 




against some forms of heart failure because it inhibits the CaMKII-mediated RyR2 leak. 
This is surprising because of the location and proximity of both residues. If we add to the 
equation the poor understanding of S2031, it is evident we need new comprehensive 
models of RyR2 regulation by phosphorylation. Hence, it is necessary to characterize 
several animal models, including S2030A, S2030A/S2808A (to determine whether PKA 
phosphorylation of RyR2 is necessary for the adrenergic response) and S2808A/S2814A 
(to determine whether CaMKII phosphorylation of RyR2 is necessary to regulate the 
channel). Our laboratory is currently working with these models and has plans to develop 
a mouse triple phospho-mutant mouse — S2030A/S2808A/S2814A — to assess cardiac 
function in the absence of all known phospho-sites. To meet the PKA:CaMKII 
phosphorylation stoichiometry proposed by Takasago et al.68 more sites are likely to be 
discovered in the future. Hence, determining which of these new sites are important for 
RyR2 regulation is an exciting future research area. For every study considering RyR2 
phosphorylation, at least two questions must be addressed systematically: is 
phosphorylation critical for the normal adrenergic response and is it involved in the 
pathogenesis of certain forms of heart disease? 
5.7.3. RyR2 distribution and Ca2+ handling in RyR2-KO Rabbits 
RyR2 haploinsufficiency is expected to reduce the number of channels in a CRU, 
decrease the number CRUs within a myocyte or, most likely, a combination thereof. 
However, it is possible that remodeling of the SR network in myocytes from RyR2-KO 
rabbits contributes to normalize Ca2+ release even with lower expression. In this case, 
corbular SR — terminal SR cisternae containing CRUs that do not forming junctions with 




cisternae forming dyads with the TT or sarcolemma, and committed to activation by LTCC 
during an AP. Hence, it is fundamental to determine the extent to which haploinsufficiency 
alters the distribution of RyR2 in a cardiac myocyte. This would allow us to weigh the 
relevance of RyR2 organization and the decrease in pS2031 phosphorylation as possible 
mechanisms that normalize cardiac function in RyR2-KO rabbits. We have already started 
these studies by collecting cardiac myocytes for immunostaining of RyR2 and other 
relevant proteins such as LTCC; unfortunately, this technique might not offer enough 
sensitivity to address this question. Other approaches such as dual-tilt tomography226 
might provide more conclusive data. This method uses three-dimensional reconstruction 
of electron micrographs of dyadic clefts to visualize the position, distribution, and 
orientation of individual RyR2 tetramers.226,227 With this information we could specifically 
compare dyad formation and RyR2 content between WT and Het RyR2-KO hearts. 
We showed in Figure 3.10 that RyR2 deficiency does not seem to affect the 
amplitude of the global cytosolic Ca2+ transient, while it slightly prolongs the time-to-peak 
under Iso stimulation. Nevertheless, there are two essential aspects that remain to be 
addressed in this model. First, the distribution of RyR2 and composition of a CRU may 
affect the properties of the unitary Ca2+ release event: the Ca2+ spark. Hence, measuring 
the properties of Ca2+ sparks in intact and permeabilized myocytes could provide more 
insights into the extent to which haploinsufficiency affects Ca2+ handling. Second, the ICaL 
density and responsiveness of RyR2 to activation by this current — e-c coupling gain — 
are critical measurements to be performed in the future. Although we did not observe 
differences in overall Cav1.2 expression, it is possible that post-translational modifications 




RyR2-KO myocytes. If these experiments showed that ICaL and/or e-c coupling gain are 
increased in RyR2-KO myocytes, these would most likely be dominant compensatory 
mechanisms for RyR2 deficiency in haploinsufficient hearts. 
5.7.4. Chronic Response of RyR2-KO Rabbits to Stress 
RyR2 haploinsufficiency is readily compensated in basal conditions, and the 
overall acute adrenergic response is maintained. To complete the results described in 
CHAPTER 3 and section 5.7.3, we must test how RyR2 haploinsufficient rabbits respond 
to chronic stress, such as myocardial infarction or aortic banding. Zou et al. suggested 
that RyR2 deficiency is beneficial in mice undergoing aortic constriction, as they develop 
less severe hypertrophy.121 In the near future, we will begin testing this in heterozygous 
RyR2-KO rabbits. These results will be reported in a separate publication. 
5.7.5. Hypertrophic Signaling Pathways Activated by P1124L 
The characterization of P1124L described in CHAPTER 4 was thorough, using 
several approaches from molecule to whole animal. Still, we have yet to identify the 
signaling pathways underlying the cardiac hypertrophy. Hence, the description of the 
clinical case and the level of characterization of P1124L and the in CHAPTER 4, may be 
suitable for a high impact factor journal such as Circulation. The elucidation of the 
signaling pathways, may be published in a follow-up report. It is possible that the 
phenotype of the P1124L mice is too mild to reach conclusive results as to specific 
hypertrophic pathways. In this case, it could be worth considering creating a P1124L 
rabbit model, as this mutation may produce a more pronounced phenotype in a species 






Figure 5.1. Overview of Cardiac Physiology in Mouse, Rabbit, and Human. 
A. Representative 2-second traces of Lead-II Electrocardiograms recorded in a mouse and rabbit — 
anesthetized — and a conscious human subject. The approximate heart rate of the ECG trace is indicated 
above. B. Representative action potentials from ventricular myocytes of the same three species. Numbers 
indicate the phases of the human action potential. Asterisk indicates the stimulation artifact. Mouse AP 
courtesy of Yan-Ting Zhao, and human AP courtesy of Daniela Ponce from the University of Michigan 
Center for Arrhythmia Research. C. Contribution of SERCA2a and NCX to cytosolic Ca2+ removal. To 
maintain homeostasis, these percentages must match the contribution of RyR2 and LTCC, respectively, to 








Figure 5.2. Comparison of Cardiac Function between Mouse and Rabbit. 
A. Heart rate measurements during echocardiographic assessment of cardiac function in anesthetized mice 
and in isolated hearts mounted on a Langendorff apparatus. B-D. Cardiac function measured in 
anesthetized animals through echocardiography: HR (B, as percentage of basal), ejection fraction (C), and 
fractional shortening (D). Measurements performed in basal conditions and under isoproterenol stimulation 
(mouse: 2 mg/kg IP; rabbit 0.5 µg/kg/min IV). E-F. Cardiac function measured in Langendorff-perfused 
isolated hearts: HR (E, mouse: 60 s post-iso, rabbit: 300 s post-iso) and LVDP (F, mouse and rabbit: 10 s 
post-iso) in basal conditions and under Iso stimulation (mouse: 300 nM, rabbit: 100 nM). Data compiled 
from Figure 2.6 and Figure 3.8 after combining genotypes per species (n = 12 per group. *: p < 0.05, **: p 





Figure 5.3. Comparison of Ca2+ Transients and Action Potentials in Ventricular Myocytes from 
Mouse and Rabbit. 
A. Representative line-scans from mouse (top panel) and rabbit (bottom panel) myocytes loaded with the 
Ca2+ indicator fluo-4AM and paced at 1 Hz with field stimulation. B. Normalized intensity profile of the traces 
shown in A. ΔF/F0 values normalized to the peak Ca2+ transient. C. Ca2+ transients from the shaded box in 
panel B, temporally realigned and at a different time scale. D. Ventricular AP recordings from myocytes 
paced at 1 Hz. Voltage values were adjusted for the resting membrane potential and normalized to the peak 










Figure 5.4. RyR2 Regulation by Phosphorylation. 
Schematic representation of RyR2 regulation by phosphorylation. The dashed line indicates the 
phosphorylation level of the channel under normal, basal conditions. To the right, increased phosphorylation 
of the channel produces an increase in channel activity that can turn pathogenic as proposed in heart failure 
(HF) and hypertrophic cardiomyopathy (HCM). To the left of the dashed line, dephosphorylation of the 
channel also produces an increase in channel activity. The level of dephosphorylation determines whether 
the channel activity remains within an optimal range for the specific model — as in the S2808A mouse and 
in the RyR2-KO rabbit. Higher dephosphorylation of the channel can have pathological implications, as in 






Table 5.1. RyR2 Mutations Reported in both Clinical Cases and WES Studies. 




L62F 4.06x10-6 CPVT ++ + 81 
L73V 4.06x10-6 SCDB ++ - 228 
V186M 2.44x10-5 CPVT + + 81 
H240R 1.08x10-5 CPVT + + 81 
S406L 2.17x10-5 CPVT + + 229 
R414C 8.13x10-6 SCD ++ + 230 
P466AC 8.68x10-5 ACA + + 231 
L555V 4.07x10-6 diLTQSB ++ - 232 
R739H 4.08x10-6 CPVT ++ + 81 
R1013QC 4.76x10-4 CPVT - + 81 
T1107M 4.26x10-4 CPVT?, HCM - + 81,113 
P1124LC 2.03x10-5 HCM + + Novel 
A1136V 7.06x10-3 CPVTB - - 233 
T1223A 4.07x10-6 Syncope ++ - 234 
P1256TC 1.63x10-5 Syncope + - 234 
N1551S 2.75x10-4 CPVT + + 235 
S1765CC 1.73x10-4 ? + - 236 
V1810L 8.14x10-5 CPVTB + - 237 
E1837K 2.04x10-5 CPVT + + 81 
I2075T 8.15x10-6 iVFB ++ - 238 
V2113M 3.97x10-4 CPVT + + 81 
R2267H 2.85x10-5 SID ++ + 239 
R2359Q 3.25x10-5 CPVT?B + - 240 
Y2392C 4.07x10-6 CPVT, SCD ++ + 241 
A2439T 1.62x10-5 ? + - 236 
A2498VC 4.82x10-5 CPVT? + - 242 
K4392R 1.64x10-5 ACA, CPVT + + 243 
G4471R 3.23x10-5 Family History of SCD + - 244 
H4552R 1.63x10-5 SUD? + - 245 
A4556T 3.98x10-5 ? + - 231 
R4790Q 4.06 x10-6 CPVT ++ + 81 
ACA: aborted cardiac arrest; CPVT: catecholaminergic polymorphic ventricular tachycardia; diLQTS: drug-induced long QT 
syndrome; iVF: idiopathic ventricular fibrillation; SCD: sudden cardiac death; SID: sudden infant death; SUD: sudden 
unexplained death. 
?: Report does not give specific details of the patient. 
A: Pathogenic potential based on variant frequency (< 1x10-5: ++, < 4x10-4: +) and reported clinical diagnosis. 
B: Mutation identified with other variants in RyR2 or other genes. 
C: More variants reported for this residue. Only the one indicated appears in HGMD. 
Table compiled from the indicated references and the following databases: variants and allele frequency from the Genome 
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